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Abstract 
The aims of this study were to characterize the gut, oral, and vaginal microbiotas of pregnant 
women with varying nutritional status and to determine if daily supplementation with 
probiotic yogurt containing Lactobacillus rhamnosus GR-1 and ground Moringa leaves, 
would ‘normalize’ the microbiota and improve pregnancy outcomes. For the latter, a clinical 
study was performed in Mwanza, Tanzania, in which consumption of yogurt for 88 ± 31 
days, starting from the second trimester, did not result in excess weight gain, altered 
pregnancy outcomes or increased blood nutrient levels compared to an under-nourished 
group not taking the yogurt. Ingestion of the probiotic yogurt did not cause a significant shift 
in the gut microbiota, consistent with previous studies. However, Bifidobacterium abundance 
increased in the gut of infants from mothers who consumed the yogurt. Furthermore, blood 
levels of mercury and arsenic were lower in these women compared to controls.  
Keywords 
Probiotics, Lactobacillus, gut microbiota, vaginal microbiota, oral microbiota, human milk 
microbiota, pregnancy, Moringa, nutrition  
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Chapter 1  
1 Introduction 
Reproduction is the most vital process of all living things as it ensures the continuation of 
a species. In humans it is an intensive and intricate process that is mainly female oriented, 
thus the health and nutritional status of the mother has a significant impact on the 
pregnancy outcomes and health of the fetus as well as longevity and quality of life of the 
newborn. The human microbiome is a powerful ecosystem that is involved in many of the 
biological processes of the human host. It is known that an aberrant microbiome can be 
the cause of many human ailments such as dental carries and periodontal disease in the 
oral cavity, inflammatory bowel disease, irritable bowel syndrome and antimicrobial-
associated diarrhea in the gut and bacterial vaginosis in the vagina. In addition, with the 
obesity epidemic plaguing North America and other countries, studies are showing an 
increased correlation between variations in the gut microbiome and obesity. However, 
little is known about the microbiome in pregnancy and in under-nutrition, albeit evidence 
for its importance exists. Thus, the purpose of this thesis is to define the gut, oral, vaginal 
and human milk microbiome in under-nourished, overweight/obese and  normal/healthy 
weight pregnant women. Furthermore, the impact of a micronutrient enriched probiotic 
yogurt on the microbiome of under-nourished women will be examined. 
1.1 Stages of Pregnancy  
Human pregnancy can be divided into two main stages; embryogenesis, which starts with 
fertilization of the female ova by the male sperm, and fetal development which begins at 
approximately 11 weeks of pregnancy and continues until birth (Figure 1). By the time 
the female fetus is twenty weeks old, the 1 million oocytes that she will possess through 
her lifetime have formed from meiotic divisions of diploid stem cells. An oocyte will 
undergo further meiotic divisions to become an ovum approximately every 28 days once 
the female has reached reproductive maturity. The mature ovum is surrounded by an 
extracellular matrix called the zona pellucida, which is composed of three types of 
glycoproteins, one of which contains an oligosaccharide that acts as a sperm receptor 1-3. 
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The ovum and zona pellucida are further surrounded by cumulus cells, which are 
suspended in an extracellular matrix composed of hyaluronic acid. The matrix of cumulus 
cells not only helps support fertilization, but it also allows transport of the ovum from the 
ovaries through the oviduct by allowing for adhesion with the oviductal fimbrae 1. Once 
the ovum is in the oviduct, there is a very short window of less than a day, for successful 
fertilization to occur with the sperm.  
Sperm are produced in the seminiferous tubules of the male testes by the thousands every 
second. The newly produced sperm then enter the epididymis, where they undergo further 
maturation and modifications before being stored in the cauda of the epididymis where 
they remain in a functionally inactive state and are unable to fertilize eggs 3,4. 
Capacitation, or maturation to a state of fertilization competence, occurs once the sperm 
have left the male and entered the female reproductive tract3. Millions of sperm are 
released during ejaculation, but only a few hundred will actually meet the ovum. It has 
been suggested that the lactobacilli of the healthy vaginal microbiota play a protective 
role in preserving sperm motility and viability5. Under diseased vaginal states, such as 
bacterial vaginosis (BV), an increase in radical oxygen species is observed which has a 
negative impact on sperm motility and viability. Those sperm that survive the journey to 
the ovum penetrate the outer matrix of cumulus cells before aiding in the success of one 
sperm carrying out a sequence of five sperm-egg interactions, which result in the 
activation of the ovum and initiation of zygotic development. The first of these 
interactions involves the binding of the sperm to the zona pellucidia. The exact molecules 
and mechanism involved in this binding reaction are still being elucidated as in vitro 
experiments do not translate in vivo and these reactions are species specific 1,6. The 
second interaction is the acrosome reaction, which involves a number of molecules on the 
plasma membrane of the sperm head that recognize and bind molecules in the zona 
pellucida. This binding initiates a series of reactions that leads to fusion of the acrosomal 
membrane with the plasma membrane and release of the acrosomal contents 7. The third 
interaction involves penetration of the zona pellucida. This is achieved by the motility of 
the sperm as well as enzymatic hydrolysis of the extracellular matrix of the zona 
pellucida, by released acrosomal contents, such as the serine protease acrosin 7. The 
fourth and fifth interactions involve binding and fusion of the sperm with the ovum 
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plasma membrane, which leads to activation of the ovum and initiation of embryonic 
development. The fertilized egg is now called the zygote and is impenetrable by 
additional sperm.   
 
Figure 1: Stages of pregnancy 
The zygote then continues its journey through the oviduct by contractions of the smooth 
muscle and the cilia lining the duct. It takes three days for the zygote to migrate through 
the oviduct to the uterus, but by 30 hours after fertilization the zygote has undergone its 
first mitosis and cellular divisions. The cell division at this stage is called cleavage, due 
to the appearance of furrows in the embryo as the cytoplasm divides. During this stage 
the zona pellucida is still present and cleavage will continue up to 3 days post fertilization 
until the embryo becomes a morula, composed of 16-32 cells. At four days post 
fertilization the morula has entered the uterus and is now called a free blastocyst due to 
the formation of a hollow blastocystic cavity. The embryo at this stage is further 
characterized by an inner cell mass of blastomeres, which will become the fetus, with an 
outer layer of trophoblast cells that form an epithelial arrangement with tight junctions. 
These trophoblast cells transform into a syncytium, which will become the placenta, and 
are involved in implantation of the embryo to the uterine lining which occurs around 5-6 
days post fertilization. Implantation of the embryo to the uterine lining can be affected by 
vaginal health. Studies have shown that BV negatively affects both in vitro and natural 
fertilization and implantation and is also associated with an elevated risk of preclinical 
pregnancy loss8-10. Growth of the embryo continues and by day 13 post fertilization the 
exta-embryonic mesoderm, choronic cavity, primitive streak and definitive yolk sac have 
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formed. By day 16, the notochordal process develops and the amniotic cavity expands 
over the yolk sac. Somites and the neural groove form by day 20 and by day 22 the neural 
folds begin to fuse to form the neural tube and the cardiac loop starts to appear. By day 
24, optic invagination begins and by day 28 the upper limb buds are distinct, the lung 
buds begin to appear and 3 brachial arches have now formed. At day 32 both the upper 
and lower limb buds are visible and the optic vesicle is now distinct. The embryo 
continues to develop with the legs, arms, eyes, body and brain becoming more mature 
and by day 46 spontaneous movements have begun to occur. By day 52-post fertilization 
all major body areas have become definite and the embryonic period draws to a close. 
Pinpointing the exact effects of under-nutrition on fertilization in humans is difficult to 
assess and most of our knowledge comes from animal studies. Studies in rats have shown 
that under-nutrition at the time of conception can lead to fewer cells in the inner cell mass 
blastomeres of the embryo which can result in reduced birth weight, postnatal growth and 
an altered organ/body weight ratio11. However, proper nutrition and its effects on brain 
development are well known and supplementation studies during pregnancy have shown 
that folic acid, iron and vitamin D are extremely important for proper neurodevelopment 
which begins during fertilization12,13. 
Despite all major structures of the fetus being formed during embryogenesis, ending at 
approximately 10 weeks post fertilization, these structures continue to grow and develop 
during the fetal development period, which begins approximately 11 weeks after 
fertilization14. Continued development of the cardiovascular system leads to the heartbeat 
being detected at approximately 21 weeks post fertilization. Muscle, bones, nails and skin 
all continue to grow and develop and by 21 weeks the fetus has become more active. The 
nervous system also continues to grow and develop and by 26 weeks it has developed 
enough to start to control some bodily functions. Gas exchange becomes possible in the 
fetal respiratory system during the end of the canalicular stage of respiratory development 
occurring approximately 16 to 26 weeks post fertilization. By twenty weeks all major 
tissue components of the mature gut have developed, while the accessory structures such 
as glands will continue to develop past this stage. During fetal development, intrauterine 
growth is measured in terms of changes in weight or size in relation to gestational age. 
Early fetal growth is largely dependent on the genome, but later stages of fetal growth 
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can become restricted by the environment or epigenetic factors. Fetal growth rates are 
determined by the increase in tissue weight (expressed in grams) divided by the total 
body weight (expressed in kilograms) divided by the gestational age (in days). A healthy 
human fetus should grow 15 g/kg per day from about 24 weeks post fertilization to 37-39 
weeks gestation. This growth rate then flattens to 6 g/kg per day for the last 2-3 weeks of 
gestation14.  
Nutrient supply to the fetus occurs through three different avenues. Nutrients can be 
supplied either directly across the placenta from the maternal circulation, they can be 
synthesized in the placenta and released into fetal circulation, or the fetal tissues 
themselves can produce certain nutrients14. The major nutrient that diffuses across the 
placental membrane from maternal circulation is oxygen, while glucose is transported 
mainly by facilitated diffusion, amino acids through active transport and free fatty acids 
through a number of transport proteins. During under-nutrition there is no change in 
oxygen consumption by the developing fetus, thus a reduction in fetal growth rate occurs 
to maintain the balance of supply and demand for nutrients14. This leads to a change in 
contributions of glucose and amino acids to fetal energy and carbon balances.   
1.1.1 Pregnancy and Nutrition 
The importance of a proper nutritional, physical and emotional environment for optimal 
fetal growth and development cannot be disputed. It has been shown that a variety of 
factors and behaviors prior to pregnancy, during pregnancy and after giving birth, as well 
as during lactation, can have major implications in infant development14,27, cognitive 
development47,72 and susceptibility to adult diseases, all of which can be passed on to 
future generations31. The developing fetus relies solely on its mother to provide the 
nutrients and energy needed for development. This puts a metabolic demand on the 
mother that may be increased due to a number of additional factors. For instance, teenage 
mothers have a greater metabolic demand as they require nutrients and energy for their 
own growth as well as that of the fetus. Furthermore, physical labor during pregnancy as 
well as stress due to infections or environmental and emotional factors will require a 
greater metabolic demand, as the amount of nutrient loss from the body is increased. The 
number of previous pregnancies as well as timing of pregnancies can also be a factor in 
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the nutrient and energy needs of the mother. The types and amounts of nutrients needed 
at different stages of pregnancy varies, thus further adding to the importance of the 
mother being in a state of optimal physical and emotional health prior too and during her 
pregnancy for good birth and infant health outcomes. The prevalence of under-nutrition is 
extremely high in low and middle-income countries, which translates to increased 
mortality and disease burden for mothers and their infants. Additionally, a number of 
factors mentioned above that further compound the effects of under-nutrition are also 
highly prevalent in low and middle-income countries. In Tanzania specifically, a 
demographic and health survey conducted in 2010, found that 5% of women interviewed 
had births 18 months apart, while 16% had births less than 2 years apart within the five 
years preceding the survey 15. Furthermore, 56 % of women are mothers by the age of 20. 
In comparison, the average age of mothers in Canada in 2010 was 29.6 years, while births 
to teenage mothers between the ages of 14 and 19 were only 11.4 per 1000 births. Pre-
natal care and birthing practices also vary widely between developed and developing 
countries, influenced by a lack of education of mothers in developing countries. In 
Tanzania, only 15% of pregnant women make their first visit to a health-care facility 
before their fourth month of pregnancy and 48% of deliveries occur at home without the 
presence of a skilled medical attendant 15. 
Despite a number of factors that influence birth outcomes, growth of the fetus is 
characterized by a net deposition of tissue, which ultimately requires the availability of 
the proper amount of energy and nutrients14.  Malnutrition is an aberrant nutritional status 
that is characterized by the decreased or excessive intake of one or more nutrients such as 
protein, energy or vitamins, and the frequent infections and disorders that result16. There 
are three types of malnutrition: secondary malnutrition occurs when the body is unable to 
utilize fully the food eaten; over-nutrition which occurs by ingesting too many calories; 
and under-nutrition when the diet does not provide enough calories or protein for the 
growth and maintenance of the body16. It is well known that the lack of certain 
micronutrients, such as vitamins and minerals, can play a critical role in fetal 
development. However, evidence is beginning to mount that both a reduced and 
excessive intake of macronutrients can also produce adverse outcomes. Thus, the effects 
of improper nutrition during pregnancy can be caused by both over and under-nutrition.  
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1.1.1.1 Maternal Over-Nutrition 
Although obesity is an exponentially growing epidemic in developed countries, 
developing countries are also beginning to see a rise in obesity as processed, sugar-rich, 
high fat foods become more readily available. The number of overweight and obese 
women in Tanzania as of the 2010 survey was 15% and 6% respectively15. In contrast, 
the percent of overweight and obese women in Canada as of 2008 was 31.5% and 24.2% 
respectively. Maternal overweight and obesity results in adverse outcomes for both the 
mothers and infants. In a meta analysis conducted by Chu et al.17, it was found that 
overweight and obese women had an increased risk of still births compared to normal 
weight woman17. Furthermore, an increased risk of miscarriage is observed in 
obese/overweight women as well as gestational hypertension, pre-eclampsia and 
gestational diabetes18. A second meta analysis found that obese and severely obese 
women were 2 and 3 times more likely to give birth by cesarean section compared to 
normal weight women19,20. Cesarean sections in overweight and obese women present 
further complications as these operations are more difficult to perform and anaesthetical 
and surgical complications such as infections and excessive bleeding, are more likely to 
occur21. This results in overweight and obese women being hospitalized for longer 
periods of time, putting a strain on health care systems and increasing the cost of 
obstetrical care. Maternal overweight and obesity can increase the risk of congenital 
anomalies such as spina bifida, cardiovascular anomalies, cleft lip and limb reduction 
anomalies in developing infants, as shown in a meta analysis performed in 200922. There 
is also an increased risk of neural tube defects in infants born to obese and overweight 
mothers22,23. Furthermore, studies have shown that children born to obese mothers, and to 
overweight and obese mothers with maternal diabetes, are at an increased risk of being 
obese by two years of age and of developing other metabolic syndromes such as 
hypertension, low high-density lipoprotein levels, elevated triglyceride levels and glucose 
intolerance 24-26. 
1.1.1.2 Maternal Under-Nutrition 
The first study that showed the adverse effects of under-nutrition was unfortunately due 
to a natural event, the Dutch Hunger Winter in 1944. The famine resulted from the 
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Netherlands being invaded by Germany in 1941, which lead to the rationing of all 
available food. These rations became smaller as time went on and by 1944 they had 
reached the lowest with individuals receiving less than 1000 kcal per day. Furthermore, 
this food consisted only of bread, potatoes and sugar beets, so micronutrients were scarce. 
Low birth weight infants, increased mortality of mothers and infants, as well as increased 
congenital anomalies were observed as a result of this famine 27. What was most 
revealing, however, were follow-up studies conducted on adults who were born to 
mothers that were pregnant when the rations were at its lowest. These studies found that 
infants conceived to women who were pregnant during the lowest food rations had 
reduced glucose tolerance, raised insulin levels, increased airway disease and increased 
heart disease later in life 28. Furthermore, women who were conceived during the famine, 
had a five times higher risk of developing breast cancer 28. Follow-up on males conceived 
by mothers exposed to the famine during the 1st half of pregnancy, had higher incidence 
of obesity than males conceived by mothers who were exposed to the famine during the 
latter half of pregnancy, providing some of the first evidence that timing of nutrient 
deprivation plays a crucial role in the lasting-effects on the development of the unborn 
infant 29. Since the Dutch Hunger Winter, the problem of under-nutrition during 
pregnancy has become more prevalent in middle and low income countries than in high 
income countries as the basic causes of under-nutrition are environmental, economic and 
sociopolitical, with the underlying causes being poverty, food insecurity and inadequate 
care and lack of health care services.   
The World Health Organization (WHO) defines undernourished individuals as having a 
BMI less than 18.5 kg/m2. In Canada only 2.5% of women over 18 years of age have a 
BMI of less than 18.5 kg/m2, as compared to 11% of women in Tanzania15. A number of 
studies have shown that inadequate nutrition during pregnancy can result in low maternal 
weight gain leading to increased occurrences of pre-term birth, low birth weights (weight 
< 2500g) and small for gestational age (SGA) infants (weight below the 10th percentile 
for gestational age)30. Meta analysis has shown that SGA and pre-term infants have an 
odds ratio of 4.51 for growing to be a stunted child31. If the stunted child is female, then 
she will grow to be a woman with short stature (height less than 145cm). This has major 
implications as maternal short stature puts the infant at risk for term and pre-term SGA, 
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thereby creating a vicious cycle that could span generations if micro- and macronutrient 
deficiencies during pregnancy are not corrected31 (Figure 2). Furthermore, maternal short 
stature has also been found to increase the risk of cesarean section when giving birth32. 
This poses a significant problem in developing countries due to the limited access to 
health care facilities to perform these operations, especially in rural areas. Finally, short 
stature in pregnant mothers has also been shown to increase the chances of mortality of 
her offspring33. Thus, maternal short stature, as well as anemia, increase the risk of 
maternal mortality and account for 20% of all maternal deaths34. In Tanzania 454 
maternal deaths occur per 100,000 live births, while in Canada the rate is only 7.8. In 
addition, 40% of woman between the ages of 14-49 in Tanzania are anemic15. Anemia in 
pregnancy is mainly attributed to iron deficiency, while folic acid deficiency can also 
occur. The implications of anemia during pregnancy can affect both the mother and fetus 
and anemia during the first and second trimesters influences birth weight and pre-term 
deliveries which may or may not be associated with adverse perinatal outcomes 
depending on the population35,36.  
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Figure 2: Overview of the effects (blue boxes) and adverse outcomes (red circles) of 
inadequate micro- and macronutrient intake during pregnancy. Improper nutrition 
can lead to long-term effects on fetal development as well as a vicious cyclic process 
whereby children of women with micro and macronutrient deficiencies grow to be 
mothers with micro and macronutrient deficiencies. IUGR: Intrauterine growth 
restriction. 
1.1.1.3 Essential Micronutrients for the First 1000 Days and 
Beyond* 
Maternal under-nutrition can be largely attributed to insufficient ingestion of essential 
micronutrients before and during pregnancy. A number of micronutrients are particularly 
critical during pregnancy for the mother, developing fetus and the newborn infant (Figure 
3). This next section will describe a selection of micronutrients of most importance to 
pregnancy and their implications during the first 1000 days of life, as well as highlight 
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studies investigating the effect and timing of supplementation. The first 1000 days refers 
to the moment of fertilization up until the child’s second birthday. During this time the 
fetus, neonate and infant are increasingly susceptible to environmental and nutritional 
factors that can affect their development. As discussed above, these effects have the 
ability to span generations, thus longitudinally perpetuating the problem. Therefore, 
targeting the first 1000 days for proper nutritional interventions has the potential to have 
a profound effect on a child’s ability to grow, learn and rise out of poverty, thereby 
improving long term health, stability and prosperity to society. 
1.1.1.3.1 Zinc 
Zinc is an essential component of enzymes and transcription factors and is important in 
cell growth, development and differentiation37,38. In addition, it is required for immune 
system function, cognitive function and reproduction38,39. One of the main clinical 
features of zinc deficiency is growth restriction, and since the period of rapid growth 
development is greatest during the first three years of life, zinc supplementation during 
this time is essential (Figure 3). For instance, a meta-analysis of studies done on zinc 
supplementation of infants less than five years old showed that supplementation for a 
period of 24 weeks, had a positive effect on linear growth40. Notably the mere addition of 
zinc to the diet does not necessarily equate to increased blood levels as found in some 
African studies41. The reason appears to be a leaky gut and aberrant gut microbiota that 
lowers zinc uptake. 
Zinc supplementation can reduce the incidence of diarrhea by ~20%, pneumonia and 
lower respiratory infections by ~15% and can reduce mortality by 6%, but only if 
supplementation is given to children 12 months and older42. Infants benefit from the 
antimicrobial effects of zinc from their mother’s milk, thus maternal zinc 
supplementation is needed for those deficient, especially during the first 6 months after 
the child is born when exclusive breastfeeding should occur. In addition, maternal zinc 
supplementation starting daily at 10-14 weeks of gestation can improve fetal autonomic 
regulation as assessed at 54 months of age43. 
12 
 
 
Figure 3. The first 1000 days from conception to 2 years of age. Nutrients deemed to 
be important in aiding and alleviating under-nutrition and the adverse health effects 
that result are listed, along with predicted time periods of administration based on 
randomized clinical trials reviewed from the literature. 
1.1.1.3.2 Iodine 
Iodine is an essential component of hormones produced by the thyroid gland, thus, iodine 
deficiencies can affect all ages and the disorders that result are some of the most common 
human diseases44.  Severe iodine deficiencies in the fetus are known to lead to abortion, 
still birth, congenital anomalies, and perinatal mortality; while deficiencies in the neonate 
can increase infant mortality and endemic cretinism44. The recommended dietary intake 
of iodine for non pregnant women is 150 µg/day and increases to 250 µg/day when 
pregnant45, due to an increase in thyroid hormone production by the mothers and passing 
of iodine to the fetus for fetal thyroid hormone production46. A meta-analysis showed that 
children with iodine deficiencies had lower IQ’s by 13.5 points47, making iodine 
deficiencies a preventable cause of mental retardation. In fact, a study in China showed 
that the administration of iodine before the third trimester of pregnancy resulted in 
improved cognitive development of infants48. 
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1.1.1.3.3 Folate 
Folate is a water-soluble B vitamin that is involved in many bodily functions including 
purine and thymidylate biosynthesis, amino acid metabolism and formate oxidation49. 
Since purine and thymidylate are important in DNA and RNA synthesis and repair, a 
deficiency can have many devastating effects, especially for fetal development, which 
relies on this process. Folate supplementation is highly recommended during pregnancy 
and should be increased by an additional 200-300 µg/d of folic acid to supplement dietary 
folate in order to prevent deficiency49. In countries where the prevalence of anemia is 
high such as Asia, Thailand and Nicaragua, iron-folic acid supplementation has shown to 
be effective in reducing maternal mortality and increasing hemoglobin levels and should 
be regularly implemented in supplementation programs in Africa50. 
1.1.1.3.4 Vitamin A and D 
Vitamin D is a prohormone that can be synthesized from sunlight through the skin with 
the use of a derivative of cholesterol51. Vitamin D is essential throughout life and is 
important in the formation of bone. Maternal Vitamin D deficiency impacts fetal bone 
health and skeletal development, tooth enamel formation and general fetal growth and 
development52. In addition, the active form of vitamin D, 1,25-dihydroxyvitamin D 
promotes the production of the antimicrobial peptide cathelicidin by monocytes. Elevated 
levels of 1,25-dihydroxyvitamin D are also found in maternal and fetal cells of the 
placenta, however, its function at this location is unknown but it may aid in combating 
pathogens that could cause adverse pregnancy outcomes53. Studies have shown that 
Vitamin D supplementation from the 12th week of gestation onward, lead to mothers with 
greater weight gain and protein-calorie nutrition54 and infants with higher birth weights 
and weight gain then the unsupplemented group54,55. In addition, children of un-
supplemented mothers at three years of age have higher rates of defect in dental enamel 
formation56. Rickets is attributed to inadequate vitamin D intake and can affect infants 
and young children, with a peak incidence occurring between 3 and 18 months of age. 
Breast milk may not be a sufficient source of Vitamin D, so it is recommended that 
infants start to receive 400 IU/day of Vitamin D at 2 months of age and that this 
continues throughout infancy and adolescence52.  
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Vitamin A plays a number of important roles in the body including immune cell 
differentiation and proliferation, integrity of epithelial cells, vision and differentiation of 
the cornea, conjunctival membranes and photoreceptor cells of the retina57,58. Vitamin A 
deficiencies can also result in the reduction of the number of lymphocytes, natural killer 
cells and CD4+ T cell counts and can affect mucosal immunity by altering the integrity of 
the mucosal epithelia of the eyes, respiratory, gastrointestinal and genitourinary tracts58. 
In addition, vitamin A deficiencies are linked to higher rates of mortality and morbidity 
in young children with measles, respiratory infections and diarrhea. Three studies have 
shown that giving newborn infants a single 50,000 IU dose of vitamin A within several 
days after birth, reduces all cause mortality during the first 6 months of life by 15%59, 
22%60and 64%61. The effect of vitamin A supplementation in pregnant women from 
developing countries, however, is inconclusive. One study showed that weekly 
supplementation can decrease maternal mortality by 40%62, while others have shown no 
affect on maternal or infant mortality63-65. This indicates that especially in populations 
who are under-nourished, other micronutrient deficiencies could be a factor in preventing 
positive outcomes of a single nutrient supplement. Despite the inconclusive results of the 
benefits of vitamin A supplementation on maternal mortality, a recent study suggests that 
weekly vitamin A supplementation of pregnant women, may reduce the prevalence of 
BV, which is thought to be associated with pre-term birth as discussed below. The study 
was done in Bangladesh and pregnant mothers were given 25000 IU beginning in their 
first trimester and continuing to three months postpartum. This resulted in a 30-40% 
reduction in the incidence of BV as compared to the placebo66.   
1.1.1.3.5 Iron 
Iron deficiency is particularly prevalent in developing countries, with an estimated 24.8% 
of the world population affected67. Iron deficiency anemia (IDA) in children can cause 
suboptimal motor and mental development, which could potentially be irreversible later 
in life. A study comparing South African mothers who were non-anemic, anemic 
receiving daily iron supplementation and anemic receiving a placebo, showed that anemic 
mothers without supplementation displayed “negative mothering” characteristics and 
their children were developmentally delayed68. IDA is also responsible for 18% mortality 
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in maternal women due to low hemoglobin levels resulting in postpartum 
hemorrhaging69. Maternal iron supplementation has been shown to decrease preterm 
births, neonatal mortality70, long term mortality and reduce the number of low birth 
weight infants71. Iron found in milk of a healthy mother is sufficient for the newborn to 
sustain hematopoiesis for the first six months of life, thus the WHO recommends that 
women of reproductive age in developing countries receive weekly iron and folic acid 
supplementation, which increases to daily once pregnant69. 
1.1.1.3.6 Summary 
Many nutrients, especially zinc, iron, copper, folate, iodine and vitamin D are critical for 
the various stages of organ, vascular and skeletal growth72-75.  The rapid rate of growth of 
the brain in the third trimester and the early postnatal stage makes it vulnerable to an 
inadequate diet, with long-term implications for cognitive development72. It is this 
cognitive impairment, which is believed to be a major barrier to education and economic 
empowerment in many developing countries. A community-based, double-blind, 
randomized controlled trial of 676 children in Nepal, showed that iron/folic acid given 
pre-natally, and not iron/folic acid/zinc, or multiple micronutrients containing these plus 
11 other micronutrients or vitamin A alone, resulted in improved intellectual and motor 
function76. This emphasizes that it is not simply a case of administering multi-vitamins 
and nutrients to optimize pregnancy outcomes, but rather a selective supplementation that 
works best.  In fact, the optimal state may even require a more sophisticated and targeted 
approach with certain supplements being administered at times in the pregnancy to match 
specific developmental processes. For example, an animal study using rats, showed that 
maternal iron restriction initiated prior to conception and during the first trimester caused 
problems with auditory brainstem development, while iron restriction initiated early in 
the third trimester did not have the same effect77. Such windows of vulnerability most 
certainly exist for other parts of the developing fetus. 
The effects of under-nutrition on the mother, developing fetus and newborn infant are 
complex, and the timing of the deficiencies can add further dimensions to the issue. Thus, 
many organizations such as the WHO, The International Micronutrient Malnutrition 
Prevention and Control, the Bill and Melinda Gates Foundation, United Nation agencies 
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and the World Bank have launched nutrition strategies based on the first 1000 days to 
promote maternal and fetal health, mainly through micronutrient supplementation and 
education in proper nutrition. Thirteen highly cost-effective interventions have been 
proposed to combat under-nutrition in the first 1000 days of life and improve maternal 
malnutrition. These include promoting good nutritional practices such as breastfeeding, 
increasing intake of vitamins and minerals, micronutrient provision through food 
fortification and, therapeutic feeding for malnourished children with ready-to-use 
therapeutic food. The estimated cost to implement these interventions is approximately 
$11.8 billion annually, with about $1.5 billion coming from households financially able 
to pay food related expenses. Such efforts have the potential to succeed in order to 
permanently eradicate under-nutrition, but will involve continual funding. An ideal 
solution would be one that is self-sustaining; especially in developing countries where a 
large underlying cause of under-nutrition is poverty.  
1.2 Microbiome 
Microbiome is the term coined by Joshua Lederberg of Rockefeller University to define 
the complex community of commensal, symbiotic and pathogenic microorganisms that 
share and inhabit our body space. It is well known that the number of microbial cells that 
reside in and on the human body, outnumber our own cells. Furthermore, the number of 
genes encoded by the members of this ecosystem is estimated to outnumber the genes 
expressed by the cells of the body by a factor of 100 to 1. Due to the development of 
high-throughput DNA sequencing technologies, it has become feasible to study the 
structure, function and interaction of the microbiome with the human body, and studies in 
this area have become an important aspect of understanding health and disease. In 2008, 
the Human Microbiome Project (HMP) was launched to identify and characterize the 
diverse microbial communities that make-up our microbiome. In 2012, the HMP 
published a landmark paper that described these communities inhabiting 18 different 
body sites in 242 healthy men and women78.  The HMP found that each body site 
sampled was characterized by one or a few signature taxa with the less dominant taxa 
being highly personalized among individuals. However, despite this personalization, 
certain pathways expressed by bacterial community members were universal among 
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individuals and body habitats and the configuration at each site was quite distinct from 
those associated with disease perturbations.  For the purpose of this thesis, only three of 
the 18 body sites (gut, oral and vaginal) will be reviewed, along with the less 
characterized microbiome of human milk. 
1.2.1 Vaginal Microbiome 
As with all microbial communities residing on and within the human body, the vaginal 
microbiome exists in a delicate balance with the host. The host provides nutrients to 
support bacterial growth, while the resident microbes protect the host from the 
colonization by pathogenic organisms.  The composition of the ‘normal’ vaginal 
microbiome varies among women within the same ethnic group, as well as between 
women of different ethnic groups. Compared to the gut or oral microbiome, the vaginal 
microbiome has the least diversity78. From classic laboratory culturing techniques, it was 
believed that Lactobacillus was the characteristic organism of a healthy vaginal 
microbiome, further supported by the fact that members of this species produce lactic 
acid, thereby maintaining the vaginal pH between 3.5 and 4.5. Culture independent 
techniques have revealed that a healthy vaginal microbiome can be characterized by the 
dominance of one of four Lactobacillus sp., (L. crispatus, L. iners, L. gasseri or L. 
jensenni), but in a small portion of women, an apparently aberrant profile composed of an 
array of strict facultative anaerobes such as Atopobium, Prevotella, Sneathia and 
Mobiluncus can be found, despite a lack of infectious symptoms or signs79. Furthermore, 
studies have shown that American women of different ethnic backgrounds tend to have 
different community profiles. For instance, a Lactobacillus dominated vaginal 
microbiome is much more prevalent in Asian and Caucasian women who have a median 
vaginal pH of 4.2-4.4, while Hispanic and African American women have a higher 
prevalence of a non Lactobacillus dominated vaginal microbiome and a higher median 
vaginal pH of 4.7-5.079-81. This has lead to classification of the vaginal microbiota into 
five community state types in order to define a healthy vaginal microbiome in North 
American populations82. Furthermore, temporal investigations have revealed that women 
can fluctuate between different state types depending on the menstrual cycle, sexual 
activity and community state, indicating that these fluctuations may be associated with 
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increased susceptibility to disease82. Limited studies have investigated the vaginal 
microbiota profiles in healthy women from different geographical locations. One study 
investigating the vaginal microbiota of African women with HIV, found that the 
microbial profiles of healthy women could be grouped into two clusters dominated either 
by L. iners or L. crispatus83.When the delicate balance of the resident microbes in the 
vagina is disrupted, a range of various urogenital diseases could potentially result, such as 
BV, vulvovaginal candidiasis, pelvic inflammatory disease and sexually transmitted 
diseases including Chlamydia and HIV. Classically, BV has been characterized as a 
reduction in Lactobacillus in the vagina and a shift to a more mixed vaginal biota with 
increased Gardnerella vaginalis, Bacteroides spp., Mobiluncus spp., Mycoplasma 
hominis and Atopobium84,85. Clinical manifestations of BV include an increased vaginal 
pH, milky creamy discharge and a amine or fishy odor, although in certain cases these 
characteristics are absent84,86,87. Hummelen et al., found that BV in African women with 
HIV was characterized by four distinct profiles, dominated by Prevotella bivia, 
Lachnospiracease or a mixture of different species88. BV is also a major risk factor for 
pregnancy complications and pre-term birth, the extent of which will be discussed below.  
1.2.2 Oral Microbiome 
The oral microbiome is composed of a complex community of microorganisms. The term 
oral microbiome is defined as the microbial communities that are found on the teeth, 
gingival sulcus, tongue, cheeks, hard and soft palates and tonsils, all of which have a 
distinct species composition. There are six dominant phyla found in the oral cavity, 
Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Spirochaetes and 
Fusobacteria, with the most dominant genera being Streptococcus89. Sampling of oral 
cavities in different countries does not reveal geographical or ethnic differences in oral 
microbial community composition90. Certain resident members of the oral microbiota are 
responsible for disease affecting the oral cavity if conditions arise, which promote their 
overgrowth. For instance, dental caries occur when aciduric organisms such as 
Streptococcus mutans, Lactobacillus species, Bifidobacterium species and 
Propionibacterium species are able to over multiply in the presence of a low pH in the 
oral cavity91-93. Gingivitis is a periodontal disease, characterized by swollen, inflamed 
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gums, which results from the build-up of plaque on the tooth enamel. Plaque is composed 
of a biofilm of Gram positive and negative anaerobic species. These organisms are 
usually prevented from forming overly dense biofilms due to standard oral hygiene 
practices. The initial organisms involved in formation of the biofilms are Streptococcus 
spp. and Actinomyces spp., which bind to the deposition of salivary pellicle on the tooth 
surface94. Studies have shown that periodontal diseases can pose a significant risk factor 
to pre-term birth95, likely because of bacterial entry into the bloodstream and induction of 
inflammatory processes. 
1.2.3 Gut Microbiome 
Due to the abundance of microbes residing in the gut and ease of stool collection, the gut 
microbiome has been the most extensively studied in both disease and healthy states. 
From these studies a number of factors have been identified which influence the 
composition of gut microbial communities. Age is associated with changes in diversity, 
while diet, illness and antibiotic use also have effects 96-98. From the age of three, when 
the adult like bacterial profile develops, the microbiome remains relatively stable99 until 
old age (>65 years) when changes occur, characterized by a decrease in overall diversity 
within individuals and an increased variability between individuals of this age 
group100,101. Geography also influences the gut microbial profile of children and adults as 
shown by the identification of different enterotypes in the gut microbiota which are 
linked to differences in diet98,102,103. Enterotypes are distinct clusters of microbial profiles 
and metagenomes that are usually driven by species composition. Three enterotypes have 
been documented; Enterotype 1 which is abundant in Bacteroides, enterotype 2 abundant 
in Prevotella and enterotype 3 abundant in Ruminococcus104. Enterotype 1 has been 
attributed to individuals who consume diets high in protein and animal fats105, while 
enterotype 2 has been attributed to individuals who consume diets rich in carbohydrates, 
the later being commonly found in adults and children in countries in West Africa such as 
Malawi and in Venezuela, while enterotype 3 is less characterized98,102. Diet also has a 
profound impact on the microbiome, which will be discussed in more detail below. 
Family kinship also affects the composition of the gut microbiome, as members within 
the same family have a more similar bacterial community structure than individuals from 
20 
 
different families106. This familial relatedness has been observed in different countries 
and can be further characterized by the carriage amounts of specific organisms98,107. 
Moreover, pregnancy and route of delivery have been shown to create major shifts and 
affect the structure of the gut microbiome, which will be discussed in separate sections 
below. Disease and treatment can significantly affect the gut microbial composition. For 
example, antibiotic use can lead to destabilization of the microbiome as well as loss of 
particular bacterial species, which may not be recovered if perturbations continue108,109. 
Use of antibiotics can be especially damaging to pre-term infants who already have an 
altered microbial landscape as discussed below110. A number of diseases and disorders 
such as psoriasis111, asthma112, inflammatory bowel disease113,114, colorectal 
carcinoma115,116 and cardiovascular disease117 have also been associated with 
perturbations in the gut microbial landscape. Understanding these perturbations and their 
triggers have huge implications for the treatment and prevention of these diseases.  
Early gut microbial colonizers can exert physiologic, metabolic and immunologic effects 
well into adulthood99. Thus, if a mother is under- or over-nourished, she could be passing 
on her potentially altered and diseased microbiota to her infant, thereby contributing an 
additional factor that may increase her child’s chances of developing metabolic disorders 
later in life. Indeed, studies have shown there are a number of factors that can influence 
the composition of the infant’s microbiome.  
1.2.4 Development of the Infant Microbiome 
It has traditionally been believed that the developing fetus is microbiologically sterile and 
the first exposure to organisms occurs during delivery. However, recent studies have 
detected microbial species in the umbilical cord blood, amniotic fluid, meconium and 
placental and fetal membranes 118, suggesting that the fetus may be exposed to microbes 
at the beginning of pregnancy. Exactly how this exposure occurs as well as how it 
influences the developing fetus still needs to be explored. However, it is postulated that 
rather than colonizing the developing fetus, this initial exposure plays a role in early 
immune development. A recent study investigating the meconium of term and preterm 
infants, found that gestational age was negatively correlated with the taxa Enterobacter, 
Enterococcus, Lactobacillus and Tannerella, all of which create inflammatory responses 
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119
. A number of studies have given support to the belief that delivery mode has an effect 
on initial microbiome colonization in infants. Sampling of multiple body sites (skin, oral 
cavity and meconium) on infants born either vaginally or by cesarean section, found that 
the dominant taxa across all sites were dependent on the mode of delivery with 
Lactobacillus and other vaginal organisms being dominant in vaginally born infants, and 
Staphylococcus spp. being dominant in infants delivered via cesarean120. Furthermore, the 
bacterial community profiles in infants delivered by cesarean are less diverse than in 
infants delivered vaginally121,122 and the former can persist well past birth and up to two 
years of age122. Colonization by Bacteroidetes is also delayed in infants born by cesarean 
which could have implications in proper immune development 122-124. Evidence exists 
that pre-term infants (gestational age of less than 37 weeks) develop a different gut 
microbiome than term infants. The methods used to assess the microbial profile in the 
preterm population differ across studies, thus, further investigations using standardized 
high-throughput sequencing techniques need to be performed in order to confirm these 
differences. Despite this, studies have shown decreased diversity of gut microbial profiles 
in preterm infants as compared to term. In addition, preterm infants who develop 
necrotizing enterocolitis have a dominance of Proteobacteria and increased abundance of 
Enterobacteriaceae and S. epidermidis125-127.  
Assembly of the gut microbiome and understanding its development from birth to 
establishment of the adult like configuration is of great interest due to the influence of the 
microbiome on the human host. If the development of the microbial gut communities is 
understood in health and disease, then specific interventions for promoting a healthy 
microbiome throughout the lifetime of the host could be conceived. Three important 
studies have been conducted that provide a greater insight into the initial gut microbial 
assembly. Two studies investigating multiple infants found that variability in the overall 
gut microbial profiles between infants was greater than the variability observed between 
adults and that this persisted from birth up until either the establishment of the adult like 
configuration at three years of age98 or until the study was completed at one year of age96. 
Furthermore, differences observed in the profiles of the adult gut microbiota due to 
geographic location were also found in the gut microbiota of their infants98. A detailed 
study following one infant over 2.5 years found that illness and antibiotic use as well as 
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weaning produced significant shifts in the relative abundance of observed operational 
taxonomic units (OTUs)97. These data suggest that differences in development of an 
infant’s gut microbiota is influenced by environmental factors96,97. 
The typical colonizers of the infant gut are the facultative anaerobes Staphylococcus, 
Streptococcus and Enterobacteria96,128. It is assumed that these bacteria consume oxygen 
and create an anaerobic environment into which other species enter and take over from a 
few days after birth up to the introduction of solid food. The dominant organisms at this 
time are Bacteroides, Bifidobacterium and Clostridium128. However, these changes are 
dependent on whether the infant receives formula or breast milk. 
1.2.4.1 Microbiome of Human Milk 
Human milk is a rich source of molecules and microbes that provide nutrition to the 
infant, as well as aid in its immune development129. During the first six months of life, 
the microbial community of human milk likely has the most influence on the composition 
of the infant’s gut microbiota. On average, infants consume approximately 788 mL of 
milk per day, which contains approximately 1 x 106 colony forming units per milliliter130. 
This means that infants can ingest close to 1 million bacteria per day. The major 
phylotypes found in breast milk are Staphylococcus and Streptococcus, presumably 
originating from the skin and infant saliva respectively. Other organisms have been 
detected such as Serratia, Ralstonia, Prevotella and Corynebacterium, with Lactobacillus 
and Bifidobacterium also being detected, but at a lower abundance131-133. Besides aiding 
in immune development, the bacteria in human milk may also play a protective role in the 
infant gut. A trial involving formula milk and formula milk supplemented with 
Lactobacillus fermentum (a human milk commensal), showed that infants fed the formula 
milk supplemented with L. fermentum had a lower incidence and severity of infections 
such as upper respiratory tract infections and gastrointestinal infections as compared to 
the control134. Other studies have shown that this protective effect may be accomplished 
by competitive exclusion and production of antimicrobial compounds135,136. In addition, 
the oligosaccharides found in breast milk are extremely important and evidence has 
shown that they positively select for bifidobacteria and lactic acid producing species in 
the healthy infant gut137,138. The important influence of human milk on the infant gut 
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microbiota has been shown in studies comparing breastfed and formula fed infants. 
Bifidobacteria are dominant in the gut microbiota of breastfed infants, while formula fed 
infants have higher proportions of Bacteroides and Clostridium species139,140. 
1.2.5 Maternal Microbiome and Healthy Pregnancy 
As discussed above, the maternal microbiome could have major implications on the 
developing fetus. So far, only changes in the gut and vaginal microbiome during a 
healthy pregnancy have been studied. Only two studies have used high throughput 
sequencing technologies to monitor the vaginal microbiome during a healthy pregnancy. 
The first looked at a total of 24 women, 16% Hispanic American, 13% African American 
and the rest Caucasian, and no distinction was found between the ethnic groups141. 
Sampling occurred a maximum of 3 times during the pregnancy, but in the final analysis, 
all samples were grouped together. This study found that the vaginal microbiome of 
pregnant woman had distinct community profile clustering compared to the vaginal 
microbiome of non-pregnant women, suggesting changes due to hormonal alterations. 
This study also found an overall reduction in species richness and diversity with an 
increased abundance of L. iners, L. crispatus, L. jensenni and L. johnsonni141. The second 
study performed a longitudinal analysis on the vaginal microbiome of 22 healthy 
pregnant women, analyzing a median of 6.5 samples per subject from recruitment to 
birth142. The investigators also collected serial samples from non-pregnant women for 
comparison and found that the abundance of L. vaginalis, L. crispatus, L. gasseri and L. 
jensenii were enriched in pregnant women who delivered at term compared to non-
pregnant woman. Furthermore, they also observed in pregnant women a lower abundance 
of 22 phylotypes found in non-pregnant individuals. The researchers noted that the 
vaginal microbiome in healthy pregnant women was more stable over time than non-
pregnant women, perhaps due to cessation of the menstrual cycle and very few pregnant 
women had a non Lactobacillus dominated community type. Of further interest, the 
majority of women both in the pregnant and non-pregnant cohorts were African 
American, and as previously reported by Ravel et al., community state types dominated 
by Lactobacillus are less common in non-pregnant individuals of this ethnic group79. This 
could indicate that physiological changes occurring during pregnancy may select for the 
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preferential growth of Lactobacillus, independent of the woman’s community state type 
prior to conception. 
Only two studies have been conducted using high-throughput sequencing technologies to 
investigate the differences between the gut microbiota of pregnant and non-pregnant 
states. The first study compared the fecal microbiomes of women in their first trimester, 
third trimester and one month post partum143. The researchers found an expansion in β 
diversity (variability between samples) with gestational age and an increase in the relative 
abundance of Proteobacteria and Actinobacteria in over 50% of the study subjects, 
between the first and third trimesters. Furthermore, there was a reduction in the number 
of OTUs as women progressed to their third trimester, and the changes observed were 
still present at 1-month post partum. Koren et al., also observed characteristics of 
metabolic inflammation in the third trimester women, and studies in germ-free mice led 
them to predict that the changes in microbial profiles drove this outcome144. However, the 
microbiota observed in the third trimester differed from women with metabolic syndrome 
in that the relative abundance of Firmicutes and Bacteroidetes remains the same in 
pregnancy, while it changes in obesity144. Another interesting finding was that the infant 
gut microbial profile at one month was more similar to the mother during the first 
trimester than the third. Unfortunately, infant stool samples were not collected at birth to 
determine if the microbial profile at this time was similar to the mothers gut microbial 
profile observed during the third trimester. A second study, investigated the gut microbial 
profile of pregnant women in their third trimester and one-month post-partum145. They 
found that the microbial profile was stable between the two time points, as found by 
Koren et al.144, and they also observed an increase in short chain fatty acids and 
calprotectin, indicative of metabolic changes and low grade inflammation, again 
consistent with the previous findings. However, Jost et al. 145 did not observe the same 
changes in the gut microbial profile in the third trimester as Koren et al. 144, perhaps due 
to different methodologies, as Koren et al. 144 amplified the V1V2 variable region of the 
16s rRNA gene, while Jost et al. 145 amplified the V5V6 region. 
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1.2.6 Dysbiosis of the Maternal Microbiome During Pregnancy and 
Adverse Outcomes 
There is evidence that perturbations in the microbiome contribute to adverse pregnancy 
outcomes. This is especially important in developing countries where access to proper 
medical care during pregnancy is limited and assessment of microbial shifts is not 
commonly practiced. The clearest link between alterations in the microbiome and adverse 
pregnancy outcomes is in relation to changes of the vaginal microbiota. Recently, a study 
found decreased diversity of the vaginal microbiome was related to occurrence of pre-
term birth146. However, limitations of this study included a small sample size and the use 
of Sanger sequencing which limited the amount of samples sequenced and reads 
produced. Thus, more studies using cost-effective high-throughput sequencing 
technologies should be performed to validate this. Another clear connection between 
adverse pregnancy outcomes and dysbiosis of the vaginal microbiome is due to BV. A 
number of studies and a meta-analysis published in 2003, have shown that BV early in 
pregnancy increases a woman’s risk of having preterm labor and spontaneous abortion 
147-149
. The prevalence of BV in developing countries such as Tanzania has been 
monitored. In a study conducted in 2013, 28.5% of 284 women delivering at a tertiary 
care hospital in Mwanza, Tanzania had BV at time of delivery150. The rates of BV in 
Africa are not necessarily higher in proportion than in Canada as BV prevalence in sub-
Saharn Africans does range from 6.4% in Burkina Faso to as high as 58.3 % in South 
Africa151. However, the rates of BV in non-pregnant Tanzanian women is between 20-
30% which is in stark contrast to the BV prevalence in Canada at approximately 7.1%151. 
Thus, the increased incidence of BV can contribute an additional factor to the high rates 
of adverse pregnancy outcomes for mothers in developing countries.  
Furthermore, as discussed above, obese and overweight mothers are at risk of 
complications during pregnancy and delivery, and their infants are at a greater risk of 
disease, both in infancy and later in life. Differences have been observed in the microbial 
composition of the gut between overweight and normal weight mothers152,153 and changes 
in this composition have also been associated with excessive weight gain during 
pregnancy152,153. Interestingly, pre-pregnancy weight and weight gain during pregnancy 
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affect the mother’s gut microbial composition which has an additional effect on the 
microbiota development of the infants154. This could indicate that altered gut microbial 
configurations due to nutrition or disease could be passed on from mother to infant, 
thereby providing yet another factor in adverse outcomes for the newborn. The potential 
to correct adverse development patterns in infants, through modulation of the mothers 
microbiome has been suggested155. Probiotic supplementation of mothers four weeks 
prior to delivery and six months postnatal, appeared to reduce excessive weight gain in 
their children during the first year of life155. 
1.2.7 Microbiome and Diet 
The beneficial role that the gut microbiome plays in helping its human host utilize 
nutrients from the diet that would other wise be unattainable, has been known for some 
time. Due to the obesity epidemic plaguing North America and the trouble that obese and 
overweight individuals have in losing their excess weight, researchers questioned if it 
was something more than just food consumption perpetuating the disease. The first 
studies to spark an interest in the relationship between obesity and the gut microbiota 
came from mice. In 2004, Backhed and co-workers found conventional mice had 42% 
more body fat then germ free (GF) mice, despite the conventional mice consuming 29% 
less than their GF counterparts156.  They also found that if the caecal contents of 
conventional mice were spread on the fur of young GF mice, their total body fat 
increased by 57% after 14 days, but did not result in a difference in total body weight 
from the conventional mice. Then in 2005, Ley and coworkers analyzed the 16S rRNA 
gene sequences of the microbiota from lean and obese mice (who had a mutation in the 
leptin gene to produce obesity) and found that obese mice had a significant reduction in 
the number of Bacteroidetes as compared to lean mice and a greater proportion of 
Firmicutes157. Instead of amplifying the 16S rRNA genes, the researchers performed 
shotgun sequencing of the entire microbiota obtained from the obese and lean mice and 
found the same trend characterized in their previous study. They also found that the obese 
microbiome was enriched for enzymes involved in the breakdown of indigestible dietary 
polysaccharides as well as for transport and generation of the end products of 
fermentation. Furthermore, they observed that the feces of obese mice had significantly 
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less energy than that of lean mice and when GF mice were transplanted with the 
microbiota from the caecum of obese and lean donors, the recipients of the obese 
microbiota had more Firmicutes and 47% more body fat than the recipients of the lean 
microbiota, who only had a 27% increase in body fat158. Studies then shifted to human 
populations, and a landmark paper showed that changes in diet and weight loss can also 
promote changes in the gut microbial composition. This study showed that members from 
the phyla Bacteroidetes were lower in individuals who were obese, but increased with 
weight loss independent of whether or not an individual was on a carbohydrate reduced 
or fat reduced diet159. By analyzing the gut microbiota in obese and lean monozygotic 
and dizygotic twin pairs, the same group found that obesity is not only linked with the 
microbial composition but also with the expression of a set of “core” obesity associated 
genes within the microbiome106.  
Due to the incredible differences observed between a normal and obese gut microbiota, 
studies shifted to determine whether standard dietary factors might also produce these 
major changes. Specifically, one of the earliest indications that dietary factors within 
ethnic groups can shape the microbiome was observed in the Japanese population, where 
on average 14.2 g of seaweed is consumed daily. It was found that a common gut 
symbiont, Bacteriodes pleibus, has acquired genes for prophyranases and agarases 
needed to digest the polysaccharides from seaweeds, whereas these genes are absent from 
North American metagenomes103. Yatsunenko et al.’s (2012)98 study then showed 
differences between the composition of Western populations gut microbitota and those of 
Malawians and Amerindians. These differences were attributed to differences in diet, as 
both Malawians and Amerindians consume diets high in maize and plant derived 
polysaccharides, while Westerners consume diets higher in fats and fructose corn syrup. 
This difference in gut microbiome composition of individuals from developing countries 
and those from developed countries was also noted by De Filippo et al. 102. They 
compared the fecal microbiota of European children to that of children from Burkina 
Faso. The diets of the latter were low in fat and animal protein and rich in fiber, starch 
and plant polysaccharides and were mainly vegetarian. The researchers found that the 
microbiota of children from Burkina Faso was dominated by Prevotella (also observed in 
the Yatsunenko study), Xylanibacter and Treponema, while that of children from Europe 
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had higher proportions of Firmicutes102. Yet another study supported the findings of 
Yatsunenko and De Filippio, showing that diet had a greater effect on gut microbial 
composition than ethnicity160. In this study, Prevotella dominated the gut of native 
Africans, while the gut of African Americans was dominated by Bacteroides160. 
Furthermore, saccharolytic fermentation was lower, proteolytic fermentation was higher 
and secondary bile acid production was higher in African Americans, likely due to how 
their gut microbiotas processed their high meat and fat diet160. Differences in diet are also 
reflected in the gut microbiotas of vegans and omnivores, as strict vegans have 
significantly lower counts of Bacteroides spp., Bifidobacterium spp., Escherichia coli and 
Enterobacteriaceae spp., than omnivorous controls161. Furthermore, as observed with 
obese individuals, switching between diets can also produce changes in the composition 
of the gut microbiome as well as in the metabolic pathways and genes expressed by the 
different communities162. These changes can occur within twenty four hours of switching 
diets, but the core enterotype remains stable105,162,163. This could imply that in order to 
make long lasting changes to the microbiome, long-term changes in dietary habits must 
be instigated.  
Very few studies have been conducted investigating the microbiome of under-nourished 
individuals. Two studies released in 2011 compared malnourished children in India to 
nourished controls. Although both utilized high-throughput sequencing techniques, their 
methodology differed from standard practice and both studies were limited by small 
sample size164,165. Nevertheless, a difference in the gut microbiota composition of 
malnourished children was found to differ from that of the healthy controls in both 
studies. An in depth analysis conducted in 2013 on the gut microbiome of twin pairs 
discordant for Kwashiorkor (a form of protein malnutrition) revealed that the gut 
microbiome of children with Kwashiorkor failed to follow the same development 
trajectory to an adult-like configuration as observed in their healthy twin counterpart, 
even with a therapeutic food intervention166. The power of this study lay in an adjoined 
gnobiotic mouse model used to assess the effect of the Kwashiorkor microbiome on 
microbial community structure, metabolism and host-microbial co-metabolism. Mice 
were transplanted with fecal microbiota samples from twins with Kwashiorkor and co-
twins without Kwashiorkor and fed a diet modeled after that consumed by Malawians. 
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Greater weight loss was observed in the mice transplanted with the Kwashiorkor 
microbiota, but if the mice were fed a standard chow diet they maintained their weight 
and if they were fed a therapeutic food their weight rapidly increased166. There were also 
observed differences between the community profiles of mice with the Kwashiorkor 
microbiota and these profiles shifted with the introduction of the therapeutic food166. 
1.3 Probiotics 
The definition of probiotics introduced by the Food and Agriculture Organization of the 
United Nations and the WHO is “live microorganisms which when administered in 
adequate amounts, confer a health benefit on the host.”167.The benefits of fermented 
foods date back over 900 years, but the observations of Elie Metchnikof are regarded as a 
stepping stone to the renewed interest in the field. He believed that lactic acid bacteria in 
fermented milk, helped prolong life by displacing toxic bacteria in the gut, caused by 
aging. The book he wrote on the subject168, inspired a Japanese scientist, Minoru Shirota, 
to be the first to culture a strain of Lactobacillus casei for promoting human health. 
Shirota then went on to produce the world’s first probiotic product in 1935, a fermented 
milk product called Yakult, which is still being used today. Most of the organisms used in 
probiotic products and studied today are from the genera Lactobacillus and 
Bifidobacterium, because of their history of safe use. Probiotics can be strain specific in 
their action169-171, for example in a study investigating the effects of two Lactobacillus 
fermentum strains on the intestinal barrier integrity following hemorrhagic shock, only 
one strain was found to reduce endotoxin levels and bacterial translocation using a 
hemorrhagic shock model in rats169.  For other conditions, however, a mixture of different 
strains can be therapeutic such as in the treatment of necrotizing enterocolitis in pre-term 
infants172.  
For many probiotics, the mechanism of action is still poorly understood as it can vary 
from strain to strain and depend on route of administration and dosage. Overall, 
probiotics are thought to enhance the epithelial cell barrier function in the gut, thereby 
protecting from pathogen invasion and inflammation173,174, promote immunity through 
production of antibodies and reduction of inflammation175-177, as well as act as anti-
microbials through secretions of antimicrobial peptides and compounds178,179. Probiotics 
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have been shown to aid in the treatment of acute infectious diarrhea180, irritable bowel 
syndrome181,182, necrotizing enterocolitis in preterm infants183,184, cardiovascular 
disease185, and recurrent urinary tract infections186,187, vulvovaginal candidiasis188 and 
BV189. All of these observations make probiotics a desirable therapeutic agent for the 
developing world, yet few products are available or affordable in developing countries. 
Thus, simpler and sustainable means of introducing probiotics are needed.  
Dairy foods are the most common delivery system for probiotics as the milk acts as a 
buffer to ensure the survival of probiotics during fermentation and storage271. Yogurt is a 
popular food product that is one such dairy food used as a delivery system for probiotics. 
It provides a suitable option for bringing probiotics to developing countries as it is simple 
to make and is stable at room temperature, the later being especially important if 
electricity is restricted or fridges are not available. Furthermore, the normal yogurt 
cultures Streptococcus thermophiles and Lactobacillus delbreukii subspecies bulgaricus 
do not survive in the intestinal tract272. In 2003 a group of faculty and staff at Western 
University decided to try and have local women in Tanzania develop and distribute 
probiotic yogurt to individuals suffering from HIV/AIDS. The driving force was the gut 
and immune benefits of the probiotics, the empowerment of women and the self-creation 
of a nutritious therapeutic food. From this, Western Heads East was formed, a project that 
trains and empowers women’s groups to produce and distribute probiotic yogurt using 
Lactobacillus rhamnosus GR-1, in Mwanza, Tanzania 190-192. Since the projects 
implementation in 2004, 10 kitchens have emerged in the Mwanza region (Figure 4) and 
the project is spreading to Kenya and Rwanda193. L. rhamnosus GR-1 was originally 
isolated from the urogenital tract of healthy women273. Since then it has been shown to be 
a beneficial and safe probiotic in a number of studies including women’s vaginal 
health274-276, supporting immune function in HIV/AIDS individuals277 and more recently 
a study was released showing L. rhamnosus GR-1 supernatant could attenuate 
lipopolysaccharide-induced inflammation and pre-term birth in a mouse model278. L. 
rhamnosus GR-1 has also been shown to colonize the intestinal tract279 and our lab has 
shown that it can also sequester heavy metals such as mercury in vitro (un-published 
data). Furthermore, it has been suggested that probiotic food products contain at least 106 
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colony forming units (CFU)/100g280 and it has been shown that L. rhamnosus GR-1 can 
maintain these counts in yogurt for up to a month after inoculation281.  
 
Figure 4: Location of Western Heads yogurt kitchens in the Mwanza region of 
Tanzania. 
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1.4 Moringa 
The milk used to make probiotic yogurt provides animal fat, protein and other nutrients 
that otherwise may be unattainable in the limited diets of poor rural populations. 
However, milk is lacking in important nutrients such as iron, zinc and vitamin A, which 
are beneficial during pregnancy. Moringa oleifera could be an option for a sustainable 
source of micronutrients in developing countries, as it is a highly nutritious, fast growing 
deciduous tree native to northern India, Pakistan and Nepal. It has also been successfully 
cultivated in all tropical and sub tropical regions of the world, such as Africa and 
especially those regions most ravaged by malnutrition (Figure 5).  
 
Figure 5: Areas of the world where Moringa has been successfully cultivated and 
grows natively compared to areas of the world ravaged by under-nutrition. 
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It is commonly referred to as either the ‘drumstick tree,’ or the ‘horse radish’ tree in 
English and in swahili, it is called ‘Mlonge.’ Moringa can grow to between 5 and 10 m in 
height and is drought tolerant and viable from sea level to an elevation of 1400 m 194. 
Most of the tree is edible and the fruits (pods), leaves (Figure 6), flowers, roots and seed 
oil have been used as traditional medicines, while recent studies have been investigating 
its use as a potential cancer therapy drug195,196. The leaves are extremely nutrient rich 
(Table 1), and when dried they can be added to a number of different foods like yogurt, 
with very little change to the flavor197. Knowledge regarding the many benefits of 
Moringa has been starting to spread to areas of Africa. A survey done in Nigeria found 
that a number of ethnic groups use Moringa as a food source as well as a medicinal 
treatment for various ailments including HIV/AIDS198. A second study in Zimbabwe 
found that 68% of individuals on antiretroviral therapy had taken Moringa oleifera, due 
to advice from family or community members199.  Despite the knowledge of its health 
benefits, it is still widely underused and understudied. The addition of Moringa leaf 
powder to probiotic yogurt produced by the Western Heads East Kitchens provide a 
means for us to examine its nutritional value in pregnant women in Mwanza, Tanzania197. 
Although the addition of Moringa reduces the sensory properties of the yogurt it is not 
disliked and the combination of Moringa and probiotic yogurt, could have major success 
if marketed as a health product.  
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Figure 6: Moringa oleifera tree (A) and leaves (B) growing on the grounds of a 
community center in Mwanza Tanzania. 
Table 1: Micro and macronutrient properties contained in 100 grams of dried 
Moringa oleifera leaves. 
Nutrient Amount 
Calories (kcal) 
Protein (g) 
205.0 
29  ± 6 
Fat (g) 8  ±2.5 
Carbohydrates (g) 38  ± 7 
Fibre (g) 10  ± 3 
Minerals (g) 11 ± 2.2 
Calcium (mg) 1924 ± 288 
Cooper (mg) 1.0 ± 0.2 
Iron (mg) 28 ± 6 
Potassium (mg) 1384 ± 420 
Magnesium (mg) 422 ± 52 
Phosphorus (mg) 267 ± 49 
Manganese (mg) 8.4 ± 2.4 
Zinc (mg) 2.5 ± 0.6 
Vitamins Amount 
Vitamin A (IU) 15620 ± 6475 
Vitamin B1 – Thiamin (mg) 2.6 
Vitamin B2- Riboflavin  (mg) 20.5 
Vitamin B3- Nicotinic  Acid (mg) 8.2 
Vitamin E – Tocopherols Acetate (mg) 113 
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1.5 Purpose and Aims 
The health and nutritional status of a mother during the first 1000 days of life of her 
infant has major effects on the development and lifelong health of that child. As 
discussed above, evidence indicates that the gut micobiome is altered in individuals who 
are obese/overweight but the microbiome of individuals who are under-nourished has 
barely been studied. Although under- and over-nutrition are a global issue and can result 
in adverse pregnancy outcomes, under-nutrition is not as prevalent in developed 
countries, thus we decided to perform a study of the microbiome of under-nourished 
pregnant women in Tanzania in order to determine whether the microbiome of women in 
their second trimester differs based on their nutritional status. It was hypothesized that a 
difference in the microbiome would be observed, especially in the gut. Adequate intake 
of essential nutrients has been shown to improve birth outcomes and continued nutrition 
after birth has been shown to improve the health status of children. The microbiome is a 
compounding factor that affects the health status of an individual. Passage of an adverse 
microbiome from mother to infant can also effect the development and life long health of 
that infant. Probiotic yogurt has been shown to have many beneficial effects to those who 
consume it. The ease of producing this yogurt in rural settings in Mwanza, Tanzania 
made it an excellent candidate for nutritional interventions in developing countries. Thus, 
the current study also set out to determine if supplementation of mothers with probiotic 
yogurt containing Moringa would have an effect on either the mother’s health status or 
birth outcomes. Moringa contains a number of nutrients such as zinc and vitamin A that 
are important for pregnant mothers, especially more so for mothers in resource poor 
settings (see Table 2 and the discussion above), thus, it was also hypothesized that 
combining Moringa with the benefits of probiotics could improve birth outcomes and the 
health status of at risk populations. Finally, fish is a staple food among individuals living 
in Mwanza and the Mwanza region is home to a number of large gold mines that leach 
mercury into the soil and lake. In vitro studies in our lab have shown that the probiotic 
strain Lactobacillus rhamnosus GR-1 has the ability to sequester mercury, thereby 
providing evidence that it could be beneficial in vivo for protecting against heavy metal 
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exposure. Due to poverty, women in rural areas of Mwanza cannot afford to change their 
diet and fish is among the cheaper sources of protein. Thus, it was hypothesized that 
consumption of probiotic yogurt during pregnancy could protect against mercury 
exposure and absorption. 
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Chapter 2  
2 Materials and Methods 
2.1 Human Study in Mwanza, Tanzania 
This pilot study was designed to investigate the microbiome of undernourished, 
nourished and obese/overweight pregnant woman and to determine if micronutrient 
enriched probiotic yogurt supplementation altered the microbiota profiles and/or 
improved pregnancy outcomes. 
2.1.1 Study Location and Ethics Statement 
This study was organized with assistance from the National Institute of Medical Research 
(NIMR) and Nyerere Dispensary in Mwanza, Tanzania.  The study was conducted in two 
locations in Mwanza. Sample processing and storage was done at NIMR, while 
participant recruitment and visits and sample collection were carried out at Nyerere 
Dispensary in Buswelu, a sub-rural municipality located 30 minutes from Mwanza 
(Figure 7). Upon completion of the study, all samples were shipped to Canada on dry ice.  
The study protocol was approved and received ethical clearance from both the Ministry 
of Health in Tanzania (Appendix 2) as well as from the Health Sciences Research Ethics 
Board at Western University (Appendix 1). Prior to sample collection, participants signed 
a consent form after having had the study and procedures fully explained to them in 
Swahili. Those who could read were given a copy of this consent form, also in Swahili, 
which outlined the study and procedures (Appendix 3).   
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Figure 7: Location and relative distance of study locations in the Mwanza region of 
Tanzania  
2.1.2 Study Population and Recruitment 
The antenatal nursing staff at Nyerere Dispensary were trained to screen women 
attending the antenatal clinic. Screening included standard antenatal assessment, as well 
as completion of an Eligibility Questionnaire, which included an additional assessment of 
the woman’s nutritional status (Appendix 4). Women were invited to meet the research 
staff if they met the inclusion criteria of being between 12 and 24 weeks pregnant and 
being between 18 and 40 years of age. Consented participants were designated either 
nourished, under-nourished or obese which were defined based on a nurses assessment, 
as well as mid-upper arm circumference (MUAC) measurements and deviations from the 
expected weight based upon height and gestational age as predicted by Gueri et al. 
(1982)200. Participants who were defined as under-nourished and nourished were 
randomly assigned to receive Moringa supplemented probiotic yogurt. This resulted in 
five groups; under-nourished (UN), under-nourished receiving probiotic yogurt 
supplemented with Moringa (UNP), nourished (N), nourished receiving probiotic yogurt 
supplemented with Moringa (NP) and overweight/obese (O).  
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2.1.3 Defining Nutritional Status 
In resource poor settings, pre-pregnancy records of weight and other health indicators are 
not kept. Defining nutritional status is commonly based upon body mass index (BMI), 
calculated from a non-pregnant weight measurement in kilograms and height in meters. 
Since women were recruited in their second trimester, defining their nutritional status 
based on BMI could not be done. Gueri et al. (1982) constructed a table of weight-for-
height based on week of pregnancy200, and this along with the MUAC, was used to 
determine nutritional status and group placement. The nursing staff at Nyerere dispensary 
determined the gestational age based upon last menstrual period and symphysis fundus 
height. They also measured height within 1 cm. Weight was measured in kilograms using 
an analogue scale.  Furthermore, the MUAC of the participants was measured to the 
nearest millimeter using a tape measure. There is no universal MUAC cut-off value for 
pregnant women in resource poor settings that are a reliable indicator of adverse 
pregnancy outcomes201.  Studies on various populations have shown that MUAC 
measurements between 21.0 cm and 24.0 cm can be associated with pre-term delivery 
and intra-uterine growth restriction (IUGR), resulting in low birth weight infants (LBW) 
or SGA infants201. Thus, an MUAC of less than 23.5 cm was arbitrarily set as an 
indicator of under-nourishment and an MUAC greater than 36.0 cm was set as a cut-off 
for determining over-nourishment. From the tables constructed by Gueri et al (1982)200, 
height and gestational age were used to determine the expected weight. If the actual 
weight deviated from the expected weight by 90% or less, then an undernourished 
classification was assigned. If the actual weight deviated from the expected by 110% or 
greater, then an over-nourished classification was assigned. 
2.1.4 Preparation and Consumption of Moringa Supplemented 
Probiotic Yogurt 
Participants in the supplementation group received 250 mL of yogurt six days a week. A 
trained study driver, who was instructed to observe the participants drink the yogurt in 
order to ensure compliance, delivered the yogurt to the participants. Furthermore, in order 
to monitor consumption, a detailed log book was kept by the driver for each day of 
delivery and participants receiving the yogurt were given unique tokens, which they were 
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instructed to give to the driver for each cup of yogurt they received. Upon delivery, the 
driver added 1 tablespoon of Moringa (approximately 4.3 grams) to each cup (see Table 
2).  
The yogurt was prepared daily at a Western Heads East Community Kitchen. Women at 
the community kitchen were trained to ensure proper yogurt preparation. Seven liters of 
fresh cow’s milk was boiled in a stainless steel pot over coals for 30 minutes, before 
being removed and cooled by continual stirring to approximately 30oC. Once the milk 
was cool, it was transferred to a clean plastic container and approximately 140 mL of 
store bought plain yogurt was used as a starter culture and was stirred in, along with 280 
mL of Lactobacillus rhamnosus GR-1 milk culture. The container was then sealed and 
left to incubate overnight before being put in the fridge the following morning. Samples 
of the yogurt were collected weekly to monitor the number of GR-1 CFU/mL in the final 
yogurt product.  
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Table 2: Nutritional content of 250 mL yogurt, with 4.3 grams of Moringa 
Nutrient 
Amount in 250 mL 
Yogurt 
Amount in 4.3 
grams Moringa 
% of RDI for 
Pregnant 
Women* 
Protein (g) 8.75 1.2 13 
Fat (g) 8.25 0.344 - 
Carbohydrates (g) 11.75 1.634 8 
Fibre (g) - 0.43 2 
Minerals (g) - 0.473 - 
Calcium (mg) 302.5 82.73 39 
Copper (mg) - 0.043 4 
Iron (mg) - 1.204 4 
Potassium (mg) 387.5 59.5 10 
Magnesium (mg) 30 18.12 14 
Phosphorus (mg) 237.5 11.48 36 
Manganese (mg) - 0.36 72 
Zinc (mg) - 0.108 1 
Vitamins    
Vitamin A (µg retinol) 67.5 201.5 35 
Vitamin B1 – Thiamin 
(mg) 
- 0.112 8 
Vitamin B2- Riboflavin 
(mg)  
0.25 0.882 81 
Vitamin B3- Nicotinic 
Acid (mg) 
0.25 0.353 3 
Vitamin E – 
Tocopherols Acetate 
(mg) 
0 4.86 32 
*RDI: Recommended Dietary Intake. This was calculated from the Canadian dietary 
references, as Tanzania does not posses their own standard guidelines. 
2.1.5 Preparation of Lactobacillus rhamnosus GR-1 Milk Cultures 
Two liters of Lactobacillus rhamnosus GR-1 milk cultures were prepared each week at 
NIMR to be used for the production of the probiotic yogurt. GR-1 stock cultures were 
maintained using de Man, Rogosa and Sharpe (MRS) broth and MRS agar (Difco).  Each 
week an overnight culture of GR-1 in MRS grown at 30oC in a sealed test tube was used 
to inoculate 1 liter of fresh cow’s milk in a 1 liter glass screw top bottle, sterilized at 
121oC for 15 minutes.  The GR-1 cultures in milk were then incubated for 24 hours at 
42 
 
30oC. Following incubation, a small sample was taken to determine the CFUs/mL in the 
milk cultures and bottles were stored in a fridge until delivery to the kitchen.  
2.1.6 Enumeration of Lactobacillus rhamnosus GR-1 
Enumeration of GR-1 CFUs/mL in the yogurt samples and samples from the GR-1 milk 
cultures was performed by drop plating. To begin, 100 µL of sample was suspended in 
900 µL of Phosphate Buffered Saline (PBS) (Sigma-Aldrich) and serially diluted. 
Triplicate 10 µL drops of the 10-9, 10-8, 10-7 and 10-6 dilutions were plated on MRS agar 
plates containing 50 µg/mL of Vancomycin (Sigma-Aldrich).  The plates were then 
incubated at 30oC in a candle jar for 24 hours before enumerating drops containing 
between 3 and 30 colonies to determine the final CFUs/mL in the yogurt and milk 
cultures. 
2.1.7 Pre-Birth Participant Visits and Sample Collection 
Participants were asked to return for follow-up visits every month until birth. Each 
received 5,000 tsh ($3.33) per visit as well as mandazi (African donut), banana, nuts and 
soda.  At each visit, a trained study translator administered a 48-hour dietary recall 
(Appendix 5). In addition, weight using an analogue scale and MUAC were measured 
using a tape measure to the nearest 0.1 kg and 1 mm respectively. The participants then 
visited the clinical officer who performed a physical exam and completed the clinical 
questionnaire (Appendix 6), which included measurement of the blood pressure, heart 
rate and general medical history. The clinical officer also swabbed the vagina with three 
CultureSwab polyster-tipped swabs (BD Biosciences). Two of the swabs were put into 2 
mL screw top polypropylene tubes (VWR) and their ends cut off and stored on ice in a 
cool box. The swabs were then transported to NIMR where they were stored at -20oC, 
before being shipped to Canada for microbial DNA extractions and metabolite analysis. 
The third swab was used to streak a glass microscope slide for Nugent scoring, which 
was conducted at NIMR. The two tubes and slide were labeled with a unique barcode and 
ID.  
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The participant then visited the lab technician who instructed them to collect a stool 
sample using a weigh boat and fecal collection container (VWR). The lab technician then 
used a small amount of the stool sample to perform microscopic analysis for parasites, 
the results of which were recorded in the clinical questionnaire. The remaining sample 
was labeled with a unique barcode and ID and placed on ice in a cool box before 
aliquoting small amounts into two 2 mL screw cap polypropylene tubes (also labeled 
with a unique barcode and ID) which were then stored in a cool box for shipment back to 
NIMR where they were kept at -80oC before being sent to Canada. 
The lab technician instructed the participant on the proper collection of a urine sample in 
a 50 mL container (Laja Pharmacy, Mwanza, Tanzania). The urine sample was then 
analyzed using a multi-test dipstick system (Rapid Response Urine Dipstick, BTNX 
Urinalysis, Laja Pharmacy, Mwanza, Tanzania) and the results were recorded in the 
clinical questionnaire. The urine collection container was labeled with a unique barcode 
and ID and stored in a cool box before being brought to NIMR for storage at -20oC until 
shipment to Canada. 
The lab technician also performed a finger prick to obtain a small amount of blood to 
determine the levels of hemoglobin using a HemoCue® Hb 201+ machine (HemoCue) as 
well as to perform Malaria and syphilis testing using Bioline Malaria Ag P.F./Pan 
(Standard Diagnostics) and Syphilis Ultra Rapid Test Device (ABON). In addition, the 
HIV status of the participants was determined by first using Determine™ HIV -1/2 
(Alere) test, followed by a confirmatory test using Uni-Gold™ HIV (Trinity Biotech) if 
the Determine™ test gave a positive result. Table 3 depicts the timing of sample 
collection as well as the type of samples and information collected at each visit prior to 
birth. 
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Table 3: Heat map of pre-birth visits conducted. Timing of the visits, as well as 
samples collected and analysis conducted are given. Grey boxes indicate that 
particular information was not collected, while the boxes with diagonal lines 
indicate it was. 
 
1 
Recruitment 2 3 
4 
Mid Point 5 
Timing * 12-24 weeks 16-28 
weeks 
20-28 
weeks 28 weeks 
32 weeks-
birth 
Samples collected   
 Urine      
 Fecal      
 Vaginal Swabs      
 Saliva      
 Venous blood      
Tests conducted  
 HIV      
 Syphilis      
 Malaria      
Measurements      
 Height      
 Weight      
 MUAC      
 Hemoglobin      
 Blood Pressure      
Lab Analysis     
 
Parasite 
analysis      
 Urine dipstick      
Other  
 
48 hour Dietary 
Recall      
 
Clinical 
Questionnaire      
*Timing of each visit varied, as it was dependent on gestational age at recruitment. 
2.1.8 Birth and Final Participant Visits and Sample Collection 
The participants were instructed to contact the study staff within 48 hours of giving birth. 
At this time, they were asked to come to the clinic with their infant within three days. 
This visit followed the same format as the pre-birth visits, however samples and 
anthropometric measurements were collected from the infants as well as breast milk from 
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the mothers. Infant weight was measured on an analogue baby scale to the nearest 0.1 kg. 
Head circumference, length and MUAC were also measured using a tape measure to the 
nearest 0.1 cm. In addition, the sex of the infant, place of birth, and whether the baby was 
born vaginally or by caesarean section were recorded (Appendix 7). Fecal samples were 
collected from the infant’s diaper, and infant saliva samples were collected using a 
BBL™ CultureSwab™ (BD diagnostics). The tip of the swab was then put in a 2 mL 
polypropelene tube. All samples were transported back to NIMR where they were stored 
at -20oC (saliva, vaginal and milk samples) and -80oC (fecal samples) before being 
shipped to Canada on dry ice. 
For analysis of birth data, if the participant gave birth in a hospital and the infant weight 
recorded at the time of birth, this weight was used in the analysis. However, if the birth 
weight was not available, then the weight measured at the birth visit (approximately 3 
days after birth) was used as the birth weight. Furthermore, accurately accessing preterm 
birth in this population was difficult due to the lack of an ultra sound machine at the 
clinic. Common practice at rural clinics for assessing gestational age is via an 
approximation by the nurse who takes into consideration the pregnant woman’s recall of 
her last menstrual period (LMP) and measurement of the fundal height at her first 
antenatal visit. Both recall of LMP and measurement of fundal height have their flaws, 
thus, for the purpose of this study, both LMP and the nurse approximation (NA) were 
taken into consideration when assessing gestational age at birth.  
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Table 4: Heat map outlining samples collected and analysis conducted for the birth 
and final visits. 
 Visits 
 Birth Final 
Timing Approx. 3 days 
after birth 
1 week after birth 
visit 
Samples collected  
Mother   
 Urine   
 Fecal   
 Vaginal Swabs   
 Saliva   
 Venous blood   
 Breast milk   
Infant   
 Fecal   
 Saliva Swab   
Tests conducted 
 HIV   
 Syphilis   
 Malaria   
Measurements 
Mother   
 Weight   
 MUAC   
 Hemoglobin   
 Blood Pressure   
Infant   
 MUAC   
 Head Circumference   
 Weight   
 Length   
Lab Analysis 
 Parasite analysis   
 Urine dipstick   
Other 
 48 hour Dietary Recall   
 Clinical Questionnaire   
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2.1.9 Calculation of Hemoglobin Levels 
Anemia is difficult to assess in pregnancy as a normal increase in blood volume starting 
at the 6th week of gestation occurs, which is greater than the increase in hemocrit, leading 
to an observed reduction in hemoglobin levels. Despite this, WHO states that hemoglobin 
levels between 100-109 g/L in pregnant women is indicative of mild anemia, while levels 
between 70-99 g/L is indicative of moderate anemia and levels less than 70 g/L is 
indicative of severe anemia202. Furthermore, elevation can affect hemoglobin levels and 
the WHO states that hemoglobin measurements taken at 1000 m above sea level should 
be adjusted by -2 g/L. Since Mwanza is located at an elevation of 1147 m, all hemoglobin 
levels taken were adjusted by this amount. The hemoglobin measurements were averaged 
for each woman by trimester and then by group. The pregnancy trimester was determined 
using recall of the LMP and if this was unavailable then the NA was used. Weeks 12 to 
26 were classified as the second trimester while weeks 26 to birth were classified as the 
third trimester. In addition, the two measurements taken after delivery were averaged for 
each woman and then again by group to give the hemoglobin measurements for lactating 
woman. Furthermore, the amount of iron intake for each woman was assessed from the 
48 hour dietary recalls and used as an indicator of anemia related to iron deficiency or 
other factors. 
2.2 Dietary Recall Analysis 
Forty-eight hour dietary recall interviews were conducted at each visit. Information from 
these interviews was analyzed for nutritional content and caloric intake using the ESHA 
Food Processor SQL (version 9.8). Although this program utilizes North American food 
composition tables, nutritional data for local Tanzanian foods and recipes were imputed 
into the software from Tanzanian food composition tables prepared by Muhimbli 
University of Health and Allied Sciences, Tanzania Food and Nutrition Center and 
Harvard School of Public Health 203.  In addition, when serving sizes or sizes of specific 
vegetables were not clearly stated in the interview, the average portion size as outlined by 
the Tanzanian Food Composition Tables was used. Nutritional data for Moringa were 
obtained from Broin, 204 and also inputted into ESHA. In total, 308 48-hour dietary 
recalls were used for the final analysis. The average intake of calories, protein, calcium, 
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vitamin A, vitamin D, folate and zinc were calculated over the 48-hour period. In 
addition, for analysis pertaining to heavy metals, the average consumption of fish in 
grams for each 48-hour period was used to determine the average daily intake of fish 
during the study. For each participant, the values of the above listed nutrients were then 
averaged with all values obtained from each 48-hour dietary recall collected during the 
pre-birth visits to obtain a value representing the daily average intake of specific nutrients 
during pregnancy. The same was done for the 48-hour dietary recalls collected at the 
birth and final visits, to obtain a value representing the daily average intake of specific 
nutrients during lactation. 
2.3 Blood Collection and Analysis 
2.3.1 Blood Collection 
Blood samples were collected from the participants at the first, mid and final visits 
(Tables 3 and 4). The lab technician drew approximately 20 mL of blood; 10 mL each 
into a royal blue and lavender top vacutainer tube (BD Biosciences). Approximately, 
thirty minutes after collection of the blood, 1 mL was removed from the royal blue 
vacutainer tube and transferred to a 2 mL screw top polypropylene tube to be used for 
heavy metal analysis. The vacutainer tubes were then centrifuged at 4500 g for 15 
minutes. After centrifugation, two 1 mL plasma aliquots from the royal blue vacutainer 
tube and one 1 mL aliquot from the lavender purple tube were transferred into 2 mL 
screw top polypropylene tubes. The buffy coat was removed from the lavender tube and 
the remaining red blood cells were transferred to a 2 mL screw top polypropylene tube. 
All tubes were labeled with a unique barcode and ID and were placed in a cool box for 
transfer back to NIMR where they were stored at -20oC before being shipped back to 
Canada. 
2.3.2 Heavy Metal Blood Analysis  
Twelve participants from both the nourished and undernourished groups who were 
receiving moringa supplemented probiotic yogurt were selected for further analysis of the 
heavy metal concentration in whole blood samples based on a greater than 75% 
consumption compliance one month prior to their final visit. These subjects were 
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matched to 12 participants who did not receive probiotic yogurt based on MUAC and fish 
consumption from their first and final 48-hour dietary recall interviews. The 1 mL aliquot 
of whole blood from the royal blue vacutainer tubes was used for heavy metal analysis, 
specifically mercury, lead, arsenic and cadmium. The Trace Elements Laboratory through 
the London Laboratory Services Group in London, Ontario, Canada, conducted analysis 
of the heavy metals in the whole blood by High Resolution Sector Field Inductively 
Coupled Mass Spectrometry. 
2.3.3 Blood Nutrient Analysis 
The plasma aliquoted from the purple top vacutainer tubes was used for analysis of 
Vitamin A and protein. The Core Laboratory through the London Laboratory Services 
Group in London, Ontario, Canada conducted the analysis of plasma Vitamin A levels by 
HPLC, while the total plasma protein levels were determined by a colorimetric Biuret 
assay. Due to hemodilution that occurs during pregnancy, only samples from women who 
were in their second trimester of pregnancy were used in analysis for the visit 1 samples. 
This resulted in 3 women being removed from this analysis, one in each of the UN, UNP 
and N groups. 
2.4 Breast Milk Analysis 
The breast milk samples collected at birth and at the final visit for all women in the study 
were analyzed for fat, protein and lactose content. From the calculated lactose amount, 
total carbohydrates were estimated. A total of 12 breast milk samples were excluded from 
this analysis due to the provider being HIV positive. The values obtained were averaged 
as these samples were taken approximately one week apart. Samples were homogenized 
for 10 seconds prior to a 500 µL aliquot being removed for DNA extraction using a 
sonicator (VCX 130; Chem- ical Instruments AB, Sollentuna, Sweden). The remaining 
sample (approximately 500 µL – 1 mL) was used for nutrient analysis.  Lactose content 
was measured as described by Fusch et al, 205. In brief a Waters ACQUITY Tandem 
Quadruple Dector coupled to an ACQUITY UPLC (waters Corporation, Manchester, 
UK) was used in negative ion mode with source temperature, capillary voltage, and cone 
voltage set at 150oC, 2.00 kV and 22 V respectively. Quantification of lactose was done 
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by using multiple reactions and labeled lactose as a control. Fat was extracted from the 
milk using Mojonnier ether extraction and then gravimetrically analyzed to get total fat 
content206. Protein content of the breast milk was determined as per the methods of Choi 
et al.)206. In brief, the nitrogen content and non-protein nitrogen in the breast milk 
samples was measured using an elemental analyser (Vario PYRO cube, Elementar 
Americas Inc.). The true protein content was then determined by subtracting the non-
protein nitrogen from the total nitrogen and multiplying this by 6.25207. 
2.5 Microbial DNA Extractions 
DNA was extracted from all samples using the PowerSoil®-htp 96 Well Soil DNA 
Isolation Kit from MoBio (Carlsbad, California). The extraction was carried out as per 
the manufacturer’s protocol. However, two changes were made; one was the addition of a 
10-minute incubation step at 65oC in a dry bath before the bead-beating step and the other 
was doubling the centrifugation times, due to using a centrifuge that only reached a 
maximum of 2500 xg. Approximately 250 mg of fecal sample, 500 µL of saliva and 500 
µL of breast milk were used for the extractions. The vaginal swabs and infant oral swabs 
were cut directly into the wells using scissors sterilized with RNAse Away™ Reagent 
(Life Technologies). In total, 1131 samples were extracted for sequencing.  
2.6 Sequencing and Microbial Community Analysis 
Samples were sequenced by amplifying the V4 hypervariable region of the 16SrRNA 
gene using bacterial/archaeal primers 515F and 806R, and the PCR conditions used were 
those described by the Earth Microbiome Project. Sequencing of the obtained pool of 
16SrRNA amplicons was carried out on the Illumina MiSeq platform as outlined in the 
methods of Caporaso et al, 2012208. Obtained reads were quality filtered and de-
multiplexed using the open source software QIIME209. A total of 1105 samples were 
sequenced yielding 17944744 sequences total with an average of 16,240 ± 11,856 per 
sample. Samples that generated less than 1000 sequences were discarded after the initial 
filter. This resulted in 22 human milk, 3 vaginal, 19 oral and 10 fecal samples being 
discarded from further analysis. The remaining sequences were then binned into 
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operational taxonomic units (OTUs) using closed-reference otu-picking based on 97% 
identity using the Greengenes reference database (May 2013 release)210. After matching 
to OTU’s in Greengenes, an additional 17 samples were discarded due to having less than 
1000 matches per sample. A total of 1034 samples were used for further downstream 
analysis. Beta diversity analysis was conducted using QIIME scripts and PCoA plots 
were visualized using the open source tool EMPeror211. In addition, alpha diversity of the 
vaginal samples at both the first and final visits was determined using the Shannon index 
in QIIME. 
The following analysis was conducted in R270. To compare differences between the gut 
microbiota of participants of varying nutritional status at baseline, a differential 
abundance test of OTUs grouped by genus annotation was run using the ALDEx version 
2 package (Fernandas et al, 2014 accepted. The open source tool can be downloaded 
here: https://github.com/ggloor/ALDEx2). A Welches t-test was used and the resulting P 
values were corrected for multiple comparisons by a Benjaminin-Hochberg post-test and 
a false discovery rate (FDR) of <0.05. The results are represented as MW plots that show 
the difference between conditions versus the maximum difference within conditions.  
Variability of the microbial profile of infant fecal samples is quite high, especially during 
the first few months98. Because of this, only samples from infants who were between ten 
and twenty days old at the final visit were used for analysis. Furthermore, infant fecal 
samples born to mothers in the probiotic group who had less than 80% compliance during 
the month before the final visit were excluded from analysis. Thus, 29 infant fecal 
samples were analyzed. ALDEx was also performed on these samples as described above 
and MW plots were created to determine differences between the groups at the genus and 
phyla taxonomic designations. In addition, the proportion of the top five representative 
genera were calculated and this data was managed and statistical analysis performed in 
GraphPad Prism 5 (version 5.0a). A one-way ANOVA was performed to determine 
differences between the five groups, along with a Bonferroni post-test to compare 
differences between pairs of groups.  
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Bar plots representing the genera and phyla of each sample for participants at the baseline 
and final visits were also created in R. 
2.7 Statistical Analysis 
Data obtained for weight gain, nutrient intakes, hemoglobin, blood levels of vitamin A, 
protein and heavy metals and nutrient levels of breast milk were managed in GraphPad 
Prism 5 (version 5.0a). Statistical analysis on these data was also performed using this 
software. To assess differences between groups, a one-way ANOVA was used. 
Furthermore to compare differences between pairs of groups a Bonferonni’s Multiple 
Comparisons test was used. For comparison of alpha diversity observed in the vaginal 
samples at the first and final visits, a Wilcoxon matched pairs t-test was used. 
Significance was set at a confidence interval of 95%. 
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Chapter 3  
3 Results 
3.1 Anthropometric Baseline Data of Study Participants 
Nutritional status is difficult to assess among pregnant women, especially in resource 
poor settings. Furthermore, a survey of Tanzanian Demographics and Health published in 
2010 stated that only 39% of women living in rural areas visit the antenatal clinic more 
than four times during the course of their pregnancy. The majority of women (54.5%) 
visit the antenatal clinic only 2-3 times during their pregnancy and the first of these visits 
occurs after the fourth or fifth month of pregnancy in 49.9% of women, while 31% wait 
until their sixth or seventh month 15. Thus, it is very uncommon to know pre-pregnancy 
weight for calculation of body mass index and assessment of nutritional status. As a 
result, two methods were employed; MUAC and weight for gestational age, in order to 
assess nutritional status. Table 5 outlines the average percent deviation from the expected 
weight for gestational age based on the tables by Gueri et al. 200 of participants in all 
study groups.  
Table 5: Average percent deviation of actual weight-for-height of participants in 
each group from the predicted value described in Gueri et al. 200. 
Groups 
UN UNP N NP O 
83.4 ± 6.0  82.0 ± 4.7  98.2 ± 8.8  94.7 ± 5.9 132.3 ± 21.9 
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In total, 60 women were recruited into the study. Eight were excluded from the final 
analysis, as they did not return for more than three follow-up visits. The most common 
reason for not returning for follow-up visits was due to moving out of the study area. 
Figure 8 is a heat map showing all sixty women recruited into the study and the visits 
attended and samples collected at each visit. At the first study visit, weight, age, height, 
HIV and malaria status, along with information regarding pregnancy history were 
collected. Table 6 outlines the baseline demographics of the 52 women used for the final 
analysis in the five different groups. 
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Figure 8: Heat-map depicting visits attended by all women recruited into the study. 
Dark grey boxes denote visits attended and samples collected, while light grey boxes 
denote visits missed and samples not collected. Black boxes and bold study ID’s 
indicate participants excluded from the final analysis due to not returning for more 
than three follow-up visits. 
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Table 6: Baseline demographics of women participating in the micronutrient enrich 
probiotic yogurt trial in Mwanza, Tanzania. 
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3.2 Compliance of Participants on Probiotic Yogurt 
Due to the strict system in place for monitoring probiotic yogurt consumption, 
compliance was high in the undernourished and nourished groups receiving it. 
Compliance, however, was not 100% due to women travelling to different cities during 
the study, making probiotic yogurt delivery impossible. Average compliance during the 
course of the study, and compliance during the month before the last visit is given in 
Table 7. In addition, the average total number of days on yogurt is given in Table 7. 
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Table 7: Compliance and total number of days participants received the probiotic 
yogurt supplemented with Moringa. Percent and total days are given, along with the 
standard deviation. 
 UNP (n=14) NP (n=9) 
Average total compliance  
(%) 
87 ± 8 84 ± 16 
Average compliance month 
before final visit (%) 
79 ± 33 87 ± 27 
Average total days on 
yogurt (days) 
91 ± 27 85 ± 37 
 
3.3 Probiotic Yogurt with Moringa Supplementation During 
Pregnancy Has No Effect on Weight Gain 
Figure 9 shows the weight gain of women in each group as pounds per week from the 
first visit till birth. There was no difference in the mean weight gain between groups who 
received the probiotic yogurt supplemented with Moringa, as compared to those who did 
not (p>0.05). The Institute of Medicine (IOM) guidelines for weight gain during 
pregnancy state that during the second trimester, underweight and normal weight woman 
should gain an average of 1 lb per week, with an acceptable range being between 1-1.3 
lbs/week and 0.8-1lbs/week respectively, while obese woman should gain an overage of 
0.5 lbs/ week during the second and third trimester of pregnancy 212. As seen in Figure 9, 
the mean weight gain for the UN group was 1.01 ± 0.87 lbs/week, 1.17 ± 1.04 lbs/week 
for the UNP group, 0.46 ± 0.80 lbs/week for the N group, 0.55 ± 0.71 for the NP group 
and -0.01 ± 0.75 lbs/week for the O group. Although the average for the UN and UNP 
group meet the IOM recommendations, 71% of the women in the UNP group had 
inadequate weight gain during their second and third trimesters, while 53% in the UN 
group and 16.7% in the UNP group had excessive weight gain. This does not reach 
statistical significance, but the results are still revealing as are the finding that 77.8% of 
the N group and 55.6% of the NP group had inadequate weight gain. One woman and 
three women had excessive weight gain in each group respectively, and one woman in 
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the O group had appropriate weight gain as outlined by IOM while the other four had 
inadequate weight gain. 
 
Figure 9: Average weight gain of woman in each group from time of recruitment to 
the visit before birth. The purple dashed line indicates the IOM recommended 
average weight gain per week for all classes of obese/overweight women (0.5 
lbs/week). The black dotted line represents the IOM recommended average weight 
gain for normal weight and underweight women (1 lbs/week). 
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3.4 Dietary and Activity Assessment During Pregnancy 
Total kilocalorie intake, calcium, Vitamins B12, B1 and A, folate, iron and zinc as well 
as percent consumption of carbohydrates, protein and fat for the participants in all five 
groups were calculated from the 48-hour dietary recalls. The means of the total average 
consumption per day and percent consumption during the 48-hours prior to the first visit 
are given in Table 8. There was no difference in the daily caloric intake between the five 
groups at baseline (p > 0.05,). Furthermore, there was no difference in daily intake of any 
other macro- and micronutrients as assessed from the 48-hour dietary recalls collected at 
the first visit.  
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Table 8: Average nutrient intakes per day (macro- and micronutrients) based on the 
two days prior to the first visit for all participants in each of the five groups. Values 
are given as a percent of average daily intake or total average daily intake with 
standard deviation. 
 UN (n=15) UNP 
(n=14) 
N (n=9) NP (n=9) O (n=5) 
Total Kilocalories 1746 ± 878 1817 ± 650 1779 ± 636 1705 ± 957 1989 ± 249 
Carbohydrate 
(%) 
18.34 ± 
4.25 
22.6 ± 6.29 19.54 ± 
3.81 
17.3 ± 2.31 18.84 ± 
3.05 
Protein (%) 4.55 ± 1.55 3.97 ± 1.33 3.55 ± 1.12 4.33 ± 1.12 3.53 ± 0.95 
Total fat (%) 3.82 ± 1.61 3.03 ± 1.38 2.91 ± 1.37 3.64 ± 1.51 2.46 ± 0.55 
Saturated fat (%) 2.53 ± 1.24 2.05 ± 1.24 2.04 ± 1.11 2.65 ± 1.30 1.70 ± 0.60 
Monounsaturated 
fat (%) 
0.62 ± 0.30 0.41 ± 0.23 0.36 ± 0.15 0.39 ± 0.15 0.29 ± 0.08 
Polyunsaturated 
fat (%) 
0.35 ± 0.11 0.31 ± 0.15 0.24 ± 0.06 0.28 ± 0.04 0.26 ± 0.09 
Vitamin B1 
(Thiamine) (mg) 
0.90 ± 0.41 0.87 ± 0.34 0.91 ± 0.5 0.72 ± 0.43 1.17 ± 0.48 
Vitamin B12 (µg) 1.03 ± 0.84 0.59 ± 0.65 0.64 ± 0.75 0.90 ± 0.64 0.93 ± 0.62 
Vitamin A (RAE) 619.4 ± 
683.0 
544.6 ± 
586.5 
912.0 ± 
830.0 
581.1 ± 
518.5 
454.8 ± 
346.6 
Calcium (mg) 228.1 ± 
195.6 
181.3 ± 
132.2 
248.9 ± 
145.8 
216.4 ± 
94.6 
185.0 ± 
45.8 
Folate (µg) 268.9 ± 
160.5 
285.1 ± 
246.4 
336.3 ± 
255.9 
216.7 ± 
135.1 
348.8 ± 
244.0 
Iron (mg) 35.4 ± 44.2 47.9 ± 46.9 48.9 ± 36.7 51.1 ± 59.2 46.8 ± 28.2 
Zinc (mg) 5.74 ± 2.11 5.96 ± 2.93 6.20 ± 2.87 4.76 ± 2.24 6.94 ± 3.30 
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In order to gain an understanding of the activity levels of participants, an estimation of 
kilometers walked per day as well as whether or not participants held a job was gathered 
at the first visit. The results are presented in Table 9, and there was no significant 
difference in the level of activity as based on kilometers walked per day between the five 
groups (p > 0.05). 
Table 9: Average kilometers walked per day of participants in each of the five 
groups as well as number of participants who were employed at time of recruitment. 
 UN (n=15) UNP 
(n=14) 
N (n=9) NP (n=9) O (n=5) 
Kilometers 
walked per day 
1.25 ± 0.92 1.42 ± 1.01 2.16 ± 3.27 1.38 ± 0.88 1.3 ± 0.97 
Employed 3 6 3 7 5 
Total kilocalorie intake, calcium, Vitamins B12, B1 and A, folate, iron and zinc as well 
as percent consumption of carbohydrates, protein and fat was averaged from all 48-hour 
dietary recalls collected from the first visit until birth. The means of the total average 
consumption per day and percent consumption are given in Table 10. There was a 
significant difference in calcium consumption between the groups during the course of 
the study. The NP and UNP groups had significantly higher average calcium 
consumption per day as compared to the other groups (p < 0.0001). There was also a 
significant difference between the Vitamin A intakes of the NP group compared to the 
UN group (p=0.0099). 
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Table 10: Average nutrient intakes per day (macro- and micronutrients) for all 
participants in each of the five groups from time of recruitment until birth. Values 
are given as a percent of average daily intake or total average daily intake with the 
standard deviation. 
 UN (n=15) UNP 
(n=14) 
N (n=9) NP (n=9) O (n=5) 
Total Kilocalories 1615 ± 534 1948 ± 490 1888 ± 485 1968 ± 433 1746 ± 412 
Carbohydrate 
(%) 
18.72 ± 
6.11 
18.74 ± 
4.24 
19.40 ± 
3.99 
18.04 ± 
3.74 
19.02 ± 
0.41 
Protein (%) 4.19 ± 0.58 3.74 ± 0.72 3.76 ± 0.81 3.80 ± 0.77 3.70 ± 0.07 
Total fat (%) 3.62 ± 1.98 3.36 ± 1.40 3.33 ± 1.42 3.47 ± 0.97 3.35 ± 0.09 
Saturated fat (%) 2.38 ± 1.42 2.26 ± 1.01 2.29 ± 1.09 2.38 ± 0.85 2.28 ± 0.08 
Monounsaturated 
fat (%) 
0.59 ± 0.34 0.51 ± 0.25 0.49 ± 0.22 0.48 ± 0.08 0.48 ± 0.01 
Polyunsaturated 
fat (%) 
0.32 ± 0.10 0.31 ± 0.13 0.27 ± 0.06 0.30 ± 0.07 0.30 ± 
0.006 
Vitamin B1 
(Thiamine) (mg) 
0.79 ± 0.18 0.96 ± 0.19 0.86 ± 0.18 0.93 ± 0.18 0.97 ± 0.25 
Vitamin B12 (µg) 1.12 ± 0.46 1.41 ± 0.56 0.91 ± 0.42 1.23 ± 0.46 0.80 ± 0.26 
Vitamin A (RAE) 432.1 ± 
257.0 
632.5 ± 
236.8 
666.6 ± 
294.4 
865.3 ± 
366.0 
430.5 ± 
309.2 
Calcium (mg) 178.7 ± 
84.3 
432.5 ± 
84.8 
216.9 ± 
71.2 
470.2 ± 
72.4 
190.0 ± 
80.8 
Folate (µg) 195.8 ± 
67.1 
278.6 ± 
97.1 
277.2 ± 
86.3 
299.6 ± 
79.3 
298.1 ± 
151.0 
Iron (mg) 31.5 ± 17.4 37.4 ± 16.1 41.3 ± 12.5 46.6 ± 22.7 32.4 ± 15.5 
Zinc (mg) 5.25 ± 1.08 6.38 ± 1.89 5.92 ± 1.34 5.97 ± 0.83 5.72 ± 1.19 
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The average daily intake of micro- and macronutrients consumed during pregnancy was 
also compared to the Canadian Reference Dietary Intakes (RDI) for pregnant women. 
This was done to assess if pregnant women in this population meet the recommended 
intakes of certain micro- and macronutrients for a healthy pregnancy. The calculated 
average daily intakes in Table 10 are expressed as a percent of the Canadian RDI and are 
given in Table 11 for the participants in this study. Based on the 48-hour dietary recalls, 
participants in all groups only met the RDI of carbohydrates and iron. Participants in the 
NP group met the RDI for daily vitamin A intake and were close to meeting the RDI for 
protein intake (92%, Table 9). For all other micro- and macronutrients, all groups were 
below 90% of the RDI. 
Table 11: Percent RDI based on Canadian values of the mean daily intake of micro- 
and macronutrients consumed by study participants during pregnancy. 
 UN (n=15) UNP 
(n=14) 
N (n=9) NP (n=9) O (n=5) 
Carbohydrate  142 320 176 177 162 
Protein  79 87 83 92 86 
Vitamin B1 
(Thiamine)  
56 69 61 66 69 
Vitamin B12  43 54 35 47 31 
Vitamin A  56 82 87 112 56 
Calcium  18 56 28 61 25 
Folate  33 46 46 50 50 
Iron  117 139 153 173 120 
Zinc  48 58 54 54 52 
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Forty-eight hour dietary recalls were also collected at the birth visit, which occurred 
approximately three days after birth, and the final visit, which occurred approximately 
one week after the birth visit. Daily average intakes were determined for the same 
nutrients listed in Table 10 for each participant and were used to determine the average 
daily intake and standard deviation for the group. If participants only attended one of the 
two post-partum visits, then the average of the 48-hour dietary recall collected at that 
visit was used for analysis of the group average. The results are listed in Table 12. There 
was no significant difference between the daily average intake of any of the micro- and 
macronutrients between the groups except for calcium. The daily average intake of 
calcium was significantly higher in the UNP and NP groups as compared to the other 
groups (p >0.05). However, the daily average intake of calcium was not significantly 
different between the UNP and NP groups (p < 0.05). 
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Table 12: Average daily intakes of micro- and macronutrients for all participants 
after giving birth. Values are based on the averages from 48-hour dietary recalls 
collected at the birth and final visits. 
 UN (n=13) UNP 
(n=12) 
N (n=8) NP (n=9) O (n=4) 
Total Kilocalories 1988 ± 483 1955 ± 625 1871 ± 273 1965 ± 451 2066 ± 804 
Carbohydrate 
(%) 
20.79 ± 
4.60 
18.59 ± 
6.49 
19.40 ± 
5.08 
17.25 ± 
3.52 
18.65 ± 
7.66 
Protein (%) 3.96 ± 0.86 4.21 ± 1.38 4.76 ± 2.50 3.85 ± 0.90 3.94 ± 1.48 
Total fat (%) 2.91 ± 1.39 2.94 ± 1.15 2.34 ± 0.56 3.37 ± 1.36 3.86 ± 1.76 
Saturated fat (%) 1.91 ± 1.12 1.84 ± 0.72 1.46 ± 0.45 2.28 ± 1.09 2.36 ± 1.09 
Monounsaturated 
fat (%) 
0.45 ± 0.24 0.50 ± 0.34 0.36 ± 0.19 0.56 ± 0.19 0.93 ± 0.44 
Polyunsaturated 
fat (%) 
0.29 ± 0.09 0.31 ± 0.13 0.28 ± 0.06 0.26 ± 0.11 0.26 ± 0.19 
Vitamin B1 
(Thiamine) (mg) 
0.93 ± 0.27 1.05 ± 0.37 1.04 ± 0.15 0.97 ± 0.28 1.11 ± 0.33 
Vitamin B12 (µg) 0.70 ± 0.68 1.22 ± 0.77 0.62 ± 0.75 1.53 ± 0.74 1.66 ± 1.16 
Vitamin A (RAE) 216.9 ± 
259.7 
308.4 ± 
388.0 
272.2 ± 
265.2 
371.6 ± 
267.3 
377.6 ± 
197.3 
Calcium (mg) 139.4 ± 
143.0 
343.0 ± 
111.7 
96.8 ± 39.1 431.2 ± 
94.3 
99.6 ± 60.1 
Folate (µg) 157.64 ± 
66.9 
182.2 ± 
92.6 
165.6 ± 
66.6 
156.1 ± 
51.5 
125.5 ± 
101.1 
Iron (mg) 55.3 ± 37.0 59.0 ± 33.1 65.1 ± 37.4 39.7 ± 28.1 39.1 ± 18.1 
Zinc (mg) 6.32 ± 1.55 6.40 ± 2.76 6.11 ± 1.15 5.56 ± 1.35 7.09 ± 2.47 
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The average daily intakes of the micro- and macronutrients listed in Table 11 were 
compared to the Canadian Dietary Reference Intakes for lactating women. The average 
daily intakes in Table 12 were calculated as a percent of the Canadian RDI for each 
micro- and macronutrient and these values are given in Table 13. All participants met the 
Canadian RDI for carbohydrate intake and were significantly over the RDI for iron intake 
(Table 13). Furthermore, the UNP and N groups met the RDI for protein intake while the 
rest of the groups had intakes of greater than 90% (Table 13). For all other nutrients, 
intakes of all groups were below 80% of the RDI (Table 13). 
Table 13: Percent RDI based on Canadian Recommended Dietary Intakes of micro- 
and macronutrients for lactating women. 
 UN (n=13) UNP 
(n=12) 
N (n=8) NP (n=9) O (n=4) 
Carbohydrate  164 152 154 150 154 
Protein  93 101 112 99 96 
Vitamin B1 
(Thiamine)  
66 75 74 69 79 
Vitamin B12  25 44 22 55 59 
Vitamin A  17 24 21 29 29 
Calcium  14 34 10 43 10 
Folate  32 36 33 31 25 
Iron  611 655 724 444 433 
Zinc (mg) 53 53 51 46 59 
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3.5 Prevalence of Anemia in Study Groups 
In 2002, the WHO listed iron deficiency anemia as the most important contributing factor 
to the global burden of disease. The greatest at-risk populations are pregnant women and 
children and in Tanzania 40% of woman between the ages of 15 and 49 are anemic 15. At 
each visit, Hb levels were measured.  These values were averaged to give a total value by 
trimester. In addition, the Hb measurements taken after birth were averaged to give the 
mean Hb levels of lactating women in each group. Table 14 outlines the mean Hb levels 
of each group during their second and third trimester of pregnancy, as well as during 
lactation. There were no significant differences between the mean Hb levels of each 
group at any stage of the study (p > 0.05). 
Table 14: Mean Hb levels of participants in each group during the second and third 
trimesters as well as after birth (lactation). 
 Mean Hb levels (g/L) 
Group 2nd Trimester 3rd Trimester Lactation 
UN 106.3 ± 16.0 108.0 ± 11.6 106.1 ± 15.4 
UNP 109.2 ± 12.0 101.8 ± 12.6 104.7 ± 15.7 
N 109.1 ± 11.0 101.6 ± 9.8 102.9 ± 12.1 
NP 110.7 ± 10.9 98.6 ± 15.9 100.4 ± 17.3 
O 114.2 ± 8.3 105.1 ± 12.1 99.3 ± 8.2 
Furthermore, Table 15 outlines the percentage of women in each group who were 
classified as mild, moderate or severely anemic as defined by the WHO Hb cutoff values 
for pregnant women. During pregnancy, none of the women in any group had severe 
anemia. However, anemia did appear to increase in the groups between the second and 
third trimesters. 
71 
 
Table 15: Percentage of participants in each group with various stages of anemia as 
outlined by WHO guidelines. 
 Hemoglobin cutoff levels (g/L) 
Group Mild 
(100-109) 
Moderate 
(70-99) 
Severe 
(<70) 
 2nd 
Trimester 
3rd 
Trimester 
2nd 
Trimester 
3rd 
Trimester 
2nd 
Trimester 
3rd 
Trimester 
UN 7 14 33 21 0 0 
UNP 15 14 23 50 0 0 
N 50 22 13 56 0 0 
NP 11 43 11 43 0 0 
O 40 40 0 20 0 0 
 
3.6 Moringa Enriched Probiotic Yogurt Maintains Mercury 
and Arsenic Levels in Pregnant Women 
Lactobacillus sp. have the ability to sequester mercury from solution in vitro. In order to 
determine if probiotic yogurt consumption could have the same effect on mercury 
sequestering or removal in vivo, blood samples collected at the first and final visits in the 
this study, were used to measure the concentration of heavy metals. Samples from 24 of 
the pregnant subjects were used in this analysis; 12 in the group receiving probiotic 
yogurt with a greater than 75% compliance during the last month of the study and 12 not 
receiving probiotic who were matched to the supplement group based on MUAC and fish 
consumption before the first and final visits. Participants in the supplement group 
consumed the yogurt on average 99 ± 18 days from time of recruitment to the final visit. 
Fish consumption from the time of enrollment to the final visit was determined from the 
48-hour recalls. The amount of fish reported consumed over two days prior to the study 
visit was averaged and this amount was again averaged with the amounts reported at each 
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visit from baseline to the final visit to determine an estimate of grams of fish per day 
consumed. There was no significant difference in the amount of fish consumed per day 
between participants in the control and probiotic group (Figure 10). Furthermore, when 
the amount of fish consumed per kg of body mass was calculated for the two days prior 
to blood collection at baseline and the final visit, no significant difference was observed 
between the two groups using a unpaired t-test with Welch’s correction (Figure 11). Of 
note, I organized the sample collection and yogurt consumption, as well as participated in 
the fish collection and preformed all data analysis and report writing, but Jordan Bisanz, a 
PhD student in our lab, oversaw the actual heavy metal analysis at the London 
Laboratory Services Group.  
 
Figure 10: Comparison of daily fish consumption during the course of the study 
between the group receiving probiotic yogurt and the control group (p >0.05). 
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Figure 11: Fish Consumption over a 48 hour period represented as grams per 
kilogram of body weight before blood collection at baseline (A) and blood collection 
at the final visit (B). There was no significant difference between the two groups at 
both baseline (p=0.9365) and the final visit (p=0.6461). 
Levels of lead (Pb), mercury (Hg), arsenic (As) and cadmium (Cd) were measured in the 
whole blood of all 24 women. The amount of the four heavy metals measured in the 
blood of all women used in this analysis at baseline is given in Table 18. For comparison, 
the reference values of the same heavy metals found in the blood of women between the 
ages of 20 and 39 in Canada is also given. The change in concentration of the four heavy 
metals in the blood was calculated between the baseline and the final visits. Using a 
paired t-test, a significant difference was observed between the change in blood mercury 
and arsenic levels in the probiotic group as compared to the control group (p=0.0484 and 
p=0.0054 respectively) (Figure 12). Levels of both metals seemed to increase in the 
control between the baseline and final visits, while they remained relatively the same in 
the probiotic group between the baseline and final visits. However, there was no 
significant difference between the two groups in the change of cadmium and lead blood 
levels from baseline to the final visit (p=0.1039 and p=0.3819 respectively) (Figure 12). 
What is interesting to note, is that the average amount of fish consumed per kilogram of 
body mass calculated for the two days prior to blood collection decreased between the 
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baseline and final visits for both groups (2.67 ± 2.26 g/kg and 1.67 ± 1.18 g/kg 
respectively for the probiotic group and 2.75 ± 2.79 g/kg and 1.89 ± 1.12 g/kg 
respectively for the control group, p > 0.05 for both groups), even though the levels of 
mercury appeared to increase in the control group between the baseline and final visits. 
Table 16: Average blood metal levels at baseline of pregnant women used for heavy 
metal analysis and compared to average levels observed in Canadian women aged 
20-39. 
 
Average 
(±SD) Range 
Canadian 
Average1 
Reference 
Range2 
Fold 
Difference 
Pb (µg/L) 22.6 ± 9.6 7.3 - 40.5 8.9 0.0 – 45.0 2.5 
Hg (nmol/L) 8.8 ± 3.1 4.0 – 16.0 3.5 0.0 – 18.0 2.5 
As (nmol/L) 3.0 ± 1.6 1.3 – 6.7 11.7 0.0 – 21.4 - 3.9 
Cd (nmol/L) 1.1 ± 0.6 0.0 – 2.7 3.2 0.0 – 8.9 - 2.9 
1Canadian averages obtained from the Canadian Health Measures Survey (2007-2009)213 
2Reference range provided by the London Laboratory Services group 
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Figure 12: Change in blood levels between the baseline and final visits of mercury, 
arsenic, lead and cadmium. Significant differences were observed between the 
probiotic and control group for the change in mercury and arsenic (p=0.0484 and 
p=0.0054 respectively), but no significant difference was observed between the 
changes in blood concentration of lead and cadmium (p=0.1039 and p=0.3819). 
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3.7 Plasma Protein and Retinol Levels 
Venous blood was collected at visit 1 (baseline) and the final visit to assess the nutritional 
status of the study subjects. Plasma protein levels were determined by a colometric assay, 
while plasma retinol levels were determined by HPLC. The results of this analysis are 
shown in Table 19. The nutrient levels are also expressed as a ratio of µmol 
retinol/protein, as Sapin et al.214 determined that this could correct for the hemodilution 
effect observed in pregnancy. There was no difference in the ratio of retinol blood levels 
to protein blood levels at baseline between the groups (p>0.05). There was also no 
difference in the ratio of retinol blood levels to protein blood levels at the final visit 
between the groups, however, there was a significant difference in this ratio between the 
UNP and O group (p  < 0.05,). 
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Table 17: Results of blood nutrient analysis at visit 1 and the final visit of 
participants in each group. Values are given as a mean with the standard deviation. 
 Visit 1 Final 
Group Retinol 
(µmoL/L) 
Protein 
(g/L) 
Retinol/ 
Protein 
(µmoL/g) 
Retinol 
(µmoL/L) 
Protein 
(g/L) 
Retinol/ 
Protein 
(µmoL/g) 
UN (n=14) 0.99 ± 0.36 
64.1 ± 
5.09 
0.015 ± 
0.005 1.24 ± 0.44 69.8 ± 8.27 
0.018 ± 
0.006 
UNP(n=13) 1.02 ± 0.25 
67.4 ± 
3.89 
0.015 ± 
0.004 1.48 ± 0.62 67 ± 8.94 
0.023 ± 
0.010 
N (n=8) 1.08 ± 0.58 
61 ± 
9.26 
0.018 ± 
0.013 1.46 ± 0.63 62.4 ±15.4 
0.025 ± 
0.013 
NP (n=9) 0.74 ± 0.21 
59.4 ± 
12.10 
0.013 ± 
0.003 1.44 ± 0.33 63.4 ± 7.18 
0.023 ± 
0.006 
O (n=5) 1.10 ± 0.36 
52.8 ± 
12.4 
0.021 ± 
0.008 1.85 ± 0.21 56.5 ± 8.58 
0.033 ± 
0.009 
Reference 
Range* 1.01 -1.71 57-69 - 1.2-2.8 64-83 - 
*Reference ranges for serum retinol and total protein in the second trimester (visit 1) 
were taken from Abbassi-Chanavati et al.215 and the reference ranges for both retinol and 
protein at the final visit were retrieved from the London Laboratory Services Group web 
page 
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3.8 Nutrient Content of Human Milk does not Vary Between 
Study Groups 
The average total fat and protein content of human milk collected at the birth and final 
visits were determined as well as an estimate of the average total carbohydrate content 
based on calculation of lactose. There were no significant differences in total fat, protein 
and carbohydrate content of the milk samples between the groups, Figure 13 depicts the 
average carbohydrate, fat and protein content of the human milk samples from 
participants in each of the five groups. 
 
Figure 13: Average carbohydrate, fat and protein content of human milk samples 
from study participants. Each symbol (, for example) indicates a participant 
sample. 
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3.9 Microbiota of Study Participants 
All biological samples collected during the study were extracted using the PowerSoil®-
htp 96 Well Soil DNA Isolation Kit from MoBio (Carlsbad, California). Figure 14 
represents all sample types collected during the entire study and shows that each sample 
type clusters separately on an unweighted PCoA plot, with infant oral (large transparent 
orange dots) and fecal samples (large transparent blue dots) clustering closest to the 
human milk samples (red dots) 
 
Figure 14: Unweighted unifrac distances of 1034 fecal, oral, vaginal and human 
milk samples collected at every time point for each study participant, plotted in 
PCoA space. Clustering is seen based upon sample type. The large transparent 
orange and blue circles represent the infant oral and fecal samples respectively, seen 
clustering around the human milk samples. 
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3.9.1 Comparison of Gut Microbiota between Groups at Baseline 
After filtering out samples that produced less than 1000 reads from sequencing, and 
filtering for samples that matched to more than 100 OTUs, a total of 47 subjects were 
used for the comparison of the gut microbiota at baseline between groups of varying 
nutritional status. Two subjects were removed from the undernourished group, one from 
the nourished and one from the nourished probiotic group due to either filtering or failed 
sequencing, resulting in an n-value of 14 for the undernourished probiotic group, an n-
value of 13 for the undernourished group, an n-value of 7 for the nourished group, an n-
value of 8 for the nourished probiotic group and an n-value of 5 for the obese group. The 
average number of reads per sample after filtering was 14216 ± 8687. The genus and 
phylum level of the resulting samples were examined and the OTUs were further filtered 
to remove any that were present as singletons across the entire sample set. As a result, the 
adult fecal samples at baseline contained 188 representative genus OTUs and 15 
representative phyla OTUs. The most abundant genus represented by the top OTUs were 
Prevotella, Succinivibrio, Bacteriodes, Ruminococcus, Faecalibacterium, Treponema and 
Ruminobacter. The most abundant phyla represented by the top OTUs in the fecal 
samples were Bacteroidetes, Firmicutes and Proteobacteria. Figure 16 is a bar plot 
summarizing the genus level OTU profile of individuals in each group and Figure 15 is a 
bar plot summarizing the phylum level OTU profile of individuals in each group. 
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Figure 15: Bar plot of representative phyla in fecal samples at baseline of each 
participant separated by group. UN=undernourished, UNP=undernourished 
probiotic. N=nourished, O=obese. The y-axis denotes the relative abundance of each 
taxa. 
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Figure 16: Bar plots representing OTUs at genus level for fecal samples of all 
participants at baseline. The legend lists the top 25 OTUs in descending order of 
abundance. UN=Undernourished, UNP=Undernourished Probiotic, N=Nourished, 
NP=Nourished Probiotic, O=Obese. The y-axis denotes the relative abundance of 
each taxa. 
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In order to assess whether or not the gut microbial composition differs between mothers 
of varying nutritional status, a differential abundance test using ALDEx version 2 of 
OTUs grouped by genus annotation was used. First, randomization of participants in the 
undernourished and nourished groups did not result in any microbial community biases. 
The results, revealed that there was no difference between the gut microbiota of 
participants in the undernourished group randomized to receive probiotic yogurt versus 
those randomized to not to receive yogurt (Figure 17 B). Furthermore, there was no 
difference of representative OTUs grouped by genus annotation in the gut microbiota 
between participants in the nourished group randomized to receive probiotic yogurt 
versus those who were randomized to not receive probiotic yogurt (Figure 17 A). This 
indicates that randomization did not result in a significant difference between those who 
were to receive probiotic versus those who were not. 
 
Figure 17: ALDEx2 results showing no difference in fecal OTUs at the genus level  
between participants in the nourished group randomized to receive probiotic yogurt 
and those randomized not to receive probiotic yogurt (A) and participants in the 
undernourished group randomized to receive probiotic yogurt and those 
randomized not to receive probiotic yogurt (B). 
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Furthermore, there was no difference of representative OTUs grouped by genus 
annotation at baseline of the gut microbiotas between participants who were classified as 
nourished and those who were classified as under-nourished (Figure 18 A). Nor was there 
a significant difference of representative OTUs grouped by genus annotation at baseline 
of the gut microbiota of those classified as nourished and those classified as obese 
(Figure 18 B). The same was observed between those classified as undernourished and 
those classified as obese (Figure 18 C). These results indicated that the gut microbiota of 
pregnant women in their second trimester did not differ based on the criteria used to 
define nutritional status used in this study. The same analysis was carried out for each 
group using representative OTUs at the phyla annotation, but again no significant 
differences were observed (data not shown). 
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Figure 18: ALDEx2 results showing no difference in fecal OTUs at genus level 
between participants in the undernourished group and those in the nourished group 
(A), those in the nourished group and those in the obese group (B) and those in the 
undernourished group and those in the obese group (C). 
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3.9.2 Oral Microbiota at the First Visit 
Oral samples were collected at every visit. The bacterial DNA was extracted and 
amplification and sequencing of the V4 region of the 16s rRNA gene were carried out as 
per the methods above. However, due to time constraints, only the oral samples collected 
at the first visit were analyzed for this thesis. Sequencing of the oral samples at the first 
visit resulted in 14,598 ± 12,306 reads per sample. These reads were annotated to 205 
representative OTUs at the genus level, the top five most abundant OTUs representing 
members form the taxa Streptococcus, Prevotella, Haemophillus, Neisseria and 
Veillonella. A barplot representing the oral microbiota profiles of each participant is 
given in Figure 19. 
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Figure 19: Oral microbiota profiles of participants at the first visit. The top 25 most 
abundant OTUs annotated at the genus level are given in the legend in increasing 
order of abundance. UN=undernourished, UNP=undernourished probiotic, 
N=nourished, NP=nourished probiotic, O=obese. The y-axis denotes the relative 
abundance of each taxa. 
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3.9.3 Vaginal Microbiota at the First and Final Visit 
Vaginal samples were collected at every visit. All samples were sequenced as per the 
methods above, however, due to time constraints only the vaginal samples at the first and 
final visits were analyzed. At the first visit, 51 out of 52 vaginal samples were 
successfully sequenced and passed all filtering steps (UN=15, UNP=14, N=8, NP=9, 
O=5). The average number of reads per sample was 14,102 ± 5,022. After filtering out 
OTUs that were present as singletons across all samples, 151 representative OTUs at the 
genus annotation remained. The most abundant taxa at the genus level was Lactobacillus, 
and as seen in Figure 20, OTUs representing this taxa were the most abundant across all 
samples in each group. The next most abundant taxa were Megasphaera, Gardnerella 
and Sneathia (Figure 20). The profiles observed after sequencing are in accordance with 
the results of Nugent scoring in Table 20. Also, Figure 21 is the samples represented in 
weighted Unifrac space and the negative Nugent score samples (Lactobacillus dominant), 
cluster together, while intermediate and positive samples spread out along PC1, most 
likely do to an lesser abundance of Lactobacillus in these samples. 
Table 18: Nugent scoring results at visit 1 and the final visit, for all participants. 
N=normal (0-3), I=intermediate (4-6), P=positive (7-10). 
 Nugent Scoring Results 
 Visit 1 Final 
Study ID Result Number Score Result Number Score 
UN     
MNIH09UP N 0 ND 
MNIH21U P 9 P 10 
MNIH23U N 0 P 7 
MNIH31U N 0 NBS  
MNIH34U N 0 ND 
MNIH37U I 5 ND 
MNIH39U I 4 N 0 
MNIH43N N 0 P 8 
MNIH45N N 0 P 8 
MNIH48N N 0 ND 
MNIH49N N 0 ND 
MNIH50N P 7 N 3 
MNIH55N N 0 ND 
MNIH56N N 0 N 3 
MNIH58N N 0 ND 
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UNP     
MNIH01UP N 0 NBS  
MNIH02UP N 0 ND 
MNIH05UP P 7 P 8 
MNIH06UP N 0 N 3 
MNIH14UP NBS  N 3 
MNIH16UP N 0 ND 
MNIH18UP N 0 ND 
MNIH20UP P 8 I 4 
MNIH83NP N 2 I 5 
MNH84NP N 3 P 8 
MNH88NP I 5 ND 
MNIH90NP N 0 ND 
MNIH92NP N 0 NBS  
MNIH95NP N 0 NBS  
N     
MNIH41N N 0 N 0 
MNIH47N N 0 ND 
MNIH51N N 0 P 8 
MNIH52N N 0 ND 
MNIH57N N 0 NBS  
MNIH59N P 8 P 7 
MNIH60N N 0 P 9 
MNIH86NP I 6 ND 
NP     
MNIH81NP N 3 ND 
MNIH82NP P 9 ND 
MNIH85NP N 0 NBS  
MNIH87NP N 0 N 0 
MNIH93NP N 0 ND 
MNH94NP N 0 ND 
MNIH96NP N 0 NBS  
MNIH97NP N 0 ND 
MNIH99NP N 0 N 2 
O     
MNIH61O I 6 I 6 
MNIH62O P 7 NBS  
MNIH63O P 9 ND 
MNIH64O N 0 N 2 
MNIH65O P 8 N 0 
Note: ND=Not collected, not sequenced, or did not pass filtering, NBS=No bacteria on 
the slide so Nugent scoring could not be preformed 
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Figure 20: Bar plot representing microbial profiles of each participant, annotated at 
the genus level of vaginal samples collected at the first visit. The 25 most abundant 
taxa are given in the legend in increasing order of abundance. UN=undernourished, 
UNP=undernourished probiotic, N=nourished, NP=nourished probiotic, O=obese. 
The y-axis denotes the relative abundance of each taxa. 
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Figure 21: Weighted Unifrac distances of vaginal samples at the first and final visits 
plotted in PCoA space. Samples are colored based on their Nugent score 
(Negative=0-3, Intermediate =4-6, Positive=7-10, NA=Nugent score not available). 
PC1 represents 42% of the variation between the samples, while PC2 represents 
12% and PC3 represents 6%. 
For analysis of the vaginal samples collected at the final visit, women who were in both 
the UNP and NP groups that had less than 80% yogurt consumption compliance in the 
month before their final visit were excluded in this analysis. This resulted in 4 women 
from the UNP group being excluded, leaving a total of 32 subjects. A number of vaginal 
samples were not collected due to women having heavy bleeding from giving birth. The 
average number of reads was 14070 ± 8825 per sample. In comparison to the first visit 
with only 151 representative OTUs, the vaginal microbiota at the final visit contained 197 
representative OTUs at the genus level. The most abundant OTU in the final vaginal 
samples was matched to Sneathia, followed by Prevotella and then Lactobacillus (Figure 
22). The vaginal profiles differed substantially from the profiles seen at the first visit 
(Figure 20) and appeared to be more representative of individuals with BV. However, the 
microbial profiles observed from sequencing were not in accordance with the Nugent 
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scoring results in Table 20. Furthermore, as observed when the weighted Unifrac 
distances were plotted in PCoA space (Figure 21), distinct clustering of the samples 
based on the Nugent score did not occur and the samples were spread along PC1. Alpha 
diversity was also assessed in the vaginal samples at both the first and final visits, and a 
significant increase in diversity was observed between the first and final visits (p < 
0.0001,). 
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Figure 22: Bar plot showing microbial profiles, based on the genus level annotation 
of vaginal samples collected at the final visit. The top 25 annotated OTUs are given 
in the legend in increasing order of abundance. UN=undernourished, 
UNP=undernourished probiotic, N=nourished, NP=nourished probiotic, O=obese. 
The y-axis denotes the relative abundance of each taxa. 
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3.9.4 Analysis of Infant Microbiota at the Final Visit 
After giving birth, participants were asked to come to the clinic with their infants, within 
three days. Following this birth visit, women and their infants were asked to return 
approximately one week afterwards for a final visit, during which fecal, oral, vaginal and 
breast milk samples were collected from mothers and oral and fecal samples from the 
infants. The number of samples used in the final analysis was less than samples analyzed 
at baseline due to women either withdrawing from the study or not giving birth by the 
time the study closed; samples not being provided at time of visit, or due to the death of 
infants (one in the UN group and one in the NP group). Furthermore, only fecal samples 
from infants between the ages of 10 to 20 days, and from mothers in the probiotic group 
who had compliance greater than 80% during the month before their final visit were used. 
This resulted in a total of 29 infant fecal samples used in the final analysis (UN=9, 
UNP=6, N=3, NP=7 (two twin sets), O=4). After sequencing and filtering, 170 OTUs 
annotated at the genus level were present in the infant fecal samples with an average 
number of 16,124 ± 14878 reads/sample. Figure 23 is a bar plot summarizing the 
representative OTUs at the genus level in the fecal samples of the infants and Figure 24 is 
a bar plot summarizing the relative abundance of phyla detected in the infant fecal 
samples. One hundred and seventy genera were detected in the infant fecal samples, 
belonging to thirteen phyla. The top six OTUs found in the infant fecal samples annotated 
to the taxa Bifidobacterium, Enterobacteriaceae, Veillonella, Streptococcus, Bacteroides 
and Prevotella. The most abundant phyla found within the infant fecal samples were 
Firmicutes, Actinobacteria, Proteobacteria and Bacteroidetes. The age of the infants in 
each of the five groups at the time of the final visit is seen in Figure 25, and there was no 
significant difference between the groups. 
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Figure 23: Bar plot of OTUs annotated at the genus level for infant fecal samples at 
the final visit. The top 25 OTUs are given in the legend in descending order of 
abundance. UN=Undernourished, UNP=Undernourished Probiotic, N=Nourished, 
NP=Nourished Probiotic, O=Obese. The y-axis denotes the relative abundance of 
each taxa. 
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Figure 24: Bar plot summarizing relative abundance of phyla detected in the infant 
fecal samples at the final visit. The 13 phyla detected are given in the legend in 
descending order of abundance. UN=Undernourished, UNP=Undernourished 
Probiotic, N=Nourished, NP=Nourished Probiotic, O=Obese. The y-axis denotes the 
relative abundance of each taxa. 
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Figure 25: Age of infants in each of the five groups in days at the time of sample 
collection for the final visit. Each symbol (, for example) indicates a participant 
sample. 
As shown earlier, analysis of the gut microbial composition of this study population at 
baseline did not show any differences using our definitions of nutritional status. Also, due 
to filtering, numbers of the final infant fecal samples were low among the groups. 
Therefore, in order to increase the power of analysis, the infant fecal samples from 
mothers receiving probiotic yogurt were grouped UNP and NP and fecal samples from 
infants whose mothers were not receiving probiotic yogurt were grouped UN and N, and 
ALDEx2 was used to assess differences in the representative OTUs annotated at the 
genus and phyla level. In addition, the results from these two groups were compared to 
the infants from obese mothers. To begin, groups were analyzed at the genus level. When 
performing ALDEx2 analysis between infant fecal samples from mothers who received 
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probiotic yogurt and infant fecal samples from mothers who did not receive probiotic 
yogurt, there was no difference (Figure 26A). In addition, there was no difference when 
comparing infant fecal samples from mothers receiving probiotic yogurt and obese 
mothers, nor when comparing infant fecal samples from mothers not receiving probiotic 
yogurt and obese mothers (Figure 26B and C, respectively). However when calculating 
the proportional representation of the top two genera (Bifidobacterium and an unknown 
Enterobacteriaceae, Figure 23) in the infant fecal samples from mothers not receiving 
probiotic yogurt and from mothers who did receive probiotic yogurt, significant 
differences were observed. Specifically, an unknown genera from Enterobacteriaceae 
was thirteen times more abundant in the infant fecal samples from mothers who did not 
receive the probiotic yogurt and Bifidobacterium was three times more abundant in infant 
fecal samples from mothers who did receive probiotic yogurt (Figure 27 A and B). 
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Figure 26: ALDEx2 results showing no difference in OTUs annotated to the genus 
level between infant fecal samples from mothers who received probiotic yogurt and 
those who did not (A), infant fecal samples from mothers who received probiotic 
yogurt and infant fecal samples from obese mothers (B) and infant fecal samples 
from mothers who did not receive probiotic yogurt and infant fecal samples from 
obese mothers (C). 
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Figure 27: Proportion of sequences aligned to an unknown Enterobacteriaceae (A) 
and Bifidiobacterium (B) in infant fecal samples from mothers who received 
probiotic yogurt (blue squares, both UNP and NP groups combined) and mothers 
who did not receive probiotic yogurt (red circles, both UN and N groups combined). 
Each symbol (, for example) indicates a participant sample. 
When comparing the infant fecal samples at the phyla level from mothers who received 
probiotic and those who did not, OTUs representing the phyla Actinobacteria were 
significantly more abundant in infant fecal samples from mothers who received the 
probiotic yogurt (p=0.03, using a Welch’s t-test with a Benjamini Hochberg correction) 
(Figure 28A). However, there was no significant difference in either the OTUs 
representing phyla between infants from the probiotic group and infants from the obese 
group or between infants from the non-probiotic group and infants from the obese group 
(p > 0.05) (Figure 28B and C). The differences between phyla represented in the infant 
fecal samples from the UN group and infants from the UNP group were investigated 
further with ALDEx2. In addition to Actinobacteria being significantly more abundant in 
the infants from the UNP group (p=0.049), Proteobacteria was found to be significantly 
more abundant in infants from the UN group using a Welch’s t-test with a Benjamini 
Hochberg correction (p=0.044) (Figure 29). 
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Figure 28: ALDEx2 results of comparisons of OTUs annotated to the phyla level 
between infant fecal samples from mothers who received probiotic yogurt and those 
who did not (A), infant fecal samples from mothers who received probiotic yogurt 
and infant fecal samples from obese mothers (B) and infant fecal samples from 
mothers who did not receive probiotic yogurt and infant fecal samples from obese 
mothers (C). Representative phyla that have significantly different abundance 
between and within the samples are depicted as red dots as seen in A, this dot 
represents the phyla Actinobacteria. 
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Figure 29: ALDEx2 results of comparisons of OTUs annotated to the phyla level 
between infant fecal samples from the UN and UNP groups. The red dots indicate 
significant phyla that are differentially abundant within and between the two 
groups and are representative of Actinobacteria and Proteobacteria. 
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3.10 Birth Data 
Once a participant gave birth, herself or a family member were instructed to contact study 
staff within forty-eight hours. At this time a birth visit was scheduled within three days 
and the participant was invited to attend this visit with her infant. There were only two 
twin sets born in the entire study and they were to mothers in the NP group. In addition, 
the infant mortality rate was only 2 in 48 live births. One infant was born deceased at 
approximately 25 weeks gestation, while the other passed away four days after birth at 
approximately 32 weeks gestation for unknown reasons. Furthermore there were only 5 
low birth weight infants out of the 48 live births. These comprised one twin set in the NP 
group who were born at approximately 37.7 weeks gestation and weighed 2.1 kg and 2.3 
kg. The mother of these infants lost on average 0.33 lbs per week during the course of her 
pregnancy and consumed on average 1788 kcal per day. A second low birth weight infant 
was born to a mother in the NP group at approximately 27 weeks gestation. This mother 
only received the yogurt for 36 days, and lost on average 0.6l lbs per week. However, she 
was consuming on average 2797 kcal per day. One low birth weight infant, weighing 2.4 
kg, was born at approximately 39 weeks gestation to an obese mother who gained on 
average 0.3 lbs per week during the course of her pregnancy and consumed 2438 kcal per 
day. The last low birth weight infant was born in the UNP group at 34 weeks gestation 
and weighed 2.3 kg. This infant’s mother gained on average 0.93 lbs per week and 
consumed approximately 2845 kcal per day. A summary of the birth data for all groups is 
given in Table 21. Gestational age at the time of birth as determined by recall of 
participants LMP and the NA was fairly similar between groups, as given by the mean 
difference between the LMP and NA in Table 19.  Based upon the LMP, 3 births were 
preterm in the UN group, 2 in the UNP group, 1 in the N group, 4 in the NP group and 1 
in the O group. Based on the NA method, 4 were preterm in the UN group, 3 in the UNP 
group, 3 in the N group, 4 in the NP group and none in the O group. The mean gestational 
age at the time of birth by both the LMP method and NA method are given in Table 19. 
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Table 19: Birth data for participants in each group. Values are given as a mean and 
standard deviation. LMP=last menstrual period and NA=nurse approximation of 
gestational age. 
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Chapter 4  
4 Discussion 
An individual’s nutritional status is determined by the intake and utilization of nutrients, 
their overall state of health and the physical environment. During pregnancy, the need for 
appropriate nutrition is increased and if these needs are not met then a number of adverse 
pregnancy outcomes can result. Adverse pregnancy outcomes that result from both over- 
and under-nutrition have been well documented in the developed and developing world 
and both over- and under-nutrition are a burden on the social and economic progress of 
developing countries and a major focus of intervention is in mothers and infants. In the 
last decade, the human microbiota has emerged as one of the most powerful determinants 
of health and disease including ones nutritional status. However, relatively little is known 
about the gut, oral and vaginal mircobiota of pregnant women, especially those who are 
undernourished. Furthermore, probiotics are showing increased potential to be a 
modulator of health of the microbiota, especially in the gut and reproductive tract and can 
easily be produced and administered in the developing world in yogurt format. Thus, it is 
reasonable to propose that the maternal gut, oral and vaginal microbiome of mothers of 
varying nutritional status differs and could have an effect on pregnancy outcomes. Also, 
providing nutrient enriched probiotic yogurt to a subset of these mothers could help 
improve their health during pregnancy as well as the health of their infants. The major 
findings of this study were that the microbiome of mothers of varying nutritional status 
did not differ in their second trimester, while supplementation with Moringa enriched 
probiotic yogurt also did not have significant effects on anthropometrics nor nutritional 
indicators of those consuming it. Furthermore, for this population, birth outcomes were 
generally positive among all groups of nutritional status. However, important and unique 
findings were observed in the gut microbiota of infants from mothers who consumed the 
yogurt during pregnancy. In addition, probiotic yogurt consumption appeared to protect 
against mercury exposure. A closer look and the implication of these findings will be 
discussed below.  
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4.1 Defining the Maternal Microbiota in Pregnancy 
In order to determine whether the maternal gut, oral and vaginal microbiome differed in 
mothers of varying nutritional status, the V4 region of the 16S rRNA gene was amplified 
and sequenced from samples collected at the first visit. The sequences were then binned 
into OTUs, which were matched to reference sequences in the Greengenes database to 
determine their identity. The microbiome at each body site was analyzed independently. 
There does not exist a consensus on defining nutritional status in pregnant women 
especially in resource poor settings, furthermore, risk indicators for low birth weight 
infants have been found to vary between developing countries201. The strongest assessor 
of adverse pregnancy outcomes and malnutrition in pregnant women is MUAC with a 
cutoff of <23 cm to define under-nutrition201. Although not as strong of an indicator, low 
maternal weight for gestational age has also shown correlation with low birth weight 
infants. Thus, a combination of MUAC and weight for gestational age as described by 
Gueri et al. 200 was used to define the nutritional status of participants entering the study. 
Based on our definition of nutritional status, there was no difference in the MUAC of 
undernourished and nourished groups, however the participants in the UN and UNP 
groups weighed significantly less than women in the N and NP groups even though 
heights and gestational ages were the same, indicating a lack of proper nourishment in 
this group (Table 7). Furthermore, the MUAC and weights of participants in the O group 
were significantly greater than all other groups indicating proper assessment of over-
nourishment. Although the weight of the women in the five groups significantly differed 
at baseline (Table 7), the maternal gut microbiota profile of mothers in their second 
trimester did not differ between groups as determined from the ALDEx2 analysis at both 
the genus and phyla level annotation (Figure 18). This was unexpected, especially for 
participants from the O group. Turnbaugh et al.106 established that a difference exists in 
the microbiome of obese and lean individuals, specifically a decrease in the phyla 
Bacteroidetes and an increase in the phyla Actinobacteria in obese individuals. However, 
this study was undertaken with African American and European American twin pairs, 
and the V2 region of the 16s rRNA gene was analyzed by 454 FLX amplicon 
pyrosequencing. For the participants of the current study, Bacteroidetes was the most 
abundant phyla, across all groups, accounting for approximately 47 ± 2% of annotated 
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OTUs, while Actinobacteria only accounted for 0.29 ± 0.04% of annotated OTUs at the 
phyla level. Turnbaugh et al.’s study106, found that Bacteroidetes accounted for 37.52 ± 
3.05% and 29.41 ± 1.49% in obese and lean African American twin pairs respectively 
and that Actinobacteria accounted for 0.97  ± 0.40% and 1.27 ± 0.21% in lean and obese 
African American twin pairs respectively. The percent abundance of both these phyla 
were even lower in the European American obese and lean twin pairs106. Although it is 
known that different sequencing platforms and amplification of different sections of the 
16s rRNA variable region do lead to certain community bias216, the differences between 
the current study and Turnbaugh et al.’s106 study are too large to be due just to 
methodology differences. The dominant members of Bacteroidetes that inhabit the human 
gut are Bacteroides and Prevotella. It has been well established that the gut microbiota of 
European and North American individuals differs from that of Amerindian and African 
individuals due to diet98,102. Specifically, Amerindian and native Africans have a gut 
microbiota dominated by Prevotella, whereas Bacteroides dominates in European and 
North American individuals. As expected, OTUs annotated to Prevotella were the most 
abundant at the genus level of classification in all individuals in our study (Figure 16), 
due to a diet high in carbohydrates.  
Normally, obesity and overweight is attributed to an energy intake that exceeds daily 
energy expenditure. However, in the current study there was no difference in any group 
in caloric intake during the 48 hours prior to sample collection at baseline (Table 8). 
Assessing activity levels in our population was done through an estimation of kilometers 
walked per day, as well as whether or not participants held a job. As seen in Table 9, 
participants in all five groups had similar levels of activity based on kilometers walked. 
Furthermore, all participants in the O group were employed. Thus, it can be assumed that 
energy intake and energy expenditure were not responsible for the increased weight in the 
O group. It has been reported elsewhere that there are additional factors that result in 
overweight/obesity in individuals that have the same energy expenditure and intake as 
well as activity levels as compared to lean individuals217, thus this result is not surprising. 
In studies investigating the gut microbiota of obese North American individuals, levels of 
activity and caloric intake are not always taken into consideration. One study by 
Santacruz et al.153, did assess the dietary intakes of obese and lean pregnant mothers and 
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also did not find any difference in intake 72 hours prior to sample collection. Participants 
in the Santacruz et al.153 study were also recruited during the second trimester, but gut 
microbiota communities were assessed using Quantitative real-time PCR. Differences in 
gut microbial composition were also observed at the genus level, but changes at the phyla 
level were not done and these observations may have been due to methodology 
limitations and low sample numbers (n=16 for the obese group). Recently, Le Chatelier et 
al.,218 noted that the number of gut microbial genes expressed by the gut microbiome, is 
reduced in individuals with increased adiposity, insulin resistance and an inflammatory 
phenotype. Furthermore, they only found nine species within the gut microbiota that 
could distinguish obese and lean individuals after an exhaustive analysis with lower 
accuracy then the differences observed in gene richness. Taking all this together, a 
greater in depth analysis into microbial gene expression by the resident flora may have 
been needed in order to observe differences in the gut microbiota of the current study 
population, however, this was beyond the scope of the project. In addition, the 
geographical differences due to diet may result in different observations due to nutritional 
status, as it has been observed that the total number of representative Firmicutes increase 
and the total number of representative Bacteroidetes decrease with increasing latitudes219. 
Thus, studies conducted in North America in relation to obesity/overweight may not 
translate to other parts of the world and larger more in depth studies in varying 
geographical locations of the world need to be conducted in order to gain a beneficial 
understanding of the alterations in the gut microbiota in obese/overweight, lean and 
under-nourished individuals. Furthermore, only one study has investigated the gut 
microbiota in pregnancy and only analyzed samples collected in the first and third 
trimesters144. Again, this study found that women in the third trimester had an altered gut 
microbiota that was representative of individuals with metabolic syndromes, while 
women in the first trimester had a microbiota representative of healthy non-pregnant 
individuals. The authors, however, did not analyze samples collected during the second 
trimester so it is not known whether shifts occur in the gut microbiome during this time. 
For the purpose of this thesis and due to time constraints, the changes in the gut 
microbiota of participants in this study were not analyzed between baseline (visit 1) and 
the final visit. However, samples were collected on a monthly basis between recruitment 
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and birth (Figure 8) and they have been sequenced and will be analyzed to determine if 
changes do occur between the second and third trimester as observed in the study by 
Koren et al.144  
This thesis is the first to investigate the oral microbiome of pregnant women. Samples 
collected at baseline were extracted and sequenced as per the methods above. There were 
no significant differences in the oral community profiles observed between the five 
groups at the first visit (Figure 19). The most abundant genus was Streptococcus, 
followed by Prevotella, Haemophilus, Neisseria and Veillonella. Bik et al.,220 amplified 
approximately 90% of the 16S rRNA gene and sequenced the entire fragment, from oral 
samples collected from 10 healthy adult individuals. They found similar results with 
Streptococcus representing 19.2% of the total sequences in their study and 19.1% of the 
total sequences in the current study. However, the second most abundant genus in our 
study was Prevotella, which represented 12.1% of the total sequences, while Bik et al.,220 
found that Prevotella was only representative of 8.6% of the total sequences. Although, 
studies on the oral micorbiome of individuals from different geographic locations did not 
result in any significant differences in the oral microbiota composition90, the differences 
in Prevotella abundance seen in the current study could be due to the diet rich in 
carbohydrates consumed by study participants. The abundance of the genus Haemophilus 
(11.7%), Neisseria (9.2%) and Veillonella (8.6%) found by Bik et al. were all very 
similar to what we observed in our study (10.2%, 10% and 9.5% respectively). Thus, for 
the current study population, the oral microbiome of pregnant women in their second 
trimester in all five groups, shared similarities to the oral microbiome of healthy North 
American individuals.  
The vaginal microbiome of participants in their second trimester was also investigated. 
At the first visit, the vaginal samples of the women in all groups were dominated by the 
genus Lactobacillus (Figure 20). The abundance of Lactobacillus was greater than 80% 
in 28 out of 51 women at the first visit and these samples clustered along PC2 in Figure 
21. The five samples that spread out along PC1 in Figure 21 had Lactobacillus present at 
an abundance of 47-43%, while women who had an intermediate or positive Nugent 
score had a greater abundance of OTUs representing Megasphaera, Gardnerella and 
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Sneathia which are representative organisms of BV. This indicates that the Nugent 
scoring co-relates with the microbiota profiles. The abundance of Lactobacillus in the 
vaginal samples of women in their second trimester is similar to the findings of 
Hummelen et al.88, who investigated the vaginal microbiota of non-pregnant women from 
the Mwanza region, who were also HIV positive. They targeted the V6 region of the 16S 
rRNA gene so were able to achieve deeper sequencing to the genus level, however, they 
did find that a Lactobacillus and Gardnerella species constituted core members of the 
vaginal microbiome in Tanzanian women. Gardnerella was also present in every sample 
of our participants at an average of 6.2% (range of 0.007%-20.8%) abundance. 
4.2 Effect of Moringa Enriched Probiotic Yogurt on Maternal 
Health Status and Birth Outcomes 
It was proposed that the supplementation of Moringa enriched probiotic yogurt could 
increase the health status of under-nourished mothers as well as improve birth outcomes. 
In order to assess this dietary intake, nutrient blood levels, weight gain, Hb levels and the 
nutrient content of breast milk were monitored. In addition, birth data and anthropometric 
measurements were collected for the infants. Gut, oral, vaginal and breast milk samples at 
the birth and final visits from the mothers, as well as fecal and oral samples at the birth 
and final visits from the infants were collected and sequenced. However, only the gut and 
vaginal samples of the mothers at the final visit, and gut samples from the infants at the 
final visit are discussed in order to determine if Moringa enriched probiotic yogurt may 
modulate the microbiota.  
4.2.1 Supplementation with Moringa Enriched Probiotic Yogurt 
Does not Increase Gestational Weight Gain 
It is well known that inadequate or excessive gestational weight gain can lead to small 
and large for gestational age infants, as well as an increased risk of pre-term birth221-226. 
The average weight gain per week from time of recruitment to birth in the UN and UNP 
groups met the IOM standards of appropriate gestational weight gain for a healthy 
pregnancy, while the average weight gain per week for the NP and N groups were below 
the recommendations (Figure 9).  Despite this, it appeared that extremes of the IOM 
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recommendations lead to low birth weight (LBW) infants (<2.5kg). Out of the four 
participants in the UN, UNP, N and NP groups who lost weight during the second and 
third trimesters, three had LBW infants while the fourth had a full term pregnancy and a 
healthy weight infant (Appendix 8-11).  Furthermore, out of eight women in the UN, 
UNP, N and NP groups who had pre-term births, only three had inadequate weight gain 
and only one had both inadequate weight gain and an infant who later passed away 
(Appendix 8-11). Due to the small sample size statistical significance was not detected, 
but it appeared that gestational weight gain outside the IOM recommendations during the 
second and third trimester did not have a significant effect on infant birth weight or pre-
term delivery. All four women in the O group were below the IOM recommendations of 
healthy gestational weight gain for obese/overweight women. In 2006, Dietz et al., 
utilized the information found in the Pregnancy Risk Assessment Monitory System 
database from the United States to determine the effects of prepregnancy BMI and 
pregnancy weight gain on adverse birth outcomes223. They found that as prepregnancy 
BMI increased, the amount of weight gained during pregnancy decreased. Specifically, 
Dietz et al. observed that 19% of women with high prepregnancy BMI had gestational 
weight gain of less than 0.26 lbs/week which was similar to the average gestational 
weight gain observed for the O group at 0.33 lbs/week in the present study. Furthermore, 
despite the below recommended gestational weight gain for the O group, none of the 
women had pre-term births (Appendix 12). Dietz et al.223, also observed that low 
gestational weight gain for obese/overweight women did not result in a significant 
association with pre-term delivery. 
The addition of 250 mL of Moringa enriched probiotic yogurt to the diet in the current 
study population did not significantly affect the daily caloric or fat intake of the UNP and 
NP groups as seen in Table 10. Determining the recommended daily caloric requirements 
for pregnant women is based on a calculation that takes pre-pregnancy weight into 
consideration. However, individuals in this population do not maintain records of their 
prepregnancy weight, it was unknown whether daily caloric intake met the recommended 
requirements for pregnancy. Thus, no assessment was made to determine if low 
gestational weight gain was associated with inadequate caloric intake. Furthermore, if 
caloric intake from the diet was significantly below the recommended intake then the 
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supplementation of 250 mL of yogurt may have been insufficient to cause a change. It 
would be beneficial for future studies to recruit women prior to pregnancy in order to 
gain an accurate assessment and understanding of gestational weight gain based on 
dietary intakes and the appropriate amount of yogurt supplementation to appropriately 
meet dietary needs.  
4.2.2 Supplementation with Moringa Enriched Probiotic Yogurt 
does not Affect Maternal Nutrient Blood Levels 
Venous blood from study participants was collected at the first, 4th (approximately 7 
months gestation) and final visits to assess nutrient blood levels of protein and Vitamin 
A. The addition of Moringa enriched probiotic yogurt provides pregnant women with 
13% of recommended intake of protein, and 35% of the recommended intake of Vitamin 
A as outlined by the Canadian RDI Tables227. Despite supplementation, there was no 
significant difference in the average daily intake from time of recruitment until birth of 
protein and vitamin A in the UNP and NP group as compared to the other three groups 
(Table 10). There was also no difference observed in the blood retinol and protein levels 
in the UNP and NP groups as compared to the other three groups at both baseline and the 
final visit (Table 19). During a normal pregnancy, blood volume increases in order to 
meet the circulatory needs of the placenta and maternal organs. The exact increase in 
blood volume can vary among women and is lffected by factors such as maternal pre-
pregnancy BMI, height and ethnicity228-230. Due to this blood volume increase, levels of 
blood nutrients can be altered and may not be reflective of the actual concentration. The 
most common circulating form of Vitamin A in the blood is retinol. The amount of 
retinol in the blood is homeostatically regulated by the liver and serum retinol levels 
reflect liver stores only if severely depleted (< 0.07 µmol/L) or extremely high (> 1.05 
µmol/L)231. Furthermore, decreased levels of serum retinol due to increased plasma 
volume during pregnancy have been reported232. Despite this, serum retinol levels in 
pregnant women are commonly monitored due to the increased occurrence of 
micronutrient deficiencies in developing countries as well as the adverse consequences of 
Vitamin A deficiencies such as impaired health of the mother and impaired growth, 
development and health of her infant. Further, the WHO has defined a serum or plasma 
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retinol concentration in pregnant women of <0.70 µmol/L as a Vitamin A deficiency, 
with a serum retinol concentration below 1.05 µmol/L being reflective of low vitamin A 
status among pregnant and lactating women233. The prevalence of pregnant women in 
Africa with serum retinol levels < 0.70 µmol/L as assessed by the WHO between 1995-
2005 was 13.5%. At baseline, in the current study, 15.4% of the participants had serum 
retinol levels below 0.70 µmol/L, which is similar to the levels observed by the WHO for 
African populations. At the final visit the average serum retinol levels of all groups were 
within the reference ranges for non-pregnant Canadian individuals as provided by the 
London Laboratory Services Group (Table 19). The average levels of serum retinol 
observed at baseline were quite a bit lower than values observed for pregnant women in 
Peru (1.46 µmol/L)234, but similar to levels observed in a study of 733 pregnant women 
with gestational ages between 7 and 42 weeks, from Guinea-Bissau in West Africa (1.03 
± 0.33 µmol/L)235. Sapin et al, examined the serum retinol levels in well-nourished 
pregnant women immediately before delivery and observed slightly higher average levels 
of serum retinol (1.27 ± 0.38 µmol/L) then what we observed in our study214. The 
maternal serum retinol levels observed by Sapin et al.214 were significantly different from 
a control group of healthy non-pregnant women, but when the retinol levels were 
expressed as a ratio of micromoles serum retinol to grams of serum total protein, then this 
difference between the pregnant and non-pregnant group disappeared. Unfortunately, 
non-pregnant women were not recruited as a control for the current study, but when the 
values of serum retinol and serum total protein were expressed as a ratio as done in Sapin 
et al.214, the values for the UN, UNP, and NP groups were lower, while values for the N 
and O group were similar to the ratio observed in Sapin et al.214 (0.021 ± 0.005 µmol/ g 
protein and Table 19). In populations where pre-pregnancy weights are unavailable it 
may be beneficial for future studies to recruit and collect venous samples from non-
pregnant aged matched individuals of varying nutritional status to compare this ratio of 
serum retinol to serum protein as an additional indicator of nutritional status in pregnant 
women. Total protein levels were also assessed at baseline and the final visits, and the 
average serum protein levels for all groups at both visits were within reference ranges 
except for the O group, who had average serum protein levels below the reference ranges 
(Table 19). Dietary analysis of protein intake between the five groups was similar based 
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on percent RDI of Canadian values, so a decreased dietary protein intake by participants 
in the O groups was not the reason for reduced serum protein levels. However, obesity is 
associated with a greater increase in blood volume, which could account for the lower 
serum protein levels observed236.  
Significant increases in dietary intake of calcium in the NP and UNP groups as compared 
to the groups who did not receive probiotic yogurt were observed. Unfortunately calcium 
blood levels were not assessed due to the blood being collected in vacutainer tubes 
containing EDTA, which bind calcium in the blood to prevent it from clotting. However, 
calcium is an important nutrient during pregnancy. If dietary calcium intake does not 
increase to meet the demands of calcium absorption, which significantly increases in the 
second and third trimesters, then pregnant women can be at an increased risk of 
preeclampsia, pre-term birth and long-term morbidities such as excessive bone loss237. 
Furthermore, maternal dietary intake of calcium has been found to be associated with 
positive bone outcomes for her offspring237. The recommended dietary intake of calcium 
during pregnancy is 1,000 mg/day227. Probiotic yogurt consumption lead to the NP and 
UNP groups meeting 61 and 56% of the RDI for calcium respectively, while the other 
three groups consumed less than 30% of the RDI for calcium (Table 11). Dietary sources 
of calcium are uncommon in the rural Tanzanian diet, which is based mainly on ugali 
(corn flour), rice, fish, tomatoes, onions and spinach. Thus, supplementation of the diet 
with probiotic yogurt to all individuals would be extremely beneficial for this population 
to maintain bone health.  
4.2.3 Supplementation with Moringa Enriched Probiotic Yogurt 
Does not Alter Hemoglobin Concentrations During 
Pregnancy 
Hemoglobin concentration of all participants was monitored at every visit using a 
Hemocue from time of recruitment until participants exited the study. Due to plasma 
volume increases, anemia in pregnancy is defined as levels < 11.0 g/dL during the first 
and third trimesters and <10.5 g/dL in the second trimester as compared to <12.0 g/dL in 
non-pregnant women238. In our study population the average hemoglobin concentration 
of all groups in the second trimester was above 10.5 g/dL (Table 14), while in the third 
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trimester all groups had average hemoglobin concentrations below 11.0 g/dL (Table 14). 
In 2008, the WHO released a report on the prevalence of anemia worldwide. In Africa, 
the prevalence of anemia was 55.8% in pregnant women239. In the current study 
population, the prevalence of anemia was quite a bit lower, with prevalence reaching the 
continents numbers for moderate anemia in the third trimester for the UNP and N group, 
and mild anemia for the N group in the second trimester (Table 15). The reduced 
prevalence of anemia seen in the current study population could be due to the low sample 
numbers. In addition, iron supplements were routinely handed out at the clinic where the 
study was conducted. Information on who received these supplements was collected and 
in the future it is important to examine the relationship between hemoglobin status of 
individuals who received iron supplements and those who did not. In another study 
conducted in a municipality near Mwanza, Tanzania which included 2,654 pregnant 
women in their third trimester, 35.3% of the participants had mild anemia which was 
similar to the prevalence observed in the present study if the five groups were combined 
(26.6%)240. However, the prevalence of participants in the third trimester with moderate 
anemia when all five groups were combined (38%) was substantially higher than 
observed in the study by Msuya et al. (9.9%)240. 
The supplementation of Moringa enriched probiotic yogurt, provided the participants 
with only an additional 4% of the RDI of iron for pregnant women (Table 2). However, 
based on the analysis of the dietary recalls all participants in each group meet the dietary 
intake requirements for iron (Table 11). Anemia can be caused by a number of factors, 
with the most common being deficiencies in either iron or folate238. Based on the dietary 
recalls, participants in the present study were only meeting between 33 and 50% of the 
RDI for folate (Table 11) and supplementation with Moringa enriched probiotic yogurt 
did not provide an additional dietary source of folate (Table 1). In another study 
conducted out of four antenatal clinics in rural northern Tanzania, low serum folate and 
malaria status was also found to be associated with anemia in a study population of 2,547 
pregnant women241. Rapid Malaria tests were performed, thus, future work can also 
involve investigating a relationship between malarial infection and anemia. In addition, 
whole blood cells were collected for folate analysis and determination of folate levels 
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would investigate whether a deficiency was responsible for the anemia observed in the 
present study.  
4.2.4 Changes in the Vaginal Microbiota between the First and 
Final Visits 
The vaginal microbiota at the first and final visits were compared. At the first visit, the 
vaginal samples were dominated by Lactobacillus, which is indicative of vaginal health 
during pregnancy141. Samples not dominated by Lactobacillus, were dominated by 
organisms associated with BV which was in agreement with the Nugent scores (Table 20 
and Figure 20)242. In the only other study that looked at the vaginal microbiota in 
pregnancy, a reduction in diversity was observed as compared to non-pregnant 
individuals, with an increase in Lactobacillus species iners, crispatus, jensenii and 
johnsonii141. However, in the present study, sequencing of the V4 region did not allow for 
identification of taxa at the species level. Thus, although 29 out of 51 samples having 
greater than 80% abundance of Lactobacillus were observed, it was not possible to 
determine the species composition or to make conclusions about diversity within these 
samples, as samples were not collected from a non-pregnant population and comparisons 
between different studies cannot be done due to different methodologies used. Future 
work could involve examining and comparing the diversity within samples 
longitudinally, as vaginal samples were collected every month during gestation. 
Furthermore, it would be beneficial to collect age-matched vaginal samples from a non-
pregnant subset for comparison in a larger scale study to determine the changes in the 
vaginal microbiome during pregnancy in a native African population. 
The vaginal microbiota significantly changed after giving birth. Alpha diversity 
comparisons using the Shannon index revealed that the vaginal microbiota of the women 
significantly increased in diversity from the first visit to the final visit. Furthermore, 
Sneathia and Prevotella dominated the vaginal microbiota at the final visit, which are BV 
associated organisms and Prevotella species have also been previously observed as a 
dominant BV associated organism in Tanzanian populations88,242. Nugent scoring of the 
final visit samples did not match the microbiota profiles. In a study conducted out of 
Bugando Medical Centre in Mwanza, Tanzania, Nugent scoring was performed at birth 
117 
 
and BV was diagnosed in 28.5% of the participants150. Based on the Nugent scores 
obtained in the current study, 41% of participants had a positive Nugent score at the final 
visit. A potential reason for the increased prevalence of a positive Nugent score, could be 
due to the fact a majority of the women gave birth at home, thus the birthing conditions 
may not have been as sanitary as in a hospital. Based on dominance of Lactobacillus, 
only two samples were BV negative (Figure 22). OTUs for Lactobacillus were present in 
every sample at the final visit except for one, and the average abundance at the final visit 
was 12.7% compared to 70% at the first visit. No other studies have examined the vaginal 
microbiota of women at birth, thus the shifts observed in the current study may not 
necessarily be indicative of disease but may be a normal disruption due to the birthing 
process. The final visit samples were collected between 8 and 30 days after birth; 
however, vaginal samples were collected and sequenced from 3 days after birth. Thus, it 
would be extremely interesting to examine these samples and compare them to the final 
visit samples to determine if this increased diversity and altered OTU dominance was 
also observed at this time point. Furthermore, in order to gain greater understanding on 
the shifts of the vaginal microbiota due to the birthing process, future studies should 
collect vaginal samples up to six months or a year after birth to determine when the 
microbiota shifts back to the pre-pregnancy profile, and the factors that might influence 
this process.  
4.2.5 Supplementation with Moringa Enriched Probiotic Yogurt 
May Modulate the Infant Gut Microbiota 
Infant fecal samples collected at the final visit had the bacterial DNA extracted and the 
V4 region of the 16S rRNA gene amplified and sequenced. Studies have shown that the 
infant gut microbiota during the first 3 years of life contains high interindividual 
variability and does not follow a defined developmental pattern due to significant 
changes caused by life events such as type of feeding, introduction of solid food and 
antibiotic exposure. However, it is generally accepted that Bifidobacterium becomes the 
dominant bacterial genus starting approximately three days after birth128,243,244. The age of 
the infants analyzed at the final visit were between 10 and 20 days and as seen in Figure 
25, Bifidobacterium was the most abundant genus in a majority of the fecal samples. 
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Bifidobacterium appeared to be more abundant in the UNP and NP groups then in any 
other group and members of the family Enterobacteriaceae appeared to be more 
abundant in the UN and N groups (Figure 23). Studies have shown that members of the 
family Enterobacteriaceae are normally the dominant organisms at birth in infants born 
vaginally and numbers normally decline once Bifidobacterium begins to 
dominate96,128,244. ALDEx2 analysis determined that the difference observed at the genus 
level between the relative abundance of Bifidobacterium and the unknown 
Enterobacteriaceae was not significant, most likely due to the low sample numbers. 
However, when the actual proportion of sequences aligned to Bifidobacterium and the 
unknown Enterobacteriaceae were compared between infant fecal samples from mothers 
who received probiotic yogurt (UNP and NP groups) and infant fecal samples from 
mothers who did not receive probiotic yogurt (UN and N groups), a significant difference 
was observed (Figure 27). Specifically, Bifidobacterium was three times more abundant 
in the infant fecal samples from mothers who received probiotic yogurt and the unknown 
Enterobacteriaceae was thirteen times more abundant in infants from mothers who did 
not receive probiotic yogurt. Further ALDEx2 analysis on the phyla level revealed that 
Actinobacteria was significantly increased in infants from mothers who received 
probiotic yogurt as compared to infants from mothers who did not. If the UN and UNP 
groups were compared alone, Proteobacteria was also significantly increased in the UN 
group as compared to the UNP group (Figures 28 and 29). Enterobacteriaceae is a 
member of Proteobacteria and evidence has suggested that an increased abundance of 
members of Enterobacteriaceae in the infant gut is associated with the development of 
atopic disease245-247. Furthermore, members of both Proteobacteria and 
Enterobacteriaceae include a number of organisms that have the potential to be 
pathogenic and an increase of representative members of this taxa coinciding with a 
decrease of members of Bifidobacterium (a genus belonging to the phyla Actinobacteria) 
is not normally associated with health. An increase of Enterobacteriaceae and a decrease 
in Bifidobacterium, has also been observed in infants receiving antibiotic treatment and 
this imbalance was seen to persist even after treatment commenced248. The exact 
consequences of persistence of this imbalance is not completely understood, nor has it 
been investigated, however, a recent study has shown that a decrease in Bifidobacterium 
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and an increase in Enterobacteriaceae is associated with Crohn’s disease in children249. 
Furthermore animal models and in vitro studies have shown that members of 
Bifidobacterium promote specific immune functions, which could translate to an 
importance of increased Bifidobacterium diversity in infant guts for proper immune 
development250-252. In addition, secreted factors from Bifidobacterium infantis (a 
prominent member of the infant gut microbiota comprising up to 90% of the total 
Bifidobacterium), have been shown to reduce colonic permeability and attenuate 
inflammation in mouse models173. Thus, supplementation of Moringa enriched probiotic 
yogurt to mothers during pregnancy, may be priming their infant’s gut microbiota for 
healthy compositional and immune development, as well as protection against infection. 
It could be extremely valuable and informative to conduct a large-scale, longitudinal 
study on probiotic supplementation from pregnancy to three years post-partum to fully 
understand the potential of this proposed modulation.  
4.2.6 Nutritional Content of Breast Milk does not Differ Between 
Mothers who Received Probiotic Yogurt and Mothers who 
did not 
Breast milk is well known for its nutritional value, immune-modulating compounds, 
stimulation of cognitive development and protection against pathogenic organisms. 
Recently, the role of breast milk in the development of the intestinal microbiota of the 
infant has gained a lot of attention. Breast milk contains between 10 and 20 g/liter of 
oligosaccharides, which are the third most abundant component after lactose and 
lipids253. These oligosaccharides are not digested by the infant, however, it has been 
shown that they play an important role in preventing adhesion of pathogens to the 
mucosal lining, as well as stimulating the growth of Bifidobacterium in the infant 
gut137,138,254. Thus, due to our findings it was further hypothesized that the probiotic 
yogurt might have an affect on the nutritional content of the breast milk thereby 
accounting for the increase in Bifidobacterium seen in the infant guts from mothers who 
received the probiotic yogurt. Determining the exact oligosaccharide content of breast 
milk can be done with a number of methods, but the most common and preferred are 
Mass Spectrometry (MS) and HPLC-Chip/time-of-flight MS137. Determining the exact 
oligosaccharide profile was beyond the scope of this study, however, protein, fat and the 
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lactose content of breast milk were examined and the estimated total carbohydrate 
content from these measurements were determined to gain an idea of the oligosaccharide 
content. As seen in Figure 13, there was no difference in the fat, carbohydrate and protein 
content of breast milk in the five groups. Fat, protein and carbohydrate content of breast 
milk collected at the birth and final visit were averaged due to low sample numbers. The 
time of collection of these two samples varied from 3 days after birth to 30 days after 
birth, thus colostrum, transitional and mature milk were used in the analysis. 
Concentration of proteins is normally higher in colostrum than in mature milk, however, 
fat and carbohydrate concentrations remain relatively the same255. The total average 
concentration of fat, protein and carbohydrate content varied from 2.69-2.81, 1.20-1.37 
and 5.51-5.72 g/dL, respectively, for all five groups. The standard concentration in 
Western populations of fat in breast milk is 2.6 to 4.1 g/dL from colostrum to mature 
milk, 2.0 to 1.3 g/dL for protein from colostrum to mature milk, and 6.6 to 7.2 g/dL for 
carbohydrates from colostrum to mature milk255. The values obtained in the present study 
for fat, protein and carbohydrate content are on the lower end of the Western norms. 
Normally, carbohydrate and protein content remain relatively stable in women of varying 
nutritional status, while fat concentration can be affected by weight gain during 
pregnancy, as well as nutritional status255. However, in the current study no major 
increase in fat concentration in women with higher gestational weight gain was observed.  
4.3 Supplementation of Moringa Enriched Probiotic Yogurt 
Provides a Protective Effect against Mercury and 
Arsenic 
Although it is recommended that pregnant women consume an appropriate amount of fish 
during pregnancy in order to provide the fetus and mother with essential omega-3 fatty 
acids and other nutrients, it is also widely accepted that consumption of fish high in 
mercury should be avoided due to the detrimental effects of the heavy metal on the 
developing fetus. The clearest documented effects of mercury on fetal neurodevelopment 
were observed in Minamata City in Japan during the 1950’s, where release of methyl 
mercury into the water resulted in deaths and physical impairment of thousands of adults, 
children and unborn babies256. These same affects were observed due to the consumption 
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of grain treated with a mercury containing fungicide in Iraq in the 1970’s257. Since then, 
it has been shown that high levels of maternal mercury can result in infertility as well as 
spontaneous abortion and stillbirths256. 
Mwanza, Tanzania is located on the shores of Lake Victoria, which is the world’s second 
largest fresh water lake by surface area and is inhabited by many species of fish that are a 
major source of income and food for those in the region. Specifically, 1% of the Mwanza 
population is employed by the fishing sector and in 2001 63,990 tons of fish were 
harvested from Lake Victoria in the Mwanza region alone258.  Furthermore, gold ore 
processing using mercury is common practice in the gold-mining industry of Tanzania 
and three of the major gold fields (Geita, Musoma and Tarime) are located near the 
shores of Lake Victoria. Mercury pollution of the water, soil sediments and fish of Lake 
Victoria is commonly acknowledged due to these activities, and thus mercury exposure is 
higher in the Mwanza region then in other regions of Tanzania259.  
Because of Lactobacillus species observed ability to sequester mercury in vitro, it was 
determined if consumption of the Moringa enriched probiotic yogurt may have an effect 
on the blood mercury and heavy metal levels of the pregnant women. Despite similar 
levels of fish consumption during the study (Figure 10), as well as similar consumption 
of fish per kilogram of body mass before blood collection at the first visit and blood 
collection at the final visit (Figure 11), participants who received the probiotic yogurt 
appeared to maintain their levels of blood mercury and arsenic, while participants who 
did not receive the probiotic yogurt, had a significant increase in mercury and arsenic 
levels (Figure 12). Mercury levels have been shown to be relatively stable in blood 
samples, unless repeated freeze thaw cycles are carried out which was not the case in the 
current study260,261. Furthermore, all samples were stored under the same conditions and 
for roughly the same amount of time from time of collection until analysis. Thus, the 
increased levels of mercury and arsenic in the control group were not likely due to 
storage conditions and length of time. Unfortunately, determining the exact mechanism 
by which the probiotic yogurt maintained the levels of mercury and arsenic in the blood 
of pregnant women is beyond the scope of the present study. However, the probiotic 
could be acting to sequester the mercury from the gut, thereby preventing its uptake. 
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Future studies could examine the mercury levels in fecal samples as has been done in 
other studies262,263, to determine if mercury levels increase in the feces of participants 
who consume probiotic yogurt as compared to those who do not. 
 Levels of lead and mercury in the blood of pregnant women in the current study were 2.5 
times increased as compared to the levels observed in Canadian women (Table 18)213.  
Levels as high as 14.9 nmol/L have been observed in Saudi Arabian pregnant women264, 
while mercury levels of 6.6 nmol/L have been observed in pregnant women in Bermuda 
who also consume a large amount of fish during pregnancy265. The increased amount of 
mercury observed in the present study is most likely due to the consumption of fish, as 
fish is one of the main sources of protein for individuals in this area of Tanzania and the 
women consumed fish on average 2 to 3 times per week during pregnancy. The 
consequences of high levels of mercury exposure during pregnancy are well known and a 
recent study conducted in Hong Kong has shown that even low levels of mercury 
exposure during pregnancy can result in adverse neurocognitive outcomes for infants266. 
For many developing countries, making adjustments to the diet is extremely difficult, due 
to the cost and availability of foods. In Bermuda, the public health sector has successfully 
educated pregnant women on fish to avoid during pregnancy due to high levels of 
mercury, which has resulted in decreased levels of mercury observed in the blood of 
pregnant women265. However, in countries such as Tanzania, educating women to eat less 
fish and to avoid species high in mercury during pregnancy may not be as successful due 
to the lack of similarly priced alternatives. Thus, the positive findings in the current study 
are that probiotic yogurt consumption can help maintain the levels of blood mercury and 
could have huge implications for a number of developing countries where mercury 
exposure is high either due to certain food consumption or pollution. An additional large-
scale study investigating the effects of longer probiotic yogurt consumption, as well as 
investigating the mercury levels in infants born to mothers who consumed probiotic 
yogurt would help support these preliminary findings.  
4.4 Conclusions 
This pilot study was the first of its kind to simultaneously analyze the gut, vaginal and 
oral microbiota of pregnant women as well as the gut, oral, vaginal and breast milk 
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microbiota of women who had just given birth and the gut and oral microbiota of their 
infants. The current study produced a wealth of information. Differences in the gut 
microbiota of mothers of varying nutritional status were not observed. Low sample 
numbers and a lack of an accurate and reliable method for determining nutritional status 
in the field and during pregnancy may have been the reason for this. Furthermore, studies 
on the gut microbiota of obese individuals in different geographical locations have not 
been conducted. Thus, the patterns observed in North America where high-fat diets are 
consumed, may not necessarily be the same in countries where the diet is composed 
largely of corn-based products, as studies have shown that a difference does exist in the 
microbial profile due to different dietary intakes98.  Furthermore, pregnancy does exert a 
number of physiological and microbial changes141,144 on the body, so differences in the 
microbiota due to nutritional status may disappear when an individual becomes pregnant.  
The preliminary analysis presented here did not reveal any significant findings leading to 
the benefits of Moringa enriched probiotic yogurt for improved pregnancy outcomes. As 
seen in Table 19, all groups except the NP group had term pregnancies and healthy birth 
weight infants, however gestational age was based on recall of the LMP and a NA, which 
are not dependable methods for assessing gestational age as ultrasound has been shown to 
be more accurate and reliable267. Unfortunately, due to location, ultrasound was not 
available for determining the gestational age. Based on the birth data, the NP group did 
appear to have the least favorable birth outcomes as compared to the other four groups 
(Table 19). However, the NP group did have two sets of twins, which does add an 
additional strain to the health status of the mother, and twin gestations are at an increased 
risk of pre-term births and of infants being born that weigh less than 2500 g, even in 
developed countries268. A study conducted in the United States in 2001, did find that the 
optimal gestational age for twin pregnancies associated with the lowest perinatal 
mortality rate was between 37 and 38 weeks gestation, which is just on the cusp of the 
cutoff for the definition of pre-term births269. Thus, for future studies it may be beneficial 
to analyze twin data separately. Due to the low sample numbers, the twin data were 
included in the overall analysis.  
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The Moringa enriched probiotic yogurt did not appear to affect the gestational weight 
gain or nutritional status of the participants. Despite some participants having weight gain 
below the IOM recommendations and dietary intake of essential nutrients not meeting the 
RDI for pregnancy, the majority of birth outcomes were positive. This leads us to 
consider what other factors may be at play in this population as based on the nutritional 
intakes and measurements collected during the study, more adverse pregnancy outcomes 
should have resulted. Intake of Moringa enriched probiotic yogurt, did significantly 
increase the dietary calcium intake of participants. No other methods were available to 
assess the impact of this increase, but calcium does play an important role in pregnancy 
and the standard Tanzanian diet is lacking in this nutrient. Thus, it is suggested that the 
intake of Moringa enriched probiotic yogurt would be extremely beneficial in improving 
the bone health of mothers and infants in developing countries. Furthermore, although the 
Moringa enriched probiotic yogurt did not modulate the maternal microbiome in any 
way, it did appear to have an effect on the infant’s microbiome. There was a significant 
increase in organisms related to healthy gut development in infants from mothers who 
received the probiotic yogurt, while infants from mothers who did not receive the 
probiotic yogurt had higher levels of organisms associated with disease. This could have 
major implications on the long-term health of the infants and this finding warrants further 
investigations. In addition, the Moringa probiotic yogurt did have a protective effect on 
the mercury and arsenic levels in pregnant women. It is well known that heavy metals 
exposure during pregnancy can cause a number of developmental deformities, and in 
developing countries, exposure to heavy metals is increased due to pollution and unsafe 
mining practices. Furthermore, diet choices are limited in developing countries due to 
availability of food products and cost, so avoiding foods known to be high in heavy 
metals is sometimes impossible. These findings are extremely promising and warrant 
further investigation to determine the extent and length of this protection both on the 
mother and her newborn infant.  
A major weakness of the present study was the low sample numbers. It was decided that 
the study be conducted in a rural clinic in hopes of targeting a demographic of increased 
under-nourished participants. However, the majority of pregnant women attending the 
clinic were well-nourished, thus, future studies may be conducted in even more remote or 
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poor areas in order to target truly under-nourished individuals. Because of the rural 
location of the clinic, obese/overweight participants were also limited. Higher numbers of 
obese/overweight mothers are more common in urban areas, thus in order to target this 
demographic, future studies should be carried out in two locations in order to gain high 
enough sample numbers for each group. It would also be beneficial for future studies to 
recruit women before they are pregnant. Assessing nutritional status is extremely difficult 
in pregnancy and the most accurate method for assessing nutritional status in developing 
countries involves knowing pre-pregnancy weight as well as pre-pregnancy MUAC. 
Pregnancy rates in Tanzania are quite high with 211 out of 1,000 women aged between 
15 and 34 years becoming pregnant each year15. Thus, it is feasible to recruit a large 
number of women and then follow them through pregnancy. Recruiting women before 
they become pregnant will also be beneficial, as pregnant women in Tanzania do not 
normally attend an antenatal clinic until late in their pregnancy. By the time a number of 
women were recruited into the present study, adverse developmental outcomes may have 
already commenced in the fetus, thus making Moringa enriched probiotic yogurt 
supplementation ineffective. Another recommendation for future studies would be to 
extend the sample collection after birth. Due to time constraints we were unable to collect 
from participants past one-week after birth, however, it would be extremely informative 
to follow the changes in both the infant and maternal microbiota up to one-year post-
partum. In addition, future studies should include age and nutritional status-matched non-
pregnant controls. As mentioned, changes in the microbiota of individuals in Africa due 
to obesity/overweight or under-nourishment, may be different then the changes observed 
in North American populations due to the differences in diet. Thus, non-pregnant controls 
are needed to accurately assess the effect of geographic location on the effect of 
nutritional status.  
The current study was extremely beneficial in laying the groundwork for future 
microbiota related studies in developing countries. Microbiota studies in developing 
countries provide a wealth of information that is not available in developed countries and 
will be extremely beneficial in examining the relationship between the microbiota in 
health and disease. Furthermore, increased knowledge on the dynamics of the microbiota 
during pregnancy will help lead to better pregnancy outcomes globally.  
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Appendix 3: English version of consent form  
 
The National Institute for Medical Research (NIMR) P.O. Box 11936, Mwanza 
 
THE INFLUENCE OF NUTRITION ON MATERNAL AND REPRODUCTIVE 
HEALTH  
 
Adult Participant Consent Form  
 
 Subject ID Sticker  
 
 
 
Introduction and purpose 
We are a joint research team from the National Institute for Medical Research, Mwanza 
Centre and the University of Western Ontario, Canada. We are here because we are 
conducting a study to investigate the influence of nutrition on an individual’s microbiome and 
how this may be related to pregnancy outcome. Previous studies have shown that maternal 
nutrition is one of the most important factors that influence either a good or an adverse 
pregnancy outcome and new studies are showing that our normal microflora has a significant 
effect on health and disease. The main objective of the study is to determine the difference in 
gut, oral, vaginal and breast milk microbiomes of under-nourished pregnant women with and 
without supplementation with micronutrient enriched probiotic yogurt and compare this to the 
microbiome of obese and healthy pregnant women The study has been approved by the 
Ministry of Health and Social Welfare. Buswelu Clinic has also given permission to conduct 
this study.  
 
We are asking if you would like to participate in this study. This form explains the study and 
you can decide to take part or refuse to participate. Please take the time to read this form or 
someone can read it to you. If you have any questions, require more information or need 
further explanation of the study, please ask the doctor or any study worker. 
 
Participant Selection 
The study will recruit 80 pregnant women attending the neonatal service at the Buswelu 
Clinic, who are approximately 20 weeks pregnant. We are asking you to participate because 
you fit the criteria for participant selection, based on a clinical assessment by a doctor. 
Twenty obese, 20 healthy, and 40 under-nourished women will be asked to participate. 
 
Procedures: Twenty pregnant women who are found to be malnourished according to the 
WHO criteria will be selected and given a daily supplementation of 250mL’s of yogurt which is 
enriched with micronutrients (powdered Moringa oleifera leaves) and a probiotic (bacteria with 
health benefits). Stool, vaginal and oral samples will be collected monthly starting with the first 
visit and continuing until the baby is born and again one week after the baby is born. In 
addition, blood samples will be collected three times during the course of the study. A breast 
milk sample from the women and a stool and oral sample from the infant will be collected 
when the infant is born and one week later. If you are selected to consume the yogurt, you will 
be required during the study period of approximately 6 months, to come to the Buswelu yogurt 
kitchen daily to consume the yogurt. If you are unwell and cannot travel to the kitchen a study 
worker will deliver the yogurt to you.  Another group of 20 well nourished pregnant women, 20 
overweight pregnant women, and 20 under-nourished pregnant women will not take any 
yogurt supplementation but stool, oral, and vaginal samples will also be collected at 
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enrolment and monthly until the baby is born. In addition, blood samples will also be collected 
three times during the course of the study. At birth, stool, oral, vaginal and breast milk 
samples will be collected from the mother and again one week after, while infant oral and 
stool samples will be collected Finally, stool and oral samples will be collected from all the 
infants born to study participants, at birth and one week later. The stool specimens will be 
tested for parasitic infections and the vaginal samples will be tested for the presence of 
bacteria. Blood will be tested for malaria parasites and will be shipped to Canada to be tested 
for vitamin and element levels. Urine samples will also be collected and tested for protein and 
glucose. In addition, small amounts of the stool, vaginal, oral and breast milk samples will be 
shipped to Canada to be sequenced in order to determine the microbial profiles of all groups. 
 
For all subject groups anthropometric assessment will be performed at enrolment and 
monthly until birth. In addition, a questionnaire will be asked to collect information on 
perceived changes in energy levels, gut health (diarrhea incidence and chronicity; bloating) 
and any adverse health effects. A 24 hour dietary recall will also be given to determine the 
subject’s energy and nutritional intakes.  
 
You will then be followed up to delivery and your child will be followed up to 2 years of age. At 
delivery all newborns will have height and weight measurements taken, time of gestation and 
general health status. Infant cognitive function will be assessed at 6 months, 12 months, 18 
months and 24 months.  
 
 
Responsibilities of the study participant:  
You have to continue with the routine pregnancy investigations as per standard of care at 
your setting, as well as come to the clinic every month for a check-up and sample collection.  
There are no specific dietary requirements for participating in this study, but you cannot 
consume probiotic yogurt during the study if you are not part of the group randomly selected 
to consume the yogurt. You will neither be allowed to smoke nor take alcohol during the entire 
study period. If you are selected to consume the probiotic yogurt, you will be asked to come to 
the Buswelu Kitchen every day to consume the yogurt. 
 Anytime during the study, if you do not feel well or you are feeling sick, you have to contact 
your study doctor immediately. Your study doctor may examine you or do tests if it is 
necessary. You will be given treatment and care by your study doctor as per the standard of 
care to pregnant women 
Tell your doctor immediately if you have the following (1) Effects (if you do not feel well or 
you are sick) (2) pain, or (3) any symptom or problem during the study period. You may 
contact your study doctor, who will be available for 24 hours, day and night; you will be given 
the number to call after joining the study. 
 
Risk/Discomforts: 
If you are selected in the group that will be receiving yogurt, we do not expect there to be any 
adverse effects to you or to your unborn baby due to consumption of the yogurt. The 
procedures and tests done in the study will also not cause harm to either you or your baby. 
 
Vaginal swabs will be taken, but these will not cause any harm to you or your baby.  
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Benefits: 
If you participate in this study and are selected to consume the yogurt you will not incur any 
additional costs. The yogurt will be provided free of charge.  You may experience positive 
effects (example you may have better health) by taking the yogurt and you may have better 
pregnancy outcomes. Other pregnant women may benefit in the future from the information 
generated from this study. It is possible that you may not have a direct health advantage by 
participating in this study and consuming the yogurt. 
 
Payment: 
To show appreciation for your time and transport costs, a total of 5,000 Tanzanian shillings will 
be paid to you when you come to the clinic for the  monthly study visits 
 
Costs:  
There are no extra costs to you for taking part in this study, except for giving up the time to 
participate in the study and to come to the Buswelu Kitchen to consume the yogurt.  
 
 
Confidentiality: 
The information obtained from you when you participate in this study, and other information 
concerning your health, will remain confidential. However the laboratory results may be shared 
with your clinical peers at this clinic. By signing the consent form, you have authorized the 
study workers to collect information about you pertaining to the study. However the study 
team will make every effort to protect your personal information and your name will not be 
used on any form, or any other information released later. If you withdraw from the study we 
will not continue obtaining personal information from you but we may still need to use the 
information already collected from you. 
 
Personal information considered to be necessary (example date of birth) will be collected and 
prepared for study purposes alone. 
 
The study information could be published in a research journal and disseminated, but your 
name will not be mentioned in any of the information disclosed. The researchers will make 
sure that your personal information is protected. 
 
Samples collected will be sent to Canada and Europe for analysis, but your name and any 
other information will be kept confidential. 
 
        
Right to refuse or withdraw from this study : 
Participating in this study is voluntary. You may decide not to participate or withdraw from the 
study at any time. The decision not to participate or to withdraw from the study will not affect 
your right to access care. After withdrawing from the study, the samples that were taken 
previously will be tested as planned unless you request not to have them tested when you 
leave the study. 
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Questions and person to contact: 
Before signing this form you may ask questions about anything that you did not understand. 
The study doctor and the study worker will answer them before, during or after the study. If 
you have questions about the study or how the study is run, contact: 
 
Name of the study doctor:                                               , mobile phone number  
 
Study Coordinator:                                                           , mobile phone number  
 
Physical address: National Institute for Medical Research, Mwanza Centre, 
P.O BOX 1462, Mwanza, Tanzania. 
 
If you have questions about your rights in the study, contact: Dr. Mwele Malecela, Chairperson 
for the Medical Research Coordinating Committee (|NIMR), Tanzania,  
The national Institute for Medical Research (NIMR) 
P.O BOX 9653, Dar-es-salaam, Tanzania 
Phone 0222121400, Fax 0222121360 
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Your Consent: 
I have read, (or someone read to me), in a language that I understand all the information 
above. I have been told that it is up to me to consent to participate in the study and that I may 
withdraw from the study at any time without any effect. If I decide not to participate or 
withdraw from the study, my right to access care will not be affected. I agree to participate in 
the study and I know that I will get a copy of the signed consent form 
 
________________________________________  
Name of the participant 
 
 
_______________________________________________________________________  
Signature of the participant Date 
 
Please put a date on your signature during signing 
 
 
 
 
 
 
 
(The witness signature is required if the participant does not 
know how to read) 
 
__________________________________________                                       Not applicable 
Name of the witness 
 
 
______________________________ __________________________________________  
Witness signature Date 
 
 
The researcher or another person assigned to explain the study and gain consent must 
also sign and date at the same time as the participant 
 
_______________________________________________ ____ 
Name of the person who explained the consent form 
 
 
_______________________________________________________________________  
Signature of the person who explained the consent form Date 
Participant’s thumbprint 
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Appendix 5: 48-hour Dietary Recall administered at every visit 
 
Maternal Nutrition and Infant Health Study 
 
                Subject ID Sticker 
48 hour Dietary Recall  
To be given every visit 
 
 
Version 1. 7th July 2012                                                                                    1 of 9 
 
IDENTITY CHECK 
Question Answer 
Visit date  |___|___| - |___|___|___| - 20|___|___| 
Date of birth?  
 
|___|___| - |___|___|___| - |___|___|___|___| 
Study group of the participant  1 
2 
3 
Under-nourished 
Healthy 
Obese 
GENERAL  
Time of recall  |___|__|:|___|__| (24hrs clock) 
Do you have a fridge?  1. Yes  
2. No  
Do you have an oven?  1. Yes  
2. No  
How do you cook your meals? (circle all that 
apply) 
1. Electric hot plate  
2. Gas stove top  
3. Gas stove top with oven  
4. Charcoal stove  
5. Fire  
Water supply (circle the type used and indicate 
whether it is drinking water, cooking water or 
both)  
1. Well ……………………………………………. 
2. Tap …………………………………………….. 
3. Bottled …………………………………… 
4. Stream ………………………………………… 
5. Lake …………………………………………… 
How far do you walk in a day?  ................................................................................... 
................................................................................... 
................................................................................... 
Do you eat Moringa?  1. Yes  
2. No  
 
Do you drink yogurt?  
 
1. Yes  
2. No  
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Do you work?  1. Yes  
2. No  
Describe your work  ................................................................................... 
................................................................................... 
................................................................................... 
 
Instructions: 
Give as detailed of information as possible. All information collected will be kept confidential, so be 
as truthful and honest as possible. The information gained will not be used against you in anyway. It 
will allow us to better assess your nutritional status so honesty is extremely important. 
Be as specific as possible with portion sizes and amounts examples of how to estimate sizes are below 
Size of fist = 1 cup 
Palm of hand = 3 ounces 
A thumb (entire thumb) = 2 tablespoons 
Thumb tip = 1 teaspoon 
If practical give the number of food items (ie. 1 banana, 1 orange, etc) 
 
Wheat/Maize/Starch Products 
Have you had any wheat/maize/rice 
products? ie. ugali, chapata, bread? 
1. Yes 
2. No 
What Kind? (circle all that apply) 1. Ugali                                   7. Keki 
2. Rice                                    8. Vitumbua 
3. Cooked Banana                 9. Uji 
4. Bread                                10. Chipsi 
5. Chapati                             11. Chipsi Mayi 
6. Mandazi                            12. Other: 
                                          __________________ 
Detailed Information: For each item circled above, give the approximate time it was consumed 
(asubuhi, mchana, jioni), the amount and how it was cooked (baked, boiled, fried, etc.) Make sure to 
state if you added any salt, cooked it in butter or oil, etc, and the approximate amounts of each additive. 
Day 1: Day 2: 
Asubuhi Asubuhi 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
Mchana Mchana 
Item Amount  Cooked Item  Amount Cooked 
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Jioni Jioni 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
 
Roots and Tubers: 
Have you had any roots and/or tubers? 1. Yes 
2. No 
What kind (circle all that apply) 1. Ginger                     5. Other:___________ 
2. Cassava 
3. Sweet potato 
4. Potato 
Detailed Information: For each item circled above, give the approximate time it was consumed 
(asubuhi, mchana, jioni), the amount and how it was cooked (baked, boiled, fried, etc.) Make sure to 
state if you added any salt, cooked it in butter or oil, etc, and the approximate amounts of each additive. 
Day 1: Day 2: 
Asubuhi Asubuhi 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
Mchana Mchana 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
Jioni Jioni 
Item Amount  Cooked Item  Amount Cooked 
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Vegetables: 
Have you had any vegetables? (carrots, green 
peppers, onions, tomatoes etc) 
1. Yes 
2. No 
 
What kind? (circle all that apply) 1. Cucumber              9. Spinach 
2. Karoti                    10. Kabichi 
3. Tomatoes              11. Corn  
4. Onions                  12. Other:   
5. Green Pepper        ________________ 
6. Eggplant               13. Pumpkin 
7. Parachichi             14. Okra 
8. Jute Mallow          15. Amaranth 
Detailed Information: For each item circled above, give the approximate time it was consumed 
(asubuhi, mchana, jioni), the amount and how it was prepared (make sure to state if you added any 
salt, cooked it in butter or oil, etc, and the approximate amounts of each additive). 
Day 1: Day 2: 
Asubuhi Asubuhi 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
Mchana Mchana 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
Jioni Jioni 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
 
 
Fruits: 
Have you had any fruits in the last 48 hours? 1 
2 
Yes 
No 
What type of fruit did you eat? 1. Watermelon           10. Other:___________ 
2. Nanasi                    ___________________ 
3. Ndazi                      11. Stafeli 
4. Oranges                  12. Papai 
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5. Mango                     13. Pears 
6. Passion fruit            14. Mapera 
7. Zambarau                15. Nazi 
8. Limau                      16. Fenesi(la(kizungu(
9. Tende 
Detailed Information: For each item circled above, give the approximate time it was consumed 
(asubuhi, mchana, jioni), and the number or amount that was consumed. 
Day 1: Day 2: 
Asubuhi Asubuhi 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
Mchana Mchana 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
Jioni Jioni 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
 
 
 
 
Meat: 
Did you have any meat in the last 24 hours? 1. Yes 
2. No 
What type of meat did you eat? (circle all that 
apply) 
1. Beef                     5. Other (specify):…………………….. 
2. Chicken                …………………………………………. 
3. Goat 
4. Pork 
Detailed Information: For each item circled above, give the approximate time it was consumed (asubuhi, 
mchana, jioni), the amount and how it was prepared (make sure to state if you added any salt, cooked it in 
butter or oil, etc, if it was marinated and the approximate amounts of each additive). 
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Day 1: Day 2: 
Asubuhi Asubuhi 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
Mchana Mchana 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
Jioni Jioni 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
Eggs:
Did you have any eggs? 1. Yes 
2. No 
What time did you eat eggs / How many did you have and how were they prepared? Make sure to state if you 
used any oils, or butter or anything else to cook the eggs and the approximate amount that you used 
I__I___I:I__I___I Time consumed / Amount:…………………….. / Prepared: ………………………………………... 
I__I___I:I__I___I Time consumed / Amount: ……………………. / Prepared: ………………………………………... 
I__I___I:I__I___I Time consumed / Amount: ……………………. / Prepared:………………………………………… 
I__I___I:I__I___I Time consumed / Amount:…………………….. / Prepared: ………………………………………. 
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Fish:
 
 
 
 
 
Beans:
Did you eat any beans or lentils in the last 24 
hours?  
1. Yes 
2. No 
What type did you eat? 1. Maharage          4. Other:_______________________ 
2. Peas                  5. Hyacinth bean 
3. Lentils                6. Cow peas 
4. Bambara ground nut 
Detailed Information: For each item circled above, give the approximate time it was consumed (asubuhi, 
mchana, jioni), the amount and how it was prepared (make sure to state if you added any salt, cooked it in 
butter or oil, etc, and the approximate amounts of each additive). 
Did you have any fish in the last 48 hours? 1. Yes 
2. No 
If “yes” what kind did you have? (circle all 
that apply) 
1. Dagaa                       4. Other:__________________ 
2. Nile Perch                 __________________________ 
3. Tilapia 
Detailed Information: For each item circled above, give the approximate time it was consumed (asubuhi, 
mchana, jioni), the amount and how it was prepared (make sure to state if you added any salt, cooked it in 
butter or oil, etc, and the approximate amounts of each additive). 
Day 1: Day 2: 
Asubuhi Asubuhi 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
Mchana Mchana 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
Jioni Jioni 
Item Amount  Cooked Item  Amount Cooked 
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Day 1: Day 2: 
Asubuhi Asubuhi 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
Mchana Mchana 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
Jioni Jioni 
Item Amount  Cooked Item  Amount Cooked 
      
      
      
 
Sugar Products:
Did you eat anything containing sugar or 
sugar products in the last 48 hours? (ie. 
candy, honey etc) 
1. Yes 
2. No 
If “yes” what did you have? (circle all that 
apply) 
1. Candy 
2. Refined sugar 
3. Honey 
What time did you eat the sugar / How much did you have? Was it mixed with anything (in Chai, in kawa, etc? 
I__I___I:I__I___I Time consumed / Amount:…………………….. / Consumed: ……………………………………… 
I__I___I:I__I___I Time consumed / Amount: ……………………. / Consumed: …………………………………... 
I__I___I:I__I___I Time consumed / Amount: ……………………. / Consumed:…………………………………… 
I__I___I:I__I___I Time consumed / Amount:…………………….. / Consumed: …………………………………. 
Milk Products:
Did you have any milk products in the last 24 
hours? (ie. yogurt, milk etc) 
1. Yes 
2. No 
If “yes” what did you have? (circle all that 
apply) 
1. Cheese 
2. Milk 
3. Yogurt (Maziwa ya Mara) 
Specify the kind: …………………………………………... 
What time did you have the milk products / How much did you have?  
I__I___I:I__I___I Time consumed / Amount:……………………………………..…………………………………… 
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IDENTITY CHECK 
Question Answer 
Visit date  |___|___| - |___|___|___| - 20|___|___| 
Date of birth?  
 
|___|___| - |___|___|___| - |___|___|___|___| 
Study group of the participant  1 
2 
3 
Under-nourished 
Healthy 
Obese 
GENERAL  
Time of recall  |___|__|:|___|__| (24hrs clock) 
Do you have a fridge?  1. Yes  
2. No  
Do you have an oven?  1. Yes  
2. No  
How do you cook your meals? (circle all that 
apply) 
1. Electric hot plate  
2. Gas stove top  
3. Gas stove top with oven  
4. Charcoal stove  
5. Fire  
Water supply (circle the type used and indicate 
whether it is drinking water, cooking water or 
both)  
1. Well ……………………………………………. 
2. Tap …………………………………………….. 
3. Bottled …………………………………… 
4. Stream ………………………………………… 
5. Lake …………………………………………… 
How far do you walk in a day?  ................................................................................... 
................................................................................... 
................................................................................... 
Do you eat Moringa?  1. Yes  
2. No  
 
Do you drink yogurt?  
 
1. Yes  
2. No  
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VISIT DATE AND IDENTITY CHECK 
QNo Question Answer 
1.1 Visit date |___|___| - |___|___|___| - 20|___|___| 
1.2 Date of birth? |___|___| - |___|___|___| - |___|___|___|___| 
What is your age today? |___|___| Years 
1.4 Is the participant eligible for the study ? 
(Has she passed the screening process ?) 
1 
2 
Yes 
No 
1.5 Study group of the participant 1 
2 
3 
Under-nourished 
Well nourished 
Obese 
Completed by (Initials): |___|___|___| 
 DEMOGRAPHICS& VITAL SIGNS 
2.1 Time of vital signs |___|__|:|___|__| (24hrs clock) 
2.2 What is the participant’s height? |___|___|___| cm 
2.3 What is the participant’s weight? |___|___|___|. |___| kg 
2.4 What is the participants MUAC I___I___I___I.I___I cm 
2.5 What is the participant’s blood pressure? 
(BP to be taken while the subject is seated) 
BP systolic  |___|___|___|. |___| mmHg 
BP diastolic |___|___|___|. |___| mmHg 
2.6 What is the participant’s pulse rate?  |___|___|___|. |___| beats/minute 
2.7 Body temperature?  |___|___|. |___| °C 
Completed by (Initials): |___|___|___| 
 
LABORATORY INVESTIGATION 
3.1 Date of specimen collection  |___|___| - |___|___|___| - 20|___|___| 
3.2 HIV results 1. Positive 2. Negative 3. Indeterminate 
3.3 Malaria rapid diagnostic test results 1. Positive 2. Negative 3. Indeterminate 
3.4 Time of haemoglobin specimen collection |___|__|:|___|__| (24hrs clock) 
3.5 Hemoglobin results |___|___|___| 
3.6 Treponema Pallidum results |___|___|___| 
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3.7 Time of blood sample collection |___|__|:|___|__| (24hrs clock) 
3.8 Number of tubes of blood collected I___I#
3.9 Type of blood tubes collected I__I 6mL#K2)EDTA#Royal#Blue#Vacutainer#tube##
I__I#K2##6#mL#EDTA#lavender#top#Vacutainer#tube#
3.10 If less than the required tubes of blood 
collected state why 
 
…………………………………………………………………. 
…………………………………………………………………. 
…………………………………………………………………. 
3.11 Has a stool sample been collected 
 
1. Yes 
2. No 
If no give reasons 
….......................................................................................
........................................................................................... 
3.12 Time of stool specimen collection |___|__|:|___|__| (24hrs clock) 
3.13 Stool results for parasitic infections …................................................................................  
…................................... .............................................  
…................................................................................  
3.14 Have vaginal samples been collected (3 
swabs collected) 
1. Yes 
2. No 
If no give reasons 
….......................................................................................
........................................................................................... 
3.15 Time of Vaginal specimen collection  |___|__|:|___|__| (24hrs clock) 
3.16 Has a BV slide been made? 1. Yes 2. No 
3.17 pH of the vagina  I___I___I 
3.18 Has a oral sample been collected 1. Yes 2. No 
If no give reasons 
...........................................................................................
...........................................................................................
.......................................................................................... 
3.19 Time of oral sample collection  I___I__I:I___I__I (24hrs clock) 
3.20 Time of urine specimen collection |___|__|:|___|__| (24hrs clock) 
3.21 Urine Protein results |___|___|___|___I mg/dL (g/L) 
3.22 Urine Glucose results |___|___|___|___I mg/dL (mmoL/L) 
3.23 Urine Urobilinogen results |___|___|___|___I mg/dL (µmol/L) 
3.24 Urine Bilirubin results |___|___|___|___I 
3.25 Urine Ketone results |___|___|___|___I mg/dL (mmoL/L) 
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3.26 Urine S.G. results |___I.|___|___|___I 
3.27 Urine  Blood results |___|___|___|___I I______________I RBC/µL 
3.28 Urine pH |___|___|___| 
3.29 Urine Nitrite |___|___|___|___I 
3.30 Urine Leukocytes |___|___|___|___I WBC/µL 
 
OBSTETRICAL HISTORY: 
4.1 Number of previous pregnancies: |___|___| 
4.2 Number of vaginal deliveries |___|___| 
4.3 Number of C-sections: |___|___| 
4.4 Number of live births |___|___| 
4.5 Number of spontaneous abortions: |___|___| 
4.6 Number of elective terminations: |___|___| 
4.7 Number of ectopic pregnancies: |___|___| 
4.8 Number of molar pregnancies: |___|___| 
4.9 History of sub fertility 1 
2 
Yes 
No 
4.10a Age of subject at delivery of the 1st pregnancy  |___|___| 
4.10b Dates of subjects delivery of 1st pregnancy: 
 
 |___|___| - |___|___|___| - |___|___|___|___| 
4.11 Number of still birth deliveries: 
 
 
 
|___|___| 
4.12 Number of obstetrical complications |___|___| 
4.13 Does the participant experience any neusea or 
vomiting in the current pregnancy 
1 
2 
Yes 
No 
4.14 Is there a family history of congenital 
abnormality/genetic diseases, consanguinity (or 
any family relation or lineage) between parents? 
1 
2 
Yes 
No 
If Yes, please specify..................................................... 
…………………………..………………………………. 
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4.15 Number of children who are currently alive. |___|___| 
4.16 Is there any other obstetric history? 1 
2 
Yes 
No 
If Yes, please specify..................................................... 
…………………………..………………………………. 
 
 
 
OBSTETRIC EXAMINATION: 
4.17 Fundal height: |___|__|. |___| cm 
4.19 Has the subject felt any fetal movements in the 
past 24 hours? 
1 
2 
Yes 
No 
4.20 Are the fetal movement Normal? 1 
2 
Yes 
No 
4.21 Fetal presentation ((Circle one that apply): 1 
2 
3 
4 
Cephalic (head down) position 
Breech (bottom down) position 
Transverse position 
Unknown 
4.22 Write a brief summary of the findings during obstetric examination: 
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………. 
 
GENERAL MEDICAL HISTORY/PHYSICAL EXAMINATION 
MEDICAL HISTORY 
Does subject have current disease 
or symptoms today? 
1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
Does subject have any of the 
following conditions? 
(Circle all that apply) 
1   Asthma  2   Diabetes  3   Hypertension 
4   Tuberculosis  5   Epilepsy  8   None of these 
Operations or serious illnesses or 
accidents 
1 Yes  If yes, specify:……………………………......….....……………… 
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2 No ………………………………………………......….………………… 
Taking any medication at the 
moment? 
1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Do you take any alcohol at the 
moment? 
1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
Does the subject smoke?  1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
CVS system 
Chest pain 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….…………………
…………………………………………………….......……………… 
SOB/orthopnoea 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Oedema 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Palpitations 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Other CVS symptoms 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
 
Respiratory system 
Cough 
 (Check colour, amount, 
consistency for sputum) 
1 
2 
3 
4 
Yes, dry cough  
Yes, productive with sputum 
Yes, with haemoptysis 
No cough 
Specify……………………………… 
……………………………………… 
………………………………..…..… 
……………………………………… 
Other RS symptoms 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
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Gastrointestinal system 
Abdominal pain) 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Nausea/vomiting 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Diarrhoea/alteration in bowel habit) 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Weight loss 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Other GI symptoms 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
CNS 
Headaches/dizziness 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Visual/hearing problems 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Motor problems (walking, etc.) 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Sensory problems (e.g. numbness) 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Other CNS symptoms 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
Skin  
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Skin rashes or other problems 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
 
 
 
 
 
 
Summary of any abnormalities found during Physical Examination 
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
………………………………………………………………………………………… 
HISTORY-DIRECTED PHYSICAL EXAMINATION (“ND” if not done) 
5.1 Cyanosis 
Clubbing 
1   Absent 2   Present,  specify …………………………… 
1   Absent 2   Present,  specify …………………………… 
5.2 Lymph nodes                           Head 
Neck 
Axillae 
Inguinal 
Other Specify  
1   Absent 2   Present,  specify …………………………… 
1   Absent 2   Present,  specify …………………………… 
1   Absent 2   Present,  specify …………………………… 
1   Absent 2   Present,  specify …………………………… 
1   Absent 2   Present,  specify …………………………… 
 5.3 Cardio Vascular System 
Blood Pressure (BP) 
Apex 
 Pulse 
Heart Sounds (HS) 
Oedema 
 
 |___|___|___| / |___|___|___| mm/Hg 
1   Normal 2   Abnormal, specify …………………………… 
|___|___|___| beats/min  1   Regular 2   Irregular 
1   Normal 2   Abnormal, specify …………………………… 
1   Normal 2   Abnormal, specify …………………………… 
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5.4 Respiratory System (RS) 
Respiratory Rate (RR) 
Percussion Notes (PN) 
Breath Sounds (BS) 
 
 |___|___|___| breaths/min 
1   Resonant 2   Dull,   specify …………………………… 
1   Normal 2   Abnormal,  specify……………………………. 
5.5 Abdomen 
 
  L                       S 
 
  K                       K 
 
Hepatomegaly  1   Yes  2   No 
Splenomegaly  1   Yes  2   No  
L kidney enlarged  1   Yes  2   No 
R kidney enlarged 1   Yes  2   No 
 (Please draw any enlargements on diagram opposite and 
circle as applicable) 
Tenderness  1   Non-tender  2   Tender 
  3   Rebound  4   Guarding 
5.6 Central Nervous System         Eyes 
Ears 
Cranial nerves 
Peripheral NS 
1   Normal 2   Abnormal, specify…………………………… 
1   Normal 2   Abnormal, specify……………………………. 
1   Normal 2   Abnormal, specify……………………………. 
1   Normal 2   Abnormal, specify…………………………… 
5.7 Skin 1   Normal 2   Abnormal, specify…………………………… 
5.8 Summary of Medical History and Examination (please detail any abnormalities found on examination):  
------------------------------------------------------------------------ --------------------------------------------------------------  
----------------------------------------------------------------------------------------------------------------------------- --------- 
---------------------------------------------------------- ----------------------------------------------------------------------------  
----------------------------------------------------------------------------------------------------------------------------- --------- 
----------------------------------------------------------------------------------------------------------------------------- --------- 
Section completed by (initials): |___|___|___| 
  
• 
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VISIT DATE AND IDENTITY CHECK 
QNo Question Answer 
1.1 Visit date |___|___| - |___|___|___| - 20|___|___| 
1.2 Study group of the participant 1 
2 
3 
Under-nourished 
Well nourished 
Obese 
Completed by (Initials): |___|___|___| 
  
DEMOGRAPHICS& VITAL SIGNS OF MAMA 
2.1 Time of vital signs |___|__|:|___|__| (24hrs clock) 
2.2 What is the participant’s weight? |___|___|___|. |___| kg 
2.3 What is the participants MUAC I___I___I___I.I___I cm 
Completed by (Initials): |___|___|___| 
 
 
LABORATORY INVESTIGATION 
3.1 Date of specimen collection  |___|___| - |___|___|___| - 20|___|___| 
3.2 HIV results 1. Positive 2. Negative 3. Indeterminate 
3.3 Malaria rapid diagnostic test results 1. Positive 2. Negative 3. Indeterminate 
3.4 Time of haemoglobin specimen collection |___|__|:|___|__| (24hrs clock) 
3.5 Hemoglobin results |___|___|___| 
3.6 Treponema Pallidum results |___|___|___| 
3.7 Time of blood sample collection |___|__|:|___|__| (24hrs clock) 
3.8 Number of tubes of blood collected I___I#
3.9 Type of blood tubes collected I__I 6mL#K2)EDTA#Royal#Blue#Vacutainer#tube##
I__I#K2##6#mL#EDTA#lavender#top#Vacutainer#tube#
3.10 If less than the required tubes of blood 
collected state why 
 
…………………………………………………………………. 
…………………………………………………………………. 
3.11 Has a stool sample been collected 
 
1. Yes 
2. No 
If no give reasons 
….......................................................................................
........................................................................................... 
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3.12 Time of stool specimen collection |___|__|: I___|__| (24hrs clock) 
3.13 Stool results for parasitic infections ……............................................. ...............................  
……............................................. ...............................  
……................... .......................... ...............................  
3.14 Have vaginal samples been collected (3 
swabs collected) 
1. Yes 
2. No 
If no give reasons 
….......................................................................................
........................................................................................... 
3.15 Time of Vaginal specimen collection  |___|__|: I___|__| (24hrs clock) 
3.16 Has a BV slide been made? 1. Yes 2. No 
3.17 pH of the vagina  I___I___I 
3.18 Metabolome tube #  I___I___I___I 
3.19 Has a oral sample been collected 1. Yes 2. No 
If no give reasons 
...........................................................................................
...........................................................................................
.......................................................................................... 
3.20 Time of oral sample collection  I___I__I:I___I__I (24hrs clock) 
3.21 Time of urine specimen collection |___|__|:|___|__| (24hrs clock) 
3.22 Urine Protein results |___|___|___|___I mg/dL (g/L) 
3.23 Urine Glucose results |___|___|___|___I mg/dL (mmoL/L) 
3.24 Urine Urobilinogen results |___|___|___|___I mg/dL (µmol/L) 
3.25 Urine Bilirubin results |___|___|___|___I 
3.26 Urine Ketone results |___|___|___|___I mg/dL (mmoL/L) 
3.26 Urine S.G. results |___I.|___|___|___I 
3.27 Urine  Blood results |___|___|___|___I I______________I RBC/µL 
3.28 Urine pH |___|___|___| 
3.29 Urine Nitrite |___|___|___|___I 
3.30 Urine Leukocytes |___|___|___|___I___I___I___I___I WBC/µL 
3.31 Time of Breast milk sample collection  |___|__|:|___|__| (24hrs clock) 
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3.32 Has a Breast milk sample been collected? 1. Yes 
2. No 
If no, give reasons 
…………………………………………………………………. 
…………………………………………………………………. 
3.34 Has an infant stool sample been collected? 1. Yes 
2. No 
If no, give reasons 
…………………………………………………………………. 
…………………………………………………………………. 
3.35 Time of infant stool sample collection I___I__I:I___I__I (24hrs clock) 
3.36 Has an infant oral sample been collected? 1. Yes 
2. No 
If no, give reasons 
…………………………………………………………………. 
…………………………………………………………………. 
3.37 Time of infant oral sample collection I___I__I:I___I__I (24hrs clock) 
Section completed by (initials): |___|___|___I 
 
NEWBORN EXAMINATION:      
4.1 Date of birth I___I___I - I___I___I – 20I___I___I (mm/dd/yy) 
4.2 Time of birth I___I___I : I___I___I (24 hour clock) 
4.3 Gestation age at birth I____I____I weeks 
4.4 Sex of Infant 1. Male                 2.  Female 
4.5 Type of birth 2. Caesarean 
3. Vaginal delivery 
4.6 Where did the birth occur? 1. Home 
2. Nyerere Dispensary 
3. Seko-toure 
4. Bugando 
5. Other: 
______________________________ 
4.7 Length: |___|__|. |___| cm 
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4.8 Weight I____I. I____I kg 
4.9 Heart rate beats/min  |___|__|___| beats/min 
4.10 Mid-upper arm circumference  I___I___I. I___I cm 
4.11 Head circumference  I___I___I. I___I cm 
4.12 Length of Labor I___I____I___I hours 
4.13 Problems with Delivery? 1. Yes 
2. No 
4.14 If “YES” to 4.13 explain …………………………………………………………… 
…………………………………………………………… 
…………………………………………………………… 
…………………………………………………………… 
4.14 Preterm Birth? 1. Yes 
2. No 
If yes: number of weeks/months: I___I___I___I 
4.15 Any health issues with infant? 1. Yes 
2. No 
If “Yes” explain: 
…………………………………………………………… 
…………………………………………………………… 
…………………………………………………………… 
 
GENERAL MEDICAL HISTORY/PHYSICAL EXAMINATION 
MEDICAL HISTORY 
Does subject have current disease 
or symptoms today? 
1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
Does subject have any of the 
following conditions? 
(Circle all that apply) 
1   Asthma  2   Diabetes  3   Hypertension 
4   Tuberculosis  5   Epilepsy  8   None of these 
Operations or serious illnesses or 
accidents 
1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
Taking any medication at the 
moment? 
1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
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Do you take any alcohol at the 
moment? 
1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
Does the subject smoke?  1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
CVS system 
Chest pain 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….…………………
…………………………………………………….......……………… 
SOB/orthopnoea 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Oedema 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Palpitations 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Other CVS symptoms 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
 
Respiratory system 
Cough 
 (Check colour, amount, 
consistency for sputum) 
1 
2 
3 
4 
Yes, dry cough  
Yes, productive with sputum 
Yes, with haemoptysis 
No cough 
Specify……………………………… 
……………………………………… 
………………………………..…..… 
……………………………………… 
Other RS symptoms 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
 
Gastrointestinal system 
Abdominal pain) 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
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Nausea/vomiting 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Diarrhoea/alteration in bowel habit) 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Weight loss 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Other GI symptoms 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
CNS 
Headaches/dizziness 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Visual/hearing problems 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Motor problems (walking, etc.) 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Sensory problems (e.g. numbness) 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
Other CNS symptoms 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
Skin  
Skin rashes or other problems 1 
2 
Yes  
No 
If yes, specify:……………………………......….....……………… 
………………………………………………......….………………… 
…………………………………………………….......……………… 
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HISTORY-DIRECTED PHYSICAL EXAMINATION (“ND” if not done) 
5.1 Cyanosis 
Clubbing 
1   Absent 2   Present,  specify …………………………… 
1   Absent 2   Present,  specify …………………………… 
5.2 Lymph nodes                           Head 
Neck 
Axillae 
Inguinal 
Other Specify  
1   Absent 2   Present,  specify …………………………… 
1   Absent 2   Present,  specify …………………………… 
1   Absent 2   Present,  specify …………………………… 
1   Absent 2   Present,  specify …………………………… 
1   Absent 2   Present,  specify …………………………… 
 5.3 Cardio Vascular System 
Blood Pressure (BP) 
Apex 
 Pulse 
Heart Sounds (HS) 
Oedema 
 
 |___|___|___| / |___|___|___| mm/Hg 
1   Normal 2   Abnormal, specify …………………………… 
|___|___|___| beats/min  1   Regular 2   Irregular 
1   Normal 2   Abnormal, specify …………………………… 
1   Normal 2   Abnormal, specify …………………………… 
5.4 Respiratory System (RS) 
Respiratory Rate (RR) 
Percussion Notes (PN) 
Breath Sounds (BS) 
 
 |___|___|___| breaths/min 
1   Resonant 2   Dull,   specify …………………………… 
1   Normal 2   Abnormal,  specify……………………………. 
5.5 Abdomen 
 
  L                       S 
 
  K                       K 
 
Hepatomegaly  1   Yes  2   No 
Splenomegaly  1   Yes  2   No  
L kidney enlarged  1   Yes  2   No 
R kidney enlarged 1   Yes  2   No 
 (Please draw any enlargements on diagram opposite and 
circle as applicable) 
Tenderness  1   Non-tender  2   Tender 
  3   Rebound  4   Guarding 
5.6 Central Nervous System         Eyes 
Ears 
Cranial nerves 
Peripheral NS 
1   Normal 2   Abnormal, specify…………………………… 
1   Normal 2   Abnormal, specify……………………………. 
1   Normal 2   Abnormal, specify……………………………. 
1   Normal 2   Abnormal, specify…………………………… 
5.7 Skin 1   Normal 2   Abnormal, specify…………………………… 
5.8 Summary of Medical History and Examination (please detail any abnormalities found on examination):  
----------------------------------------------------------------------------------------------------------------------------- --------- 
----------------------------------------------- ---------------------------------------------------------------------------------------  
----------------------------------------------------------------------------------------------------------------------------- --------- 
--------------------------------- -----------------------------------------------------------------------------------------------------  
• 
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5.9 Any prescriptions given? 3. Yes 
4. No 
5.10 If Yes which prescriptions and what is the treatment 
for? 
…………………………………………………………. 
…………………………………………………………... 
………………………………………………………….. 
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Appendix 8: Raw birth data for the UN group. A (-) indicates that birth weight was 
not collected, while a (D) indicates that the baby is deceased. 
Study ID GA LMP* 
(weeks) 
GA NA** 
(weeks) 
Difference 
(LMP-
NA) 
Preterm Birth 
Weight 
(kg) 
Mother 
Weight 
Gain 
(lbs/week) 
    LMP NA   
MNIH09UP 38.57 38.57 0.00 N N 2.5 0.47 
MNIH21U 38.57 34.00 4.57 N Y 3.4 0.48 
MNIH23U 29.71 29.29 0.43 Y Y -  
MNIH31U 37.57 37.43 0.14 N N 2.68 2.38 
MNIH39U 40.86 40.86 0.00 N N 3.3 1.53 
MNIH43N 37.86 38.00 -0.14 N N 3 0.77 
MNIH45N 38.00 30.14 7.86 N Y -  
MNIH48N 38.43 38.71 -0.29 N Y 2.7 1.05 
MNIH49N 39.00 39.14 -0.14 N N 3.7 1.21 
MNIH50N 40.43 38.43 2.00 N N 3.5 1.12 
MNIH55N 39.57 40.71 -1.14 N N 3 0.13 
MNIH56N 42.14 42.71 -0.57 N N 3.2 0.87 
MNIH58N 32.43 32.43 0.00 Y Y D -0.11 
*GA LMP: Gestational age calculated from last menstrual period 
*GA NA: Gestational age given by a nurses approximation 
 
 
Appendix 9: Raw birth data for the UNP group. A (-) indicates that birth weight 
was not collected. 
Study ID GA 
LMP* 
(weeks) 
GA 
NA** 
(weeks) 
Difference 
(LMP-
NA) 
Preterm Birth 
Weight 
(kg) 
Mother 
Weight 
Gain 
(lbs/week) 
    LMP NA   
MNIH01UP 37.14 37.86 -0.71 N N 2.6 0.49 
MNIH02UP 41.57 41.71 -0.14 N N 2.8 0.43 
MNIH05UP 35.86 36.14 -0.29 Y Y 3.4 0.64 
MNIH14UP 34.43 33.43 1.00 Y Y 2.3 0.93 
MNIH16UP 41.43 41.86 -0.43 N N 3.25 0.71 
MNIH20UP 38.71 37.29 1.43 N N -  
MNIH83NP 37.43 37.43 0.00 N N 3.25 1.63 
MNIH84NP 41.43 33.43 8.00 N Y 3.2 1.93 
MNIH88NP 44.14 40.14 4.00 N N 3 0.69 
MNIH90NP 39.86 39.86 0.00 N N 3.4 0.62 
MNIH92NP 38.57 39.43 -0.86 N N 3.8 0.58 
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MNIH95NP 42.00 42.14 -0.14 N N 3.5 4.08 
*GA LMP: Gestational age calculated from last menstrual period 
*GA NA: Gestational age given by a nurses approximation 
 
Appendix 10: Raw birth data for the N group. A (-) indicates that birth weight was 
not collected. 
Study ID GA 
LMP* 
(weeks) 
GA 
NA** 
(weeks) 
Difference 
(LMP-
NA) 
Preterm Birth 
Weight 
(kg) 
Mother 
Weight 
Gain 
(lbs/week) 
    LMP NA   
MNIH41N 40.00 47.43 -7.43 N N 3.85 0.45 
MNIH51N 36.86 37.14 -0.29 N N -  
MNIH52N 38.29 38.29 0.00 N N 3.1 0.76 
MNIH54N 43.14 36.43 6.71 N Y 3.4 0.30 
MNIH57N 46.29 38.00 8.29 N N 3 -1.44 
MNIH59N 38.14 38.14 0.00 N N -  
MNIH60N 33.86 33.71 0.14 Y Y 2.8 1.52 
MNIH86NP 38.00 38.71 -0.71 N Y 3.2 0.94 
*GA LMP: Gestational age calculated from last menstrual period 
*GA NA: Gestational age given by a nurses approximation  
 
Appendix 11: Raw birth data for the NP group. A (-) indicates that birth weight was 
not collected, while (D) indicates that the infant is deceased. This group contained 
two twin sets and the second infant is indicated by ( _2) after the study ID. 
Study ID GA 
LMP* 
(weeks) 
GA 
NA** 
(weeks) 
Difference 
(LMP-
NA) 
Preterm Birth 
Weight 
(kg) 
Mother 
Weight 
Gain 
(lbs/week) 
    LMP NA   
MNIH81NP 35.43 34.14 1.29 Y Y 3.6 0.64 
MNIH82NP 40.14 42.00 -1.86 N N 3 0.92 
MNIH85NP 40.43 37.43 3.00 N N 3.5 1.39 
MNIH87NP 39.43 40.29 -0.86 N N 3.3 1.13 
MNIH93NP 26.71 27.57 -0.86 Y Y 1.7 -0.61 
MNIH94NP 25.86 26.29 -0.43 Y Y D  
MNIH96NP 38.86 38.86 0.00 N N 3.1 1.13 
MNIH97NP 37.71 37.57 0.14 N N 2.1 -0.33 
MNIH97NP_2      2.3  
MNIH99NP 34.57 34.57 0.00 Y Y 3.2 0.72 
MNIH99NP_2      3.8  
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*GA LMP: Gestational age calculated from last menstrual period 
*GA NA: Gestational age given by a nurses approximation  
 
Appendix 12: Raw birth data for the O group. A (-) indicates that birth weight was 
not collected. 
Study ID GA 
LMP* 
(weeks) 
GA NA** 
(weeks) 
Difference 
(LMP-
NA) 
Preterm Birth 
Weight 
(kg) 
Mother 
Weight 
Gain 
(lbs/week) 
    LMP NA   
MNIH61O 36.14 40.29 -4.14 Y N 3.19 0.24 
MNIH62O 40.00 37.14 2.86 N N 3.6 0.28 
MNIH64O 37.29 37.29 0.00 N N 3.3 0.47 
MNIH65O 39.29 39.43 -0.14 N N 2.4 0.30 
*GA LMP: Gestational age calculated from last menstrual period 
*GA NA: Gestational age given by a nurses approximation   
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